No., subject, TM-score, RMSD, Sequence Identity, Subject length, Aligned length, Description
1, 1xn2C, 1.0000, 0.00, 1.000, 389, 389, NEW SUBSTRATE BINDING POCKETS FOR BETA-SECRETASE.
2, 1xn2D, 0.9989, 0.23, 1.000, 389, 389, NEW SUBSTRATE BINDING POCKETS FOR BETA-SECRETASE.
3, 2g94D, 0.9984, 0.28, 1.000, 389, 389, CRYSTAL STRUCTURE OF BETA-SECRETASE BOUND TO A POTENT AND HIGHLY SELECTIVE INHIBITOR.
4, 1xn3D, 0.9984, 0.28, 1.000, 389, 389, CRYSTAL STRUCTURE OF BETA-SECRETASE BOUND TO A LONG INHIBITOR WITH ADDITIONAL UPSTREAM RESIDUES.
5, 1xn2A, 0.9984, 0.29, 1.000, 389, 389, NEW SUBSTRATE BINDING POCKETS FOR BETA-SECRETASE.
6, 1xn2B, 0.9983, 0.30, 1.000, 389, 389, NEW SUBSTRATE BINDING POCKETS FOR BETA-SECRETASE.
7, 2g94B, 0.9982, 0.30, 1.000, 389, 389, CRYSTAL STRUCTURE OF BETA-SECRETASE BOUND TO A POTENT AND HIGHLY SELECTIVE INHIBITOR.
8, 2g94A, 0.9981, 0.31, 1.000, 389, 389, CRYSTAL STRUCTURE OF BETA-SECRETASE BOUND TO A POTENT AND HIGHLY SELECTIVE INHIBITOR.
9, 1xn3C, 0.9981, 0.31, 1.000, 389, 389, CRYSTAL STRUCTURE OF BETA-SECRETASE BOUND TO A LONG INHIBITOR WITH ADDITIONAL UPSTREAM RESIDUES.
10, 2qp8B, 0.9973, 0.39, 1.000, 389, 389, STRUCTURE OF BACE BOUND TO SCH734723
11, 2g94C, 0.9973, 0.38, 1.000, 389, 389, CRYSTAL STRUCTURE OF BETA-SECRETASE BOUND TO A POTENT AND HIGHLY SELECTIVE INHIBITOR.
12, 3lpjB, 0.9971, 0.40, 1.000, 389, 389, STRUCTURE OF BACE BOUND TO SCH743641
13, 3cidB, 0.9971, 0.39, 1.000, 389, 389, STRUCTURE OF BACE BOUND TO SCH726222
14, 3cicB, 0.9971, 0.40, 1.000, 389, 389, STRUCTURE OF BACE BOUND TO SCH709583
15, 2qmgB, 0.9971, 0.39, 1.000, 389, 389, STRUCTURE OF BACE BOUND TO SCH745966
16, 2qmfB, 0.9971, 0.39, 1.000, 389, 389, STRUCTURE OF BACE BOUND TO SCH735310
17, 2qmdB, 0.9971, 0.40, 1.000, 389, 389, STRUCTURE OF BACE BOUND TO SCH722924
18, 3cibB, 0.9970, 0.40, 1.000, 389, 389, STRUCTURE OF BACE BOUND TO SCH727596
19, 2qk5B, 0.9970, 0.41, 1.000, 389, 389, STRUCTURE OF BACE1 BOUND TO SCH626485
20, 1m4hB, 0.9970, 0.41, 1.000, 389, 389, CRYSTAL STRUCTURE OF BETA-SECRETASE COMPLEXED WITH INHIBITOR OM00-3
21, 3l58B, 0.9969, 0.41, 1.000, 389, 389, STRUCTURE OF BACE BOUND TO SCH589432
22, 1fknB, 0.9968, 0.42, 1.000, 389, 389, STRUCTURE OF BETA-SECRETASE COMPLEXED WITH INHIBITOR
23, 3lpiB, 0.9967, 0.42, 1.000, 389, 389, STRUCTURE OF BACE BOUND TO SCH745132
24, 3lpkB, 0.9966, 0.43, 1.000, 389, 389, STRUCTURE OF BACE BOUND TO SCH747123
25, 6bfeB, 0.9963, 0.45, 1.000, 389, 389, BACE CRYSTAL STRUCTURE WITH HYDROXY PYRROLIDINE INHIBITOR
26, 1m4hA, 0.9963, 0.47, 1.000, 391, 389, CRYSTAL STRUCTURE OF BETA-SECRETASE COMPLEXED WITH INHIBITOR OM00-3
27, 2zhrA, 0.9962, 0.49, 0.997, 390, 389, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH OM99-2 AT PH 5.0
28, 2vkmC, 0.9962, 0.46, 1.000, 389, 389, CRYSTAL STRUCTURE OF GRL-8234 BOUND TO BACE (BETA-SECRETASE)
29, 2qmgA, 0.9961, 0.49, 1.000, 390, 389, STRUCTURE OF BACE BOUND TO SCH745966
30, 2qmfA, 0.9961, 0.48, 1.000, 390, 389, STRUCTURE OF BACE BOUND TO SCH735310
31, 2qmdA, 0.9961, 0.49, 1.000, 390, 389, STRUCTURE OF BACE BOUND TO SCH722924
32, 3lpjA, 0.9960, 0.49, 1.000, 390, 389, STRUCTURE OF BACE BOUND TO SCH743641
33, 3cidA, 0.9960, 0.49, 1.000, 390, 389, STRUCTURE OF BACE BOUND TO SCH726222
34, 3cicA, 0.9960, 0.49, 1.000, 390, 389, STRUCTURE OF BACE BOUND TO SCH709583
35, 2qp8A, 0.9960, 0.49, 1.000, 390, 389, STRUCTURE OF BACE BOUND TO SCH734723
36, 6bfdB, 0.9958, 0.48, 1.000, 389, 389, BACE CRYSTAL STRUCTURE WITH HYDROXY PYRROLIDINE INHIBITOR
37, 3l58A, 0.9958, 0.50, 1.000, 395, 389, STRUCTURE OF BACE BOUND TO SCH589432
38, 3cibA, 0.9958, 0.50, 1.000, 390, 389, STRUCTURE OF BACE BOUND TO SCH727596
39, 2vkmD, 0.9958, 0.47, 1.000, 389, 389, CRYSTAL STRUCTURE OF GRL-8234 BOUND TO BACE (BETA-SECRETASE)
40, 2qk5A, 0.9958, 0.50, 1.000, 395, 389, STRUCTURE OF BACE1 BOUND TO SCH626485
41, 3l5fB, 0.9957, 0.49, 1.000, 389, 389, STRUCTURE OF BACE BOUND TO SCH736201
42, 3kmxB, 0.9957, 0.49, 1.000, 389, 389, STRUCTURE OF BACE BOUND TO SCH346572
43, 1xs7D, 0.9957, 0.49, 1.000, 389, 389, CRYSTAL STRUCTURE OF A CYCLOAMIDE-URETHANE-DERIVED NOVEL INHIBITOR BOUND TO HUMAN BRAIN MEMAPSIN 2 (BETA-SECRETASE).
44, 3kn0B, 0.9956, 0.50, 1.000, 389, 389, STRUCTURE OF BACE BOUND TO SCH708236
45, 4h3fB, 0.9955, 0.50, 1.000, 389, 389, STRUCTURE OF BACE BOUND TO 3-(5-((7AR)-2-IMINO-6-(6-METHOXYPYRIDIN-2- YL)-3-METHYL-4-OXOOCTAHYDRO-1H-PYRROLO[34-D]PYRIMIDIN-7A-YL) THIOPHEN-3-YL)BENZONITRILE
46, 3lpiA, 0.9955, 0.52, 1.000, 390, 389, STRUCTURE OF BACE BOUND TO SCH745132
47, 1fknA, 0.9955, 0.53, 1.000, 391, 389, STRUCTURE OF BETA-SECRETASE COMPLEXED WITH INHIBITOR
48, 3lpkA, 0.9954, 0.53, 1.000, 390, 389, STRUCTURE OF BACE BOUND TO SCH747123
49, 1xn3A, 0.9954, 0.52, 1.000, 389, 389, CRYSTAL STRUCTURE OF BETA-SECRETASE BOUND TO A LONG INHIBITOR WITH ADDITIONAL UPSTREAM RESIDUES.
50, 6bfeA, 0.9953, 0.54, 1.000, 393, 389, BACE CRYSTAL STRUCTURE WITH HYDROXY PYRROLIDINE INHIBITOR
51, 5mbwA, 0.9952, 0.52, 1.000, 390, 389, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH PEP#3
52, 4djyB, 0.9952, 0.53, 1.000, 389, 389, STRUCTURE OF BACE BOUND TO (R)-5-CYCLOPROPYL-2-IMINO-3-METHYL-5-(3-(5- (PROP-1-YN-1-YL)PYRIDIN-3-YL)PHENYL)IMIDAZOLIDIN-4-ONE
53, 3kmyB, 0.9952, 0.52, 1.000, 389, 389, STRUCTURE OF BACE BOUND TO SCH12472
54, 2p4jB, 0.9952, 0.56, 1.000, 389, 389, CRYSTAL STRUCTURE OF BETA-SECRETASE BOND TO AN INHIBITOR WITH ISOPHTHALAMIDE DERIVATIVES AT P2-P3
55, 2p4jC, 0.9951, 0.57, 1.000, 389, 389, CRYSTAL STRUCTURE OF BETA-SECRETASE BOND TO AN INHIBITOR WITH ISOPHTHALAMIDE DERIVATIVES AT P2-P3
56, 2p4jA, 0.9951, 0.57, 1.000, 389, 389, CRYSTAL STRUCTURE OF BETA-SECRETASE BOND TO AN INHIBITOR WITH ISOPHTHALAMIDE DERIVATIVES AT P2-P3
57, 1xn3B, 0.9951, 0.55, 1.000, 389, 389, CRYSTAL STRUCTURE OF BETA-SECRETASE BOUND TO A LONG INHIBITOR WITH ADDITIONAL UPSTREAM RESIDUES.
58, 6bfwA, 0.9950, 0.55, 1.000, 393, 389, BACE CRYSTAL STRUCTURE WITH HYDROXY MORPHOLINE INHIBITOR
59, 6bfdA, 0.9950, 0.55, 1.000, 393, 389, BACE CRYSTAL STRUCTURE WITH HYDROXY PYRROLIDINE INHIBITOR
60, 4djxB, 0.9950, 0.53, 1.000, 389, 389, STRUCTURE OF BACE BOUND TO 5-(3-(5-CHLOROPYRIDIN-3-YL)PHENYL)-5- CYCLOPROPYL-2-IMINO-3-METHYLIMIDAZOLIDIN-4-ONE
61, 4zspB, 0.9949, 0.53, 1.000, 389, 389, BACE CRYSTAL STRUCTURE WITH BICYCLIC AMINOTHIAZINE INHIBITOR
62, 4h3jB, 0.9948, 0.54, 1.000, 389, 389, STRUCTURE OF BACE BOUND TO 2-FLUORO-5-(5-(2-IMINO-3-METHYL-4-OXO-6- PHENYLOCTAHYDRO-1H-PYRROLO[34-D]PYRIMIDIN-7A-YL)THIOPHEN-2-YL) BENZONITRILE
63, 1sgzA, 0.9948, 0.55, 1.000, 389, 389, CRYSTAL STRUCTURE OF UNBOUND BETA-SECRETASE CATALYTIC DOMAIN.
64, 2vkmB, 0.9947, 0.59, 1.000, 389, 389, CRYSTAL STRUCTURE OF GRL-8234 BOUND TO BACE (BETA-SECRETASE)
65, 1sgzD, 0.9947, 0.57, 1.000, 389, 389, CRYSTAL STRUCTURE OF UNBOUND BETA-SECRETASE CATALYTIC DOMAIN.
66, 4h3iB, 0.9946, 0.55, 1.000, 389, 389, STRUCTURE OF BACE BOUND TO 3-(5-((7AR)-2-IMINO-6-(3-METHOXYPYRIDIN-2- YL)-3-METHYL-4-OXOOCTAHYDRO-1H-PYRROLO[34-D]PYRIMIDIN-7A-YL) THIOPHEN-3-YL)BENZONITRILE
67, 6bfxA, 0.9945, 0.57, 1.000, 389, 389, BACE CRYSTAL STRUCTURE WITH HYDROXY PYRROLIDINE INHIBITOR
68, 5hu0B, 0.9945, 0.56, 1.000, 389, 389, BACE1 IN COMPLEX WITH 4-(3-(FURAN-2-CARBOXAMIDO)PHENYL)-1-METHYL-5- OXO-4-PHENYLIMIDAZOLIDIN-2-IMINIUM
69, 4h3gB, 0.9945, 0.55, 1.000, 389, 389, STRUCTURE OF BACE BOUND TO 2-((7AR)-7A-(4-(3-CYANOPHENYL)THIOPHEN-2- YL)-2-IMINO-3-METHYL-4-OXOHEXAHYDRO-1H-PYRROLO[34-D]PYRIMIDIN-6(2H)- YL)NICOTINONITRILE
70, 1sgzB, 0.9943, 0.58, 1.000, 389, 389, CRYSTAL STRUCTURE OF UNBOUND BETA-SECRETASE CATALYTIC DOMAIN.
71, 2vkmA, 0.9942, 0.61, 1.000, 389, 389, CRYSTAL STRUCTURE OF GRL-8234 BOUND TO BACE (BETA-SECRETASE)
72, 1sgzC, 0.9942, 0.58, 1.000, 389, 389, CRYSTAL STRUCTURE OF UNBOUND BETA-SECRETASE CATALYTIC DOMAIN.
73, 5hu0A, 0.9941, 0.58, 1.000, 390, 389, BACE1 IN COMPLEX WITH 4-(3-(FURAN-2-CARBOXAMIDO)PHENYL)-1-METHYL-5- OXO-4-PHENYLIMIDAZOLIDIN-2-IMINIUM
74, 4zsqB, 0.9941, 0.58, 1.000, 389, 389, BACE CRYSTAL STRUCTURE WITH TRICYCLIC AMINOTHIAZINE INHIBITOR
75, 4zsqA, 0.9941, 0.58, 1.000, 389, 389, BACE CRYSTAL STRUCTURE WITH TRICYCLIC AMINOTHIAZINE INHIBITOR
76, 4zspA, 0.9941, 0.57, 1.000, 390, 389, BACE CRYSTAL STRUCTURE WITH BICYCLIC AMINOTHIAZINE INHIBITOR
77, 4djuB, 0.9941, 0.60, 1.000, 389, 389, STRUCTURE OF BACE BOUND TO 2-IMINO-3-METHYL-55-DIPHENYLIMIDAZOLIDIN- 4-ONE
78, 3kmxA, 0.9940, 0.61, 1.000, 395, 389, STRUCTURE OF BACE BOUND TO SCH346572
79, 2p4jD, 0.9940, 0.62, 1.000, 389, 389, CRYSTAL STRUCTURE OF BETA-SECRETASE BOND TO AN INHIBITOR WITH ISOPHTHALAMIDE DERIVATIVES AT P2-P3
80, 3l5fA, 0.9939, 0.60, 1.000, 390, 389, STRUCTURE OF BACE BOUND TO SCH736201
81, 3kmyA, 0.9937, 0.62, 1.000, 395, 389, STRUCTURE OF BACE BOUND TO SCH12472
82, 3l5eA, 0.9936, 0.62, 1.000, 390, 389, STRUCTURE OF BACE BOUND TO SCH736062
83, 3l59B, 0.9935, 0.64, 1.000, 389, 389, STRUCTURE OF BACE BOUND TO SCH710413
84, 3l5dB, 0.9934, 0.65, 1.000, 389, 389, STRUCTURE OF BACE BOUND TO SCH723873
85, 4djuA, 0.9933, 0.64, 1.000, 390, 389, STRUCTURE OF BACE BOUND TO 2-IMINO-3-METHYL-55-DIPHENYLIMIDAZOLIDIN- 4-ONE
86, 6bfxB, 0.9932, 0.47, 1.000, 388, 388, BACE CRYSTAL STRUCTURE WITH HYDROXY PYRROLIDINE INHIBITOR
87, 4zsmA, 0.9932, 0.62, 1.000, 389, 389, BACE CRYSTAL STRUCTURE WITH BICYCLIC AMINOTHIAZINE FRAGMENT
88, 4fs4A, 0.9932, 0.64, 1.000, 390, 389, STRUCTURE OF BACE BOUND TO (S)-4-(3 -METHOXY-[11 -BIPHENYL]-3-YL)-1 4-DIMETHYL-6-OXOTETRAHYDROPYRIMIDIN-2(1H)-IMINIUM
89, 4djyA, 0.9932, 0.64, 1.000, 390, 389, STRUCTURE OF BACE BOUND TO (R)-5-CYCLOPROPYL-2-IMINO-3-METHYL-5-(3-(5- (PROP-1-YN-1-YL)PYRIDIN-3-YL)PHENYL)IMIDAZOLIDIN-4-ONE
90, 4h3fA, 0.9931, 0.64, 1.000, 390, 389, STRUCTURE OF BACE BOUND TO 3-(5-((7AR)-2-IMINO-6-(6-METHOXYPYRIDIN-2- YL)-3-METHYL-4-OXOOCTAHYDRO-1H-PYRROLO[34-D]PYRIMIDIN-7A-YL) THIOPHEN-3-YL)BENZONITRILE
91, 4djxA, 0.9931, 0.64, 1.000, 390, 389, STRUCTURE OF BACE BOUND TO 5-(3-(5-CHLOROPYRIDIN-3-YL)PHENYL)-5- CYCLOPROPYL-2-IMINO-3-METHYLIMIDAZOLIDIN-4-ONE
92, 5htzB, 0.9930, 0.50, 1.000, 389, 388, BACE1 IN COMPLEX WITH (S)-5-(3-CHLORO-5-(5-(PROP-1-YN-1-YL)PYRIDIN-3- YL)THIOPHEN-2-YL)-25-DIMETHYL-124-THIADIAZINAN-3-IMINIUM 11- DIOXIDE
93, 4djwA, 0.9930, 0.65, 1.000, 390, 389, STRUCTURE OF BACE BOUND TO 2-IMINO-3-METHYL-5-PHENYL-5-(3-(PYRIDIN-3- YL)PHENYL)IMIDAZOLIDIN-4-ONE
94, 3l59A, 0.9929, 0.66, 1.000, 390, 389, STRUCTURE OF BACE BOUND TO SCH710413
95, 4zsrB, 0.9926, 0.70, 1.000, 389, 389, BACE CRYSTAL STRUCTURE WITH TRICYCLIC AMINOTHIAZINE INHIBITOR
96, 4djwB, 0.9926, 0.73, 1.000, 389, 389, STRUCTURE OF BACE BOUND TO 2-IMINO-3-METHYL-5-PHENYL-5-(3-(PYRIDIN-3- YL)PHENYL)IMIDAZOLIDIN-4-ONE
97, 4zsrA, 0.9924, 0.69, 1.000, 390, 389, BACE CRYSTAL STRUCTURE WITH TRICYCLIC AMINOTHIAZINE INHIBITOR
98, 4h3gA, 0.9924, 0.67, 1.000, 390, 389, STRUCTURE OF BACE BOUND TO 2-((7AR)-7A-(4-(3-CYANOPHENYL)THIOPHEN-2- YL)-2-IMINO-3-METHYL-4-OXOHEXAHYDRO-1H-PYRROLO[34-D]PYRIMIDIN-6(2H)- YL)NICOTINONITRILE
99, 4djvB, 0.9924, 0.73, 1.000, 389, 389, STRUCTURE OF BACE BOUND TO 2-IMINO-5-(3 -METHOXY-[11 -BIPHENYL]-3- YL)-3-METHYL-5-PHENYLIMIDAZOLIDIN-4-ONE
100, 4djvA, 0.9924, 0.70, 1.000, 390, 389, STRUCTURE OF BACE BOUND TO 2-IMINO-5-(3 -METHOXY-[11 -BIPHENYL]-3- YL)-3-METHYL-5-PHENYLIMIDAZOLIDIN-4-ONE
101, 4fs4B, 0.9922, 0.76, 1.000, 389, 389, STRUCTURE OF BACE BOUND TO (S)-4-(3 -METHOXY-[11 -BIPHENYL]-3-YL)-1 4-DIMETHYL-6-OXOTETRAHYDROPYRIMIDIN-2(1H)-IMINIUM
102, 4h3jA, 0.9921, 0.70, 1.000, 390, 389, STRUCTURE OF BACE BOUND TO 2-FLUORO-5-(5-(2-IMINO-3-METHYL-4-OXO-6- PHENYLOCTAHYDRO-1H-PYRROLO[34-D]PYRIMIDIN-7A-YL)THIOPHEN-2-YL) BENZONITRILE
103, 3ohhB, 0.9921, 0.38, 1.000, 387, 387, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH BMS-681889 AKA N~1~-BUTYL-5-CYANO- N~3~-((1S2R)-1-(35- DIFLUOROBENZYL)-2-HYDROXY-3-((3- METHOXYBENZYL)AMINO)PROPYL)-N~1~- METHYL-1H-INDOLE-13- DICARBOXAMIDE
104, 4ha5A, 0.9920, 0.68, 1.000, 390, 389, STRUCTURE OF BACE BOUND TO (S)-3-(5-(2-IMINO-14-DIMETHYL-6- OXOHEXAHYDROPYRIMIDIN-4-YL)THIOPHEN-3-YL)BENZONITRILE
105, 4ybiB, 0.9919, 0.56, 1.000, 388, 388, CRYSTAL STRUCTURE OF BACE WITH AMINO THIAZINE INHIBITOR LY2811376
106, 4ybiA, 0.9919, 0.56, 1.000, 388, 388, CRYSTAL STRUCTURE OF BACE WITH AMINO THIAZINE INHIBITOR LY2811376
107, 4gidC, 0.9916, 0.59, 1.000, 388, 388, STRUCTURE OF BETA-SECRETASE COMPLEXED WITH INHIBITOR
108, 3ohhA, 0.9913, 0.44, 1.000, 387, 387, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH BMS-681889 AKA N~1~-BUTYL-5-CYANO- N~3~-((1S2R)-1-(35- DIFLUOROBENZYL)-2-HYDROXY-3-((3- METHOXYBENZYL)AMINO)PROPYL)-N~1~- METHYL-1H-INDOLE-13- DICARBOXAMIDE
109, 6bfwB, 0.9910, 0.46, 1.000, 387, 387, BACE CRYSTAL STRUCTURE WITH HYDROXY MORPHOLINE INHIBITOR
110, 4fseD, 0.9909, 0.47, 1.000, 387, 387, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH N-(N-(4-AMINO-35- DICHLOROBENZYL)CARBAMIMIDOYL)-3-(4- METHOXYPHENYL)-5- METHYL-4-ISOTHIAZOLECARBOXAMIDE
111, 4fseB, 0.9909, 0.47, 1.000, 387, 387, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH N-(N-(4-AMINO-35- DICHLOROBENZYL)CARBAMIMIDOYL)-3-(4- METHOXYPHENYL)-5- METHYL-4-ISOTHIAZOLECARBOXAMIDE
112, 4fseA, 0.9909, 0.47, 1.000, 387, 387, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH N-(N-(4-AMINO-35- DICHLOROBENZYL)CARBAMIMIDOYL)-3-(4- METHOXYPHENYL)-5- METHYL-4-ISOTHIAZOLECARBOXAMIDE
113, 4trwC, 0.9908, 0.73, 1.000, 390, 389, STRUCTURE OF BACE1 COMPLEX WITH A SYN-HEA-TYPE INHIBITOR
114, 4fseE, 0.9908, 0.47, 1.000, 387, 387, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH N-(N-(4-AMINO-35- DICHLOROBENZYL)CARBAMIMIDOYL)-3-(4- METHOXYPHENYL)-5- METHYL-4-ISOTHIAZOLECARBOXAMIDE
115, 3l5cB, 0.9907, 0.49, 0.997, 387, 387, STRUCTURE OF BACE BOUND TO SCH723871
116, 4x7iB, 0.9905, 0.64, 1.000, 388, 388, CRYSTAL STRUCTURE OF BACE WITH AMINO THIAZINE INHIBITOR LY2886721
117, 4fslB, 0.9904, 0.49, 1.000, 387, 387, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-DB-MUT) COMPLEX WITH N-(N-(4- ACETAMIDO-3-CHLORO-5-METHYLBENZYL) CARBAMIMIDOYL)-3-(4- METHOXYPHENYL)-5-METHYL-4-ISOTHIAZOLECARBOXAMIDE
118, 4fslE, 0.9900, 0.51, 1.000, 387, 387, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-DB-MUT) COMPLEX WITH N-(N-(4- ACETAMIDO-3-CHLORO-5-METHYLBENZYL) CARBAMIMIDOYL)-3-(4- METHOXYPHENYL)-5-METHYL-4-ISOTHIAZOLECARBOXAMIDE
119, 4fslA, 0.9900, 0.51, 1.000, 387, 387, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-DB-MUT) COMPLEX WITH N-(N-(4- ACETAMIDO-3-CHLORO-5-METHYLBENZYL) CARBAMIMIDOYL)-3-(4- METHOXYPHENYL)-5-METHYL-4-ISOTHIAZOLECARBOXAMIDE
120, 4fslD, 0.9899, 0.52, 1.000, 387, 387, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-DB-MUT) COMPLEX WITH N-(N-(4- ACETAMIDO-3-CHLORO-5-METHYLBENZYL) CARBAMIMIDOYL)-3-(4- METHOXYPHENYL)-5-METHYL-4-ISOTHIAZOLECARBOXAMIDE
121, 3ohfA, 0.9898, 0.56, 1.000, 387, 387, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH BMS-655295 AKA N~3~-((1S2R)-1- BENZYL-2-HYDROXY-3-((3- METHOXYBENZYL)AMINO)PROPYL)-N~1~ N~1~-DIBUTYL-1H-INDOLE-13- DICARBOXAMIDE
122, 3lnkB, 0.9897, 0.37, 1.000, 387, 386, STRUCTURE OF BACE BOUND TO SCH743813
123, 3skfB, 0.9894, 0.56, 1.000, 387, 387, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH (2S)-2-((3S)-3-(ACETYLAMINO)-3-(BUTAN-2-YL)-2-OXOPYRROLIDIN-1- YL)-N-((2S3R)-3-HYDROXY-4-((3-METHOXYBENZYL)AMINO)-1-PHENYLBUTAN-2- YL)-4-PHENYLBUTANAMIDE
124, 3skfA, 0.9894, 0.56, 1.000, 387, 387, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH (2S)-2-((3S)-3-(ACETYLAMINO)-3-(BUTAN-2-YL)-2-OXOPYRROLIDIN-1- YL)-N-((2S3R)-3-HYDROXY-4-((3-METHOXYBENZYL)AMINO)-1-PHENYLBUTAN-2- YL)-4-PHENYLBUTANAMIDE
125, 4x7iA, 0.9891, 0.73, 1.000, 389, 388, CRYSTAL STRUCTURE OF BACE WITH AMINO THIAZINE INHIBITOR LY2886721
126, 4r91B, 0.9890, 0.42, 1.000, 386, 386, BACE-1 IN COMPLEX WITH (R)-4-(2-CYCLOHEXYLETHYL)-4-(((1S3R)-3- (CYCLOPENTYLAMINO)CYCLOHEXYL)METHYL)-1-METHYL-5-OXOIMIDAZOLIDIN-2- IMINIUM
127, 4r93B, 0.9888, 0.43, 1.000, 386, 386, BACE-1 IN COMPLEX WITH (R)-4-(2-CYCLOHEXYLETHYL)-1-METHYL-5-OXO-4- (((1S3R)-3-(3-PHENYLUREIDO)CYCLOHEXYL)METHYL)IMIDAZOLIDIN-2-IMINIUM
128, 5he5B, 0.9887, 0.45, 1.000, 387, 386, BACE-1 IN COMPLEX WITH (7AR)-7A-(5-CYANOTHIOPHEN-2-YL)-6-(5-FLUORO-4- METHYL-6-(METHYLAMINO)PYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H- PYRROLO[34-D]PYRIMIDIN-2-IMINIUM
129, 5hdxB, 0.9887, 0.45, 1.000, 386, 386, BACE-1 IN COMPLEX WITH (7AR)-7A-(5-CYANOTHIOPHEN-2-YL)-6-(4-ETHOXY-5- FLUORO-6-METHYLPYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H-PYRROLO[3 4-D]PYRIMIDIN-2-IMINIUM
130, 4zsmB, 0.9887, 0.59, 1.000, 387, 387, BACE CRYSTAL STRUCTURE WITH BICYCLIC AMINOTHIAZINE FRAGMENT
131, 4r95A, 0.9887, 0.44, 1.000, 387, 386, BACE-1 IN COMPLEX WITH 2-(((1R3S)-3-(((R)-4-(2-CYCLOHEXYLETHYL)-2- IMINIO-1-METHYL-5-OXOIMIDAZOLIDIN-4-YL)METHYL)CYCLOHEXYL)AMINO) QUINOLIN-1-IUM
132, 4r91A, 0.9887, 0.44, 1.000, 387, 386, BACE-1 IN COMPLEX WITH (R)-4-(2-CYCLOHEXYLETHYL)-4-(((1S3R)-3- (CYCLOPENTYLAMINO)CYCLOHEXYL)METHYL)-1-METHYL-5-OXOIMIDAZOLIDIN-2- IMINIUM
133, 4gidA, 0.9887, 0.62, 1.000, 387, 387, STRUCTURE OF BETA-SECRETASE COMPLEXED WITH INHIBITOR
134, 3ohfB, 0.9887, 0.61, 1.000, 387, 387, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH BMS-655295 AKA N~3~-((1S2R)-1- BENZYL-2-HYDROXY-3-((3- METHOXYBENZYL)AMINO)PROPYL)-N~1~ N~1~-DIBUTYL-1H-INDOLE-13- DICARBOXAMIDE
135, 5he7B, 0.9886, 0.45, 1.000, 387, 386, BACE-1 IN COMPLEX WITH (4AR7AS)-7A-(24-DIFLUOROPHENYL)-6-(5-FLUORO- 4-METHOXY-6-METHYLPYRIMIDIN-2-YL)-2-IMINO-3-METHYLOCTAHYDRO-4H- PYRROLO[34-D]PYRIMIDIN-4-ONE
136, 5hduB, 0.9886, 0.45, 1.000, 387, 386, BACE-1 INCOMPLEX WITH (7AR)-7A-(4-(3-CYANOPHENYL)THIOPHEN-2-YL)-6-(5- FLUORO-4-METHOXYPYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H-PYRROLO[3 4-D]PYRIMIDIN-2-IMINIUM
137, 4r95B, 0.9886, 0.45, 1.000, 386, 386, BACE-1 IN COMPLEX WITH 2-(((1R3S)-3-(((R)-4-(2-CYCLOHEXYLETHYL)-2- IMINIO-1-METHYL-5-OXOIMIDAZOLIDIN-4-YL)METHYL)CYCLOHEXYL)AMINO) QUINOLIN-1-IUM
138, 4r93A, 0.9886, 0.45, 1.000, 386, 386, BACE-1 IN COMPLEX WITH (R)-4-(2-CYCLOHEXYLETHYL)-1-METHYL-5-OXO-4- (((1S3R)-3-(3-PHENYLUREIDO)CYCLOHEXYL)METHYL)IMIDAZOLIDIN-2-IMINIUM
139, 4frsB, 0.9886, 0.45, 1.000, 387, 386, STRUCTURE OF BACE IN COMPLEX WITH (S)-4-(3-CHLORO-5-(5-(PROP-1-YN-1- YL)PYRIDIN-3-YL)THIOPHEN-2-YL)-14-DIMETHYL-6-OXOTETRAHYDROPYRIMIDIN- 2(1H)-IMINIUM
140, 5he4B, 0.9885, 0.46, 1.000, 387, 386, BACE-1 IN COMPLEX WITH (4AR7AS)-7A-(26-DIFLUOROPHENYL)-6-(5-FLUORO- 4-METHOXY-6-METHYLPYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H- PYRROLO[34-D]PYRIMIDIN-2-IMINIUM
141, 5hdzB, 0.9885, 0.46, 1.000, 386, 386, BACE-1 IN COMPLEX WITH (7AR)-7A-(5-CYANOTHIOPHEN-2-YL)-6-(5-FLUORO-4- METHYL-6-(METHYLTHIO)PYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H- PYRROLO[34-D]PYRIMIDIN-2-IMINIUM
142, 5hdvB, 0.9885, 0.46, 1.000, 387, 386, BACE-1 INCOMPLEX WITH (7AR)-7A-(5-CYANOTHIOPHEN-2-YL)-6-(5-FLUORO-4- METHOXY-6-METHYLPYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H-PYRROLO[3 4-D]PYRIMIDIN-2-IMINIUM
143, 5hu1B, 0.9884, 0.46, 1.000, 386, 386, BACE1 IN COMPLEX WITH (R)-N-(3-(3-AMINO-25-DIMETHYL-11-DIOXIDO-56- DIHYDRO-2H-124-THIADIAZIN-5-YL)-4-FLUOROPHENYL)-5- FLUOROPICOLINAMIDE
144, 4ha5B, 0.9884, 0.46, 1.000, 386, 386, STRUCTURE OF BACE BOUND TO (S)-3-(5-(2-IMINO-14-DIMETHYL-6- OXOHEXAHYDROPYRIMIDIN-4-YL)THIOPHEN-3-YL)BENZONITRILE
145, 3lnkA, 0.9884, 0.48, 1.000, 387, 386, STRUCTURE OF BACE BOUND TO SCH743813
146, 3l5eB, 0.9884, 0.47, 1.000, 386, 386, STRUCTURE OF BACE BOUND TO SCH736062
147, 4trwA, 0.9883, 0.74, 1.000, 389, 388, STRUCTURE OF BACE1 COMPLEX WITH A SYN-HEA-TYPE INHIBITOR
148, 4h1eB, 0.9883, 0.46, 1.000, 387, 386, STRUCTURE OF BACE-1 BOUND TO (7AR)-6-BENZOYL-7A-(4-(3-CYANOPHENYL) THIOPHEN-2-YL)-3-METHYL-4-OXOHEXAHYDRO-1H-PYRROLO[34-D]PYRIMIDIN- 2(3H)-IMINIUM
149, 4gidB, 0.9883, 0.63, 1.000, 387, 387, STRUCTURE OF BETA-SECRETASE COMPLEXED WITH INHIBITOR
150, 3r2fD, 0.9883, 0.47, 1.000, 386, 386, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH BMS-693391 AKA (2S)-2-((3R)-3-ACETAMIDO-3-ISOBUTYL-2-OXO-1- PYRROLIDINYL)-N-((1S2R)-1-(35-DIFLUOROBENZYL)-2-HYDROXY-2-((2R4R)- 4-PROPOXY-2-PYRROLIDINYL)ETHYL)-4-PHENYLBUTANAMIDE
151, 3r2fB, 0.9883, 0.48, 1.000, 386, 386, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH BMS-693391 AKA (2S)-2-((3R)-3-ACETAMIDO-3-ISOBUTYL-2-OXO-1- PYRROLIDINYL)-N-((1S2R)-1-(35-DIFLUOROBENZYL)-2-HYDROXY-2-((2R4R)- 4-PROPOXY-2-PYRROLIDINYL)ETHYL)-4-PHENYLBUTANAMIDE
152, 5mxdA, 0.9882, 0.82, 1.000, 390, 389, BACE-1 IN COMPLEX WITH LIGAND 32397778
153, 4r8yB, 0.9882, 0.48, 1.000, 387, 386, BACE-1 IN COMPLEX WITH (R)-4-(2-CYCLOHEXYLETHYL)-4-(((R)-1-(2- CYCLOPENTYLACETYL)PYRROLIDIN-3-YL)METHYL)-1-METHYL-5-OXOIMIDAZOLIDIN- 2-IMINIUM
154, 4gidD, 0.9882, 0.63, 1.000, 387, 387, STRUCTURE OF BETA-SECRETASE COMPLEXED WITH INHIBITOR
155, 3r2fE, 0.9882, 0.48, 1.000, 386, 386, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH BMS-693391 AKA (2S)-2-((3R)-3-ACETAMIDO-3-ISOBUTYL-2-OXO-1- PYRROLIDINYL)-N-((1S2R)-1-(35-DIFLUOROBENZYL)-2-HYDROXY-2-((2R4R)- 4-PROPOXY-2-PYRROLIDINYL)ETHYL)-4-PHENYLBUTANAMIDE
156, 3r2fA, 0.9882, 0.48, 1.000, 386, 386, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH BMS-693391 AKA (2S)-2-((3R)-3-ACETAMIDO-3-ISOBUTYL-2-OXO-1- PYRROLIDINYL)-N-((1S2R)-1-(35-DIFLUOROBENZYL)-2-HYDROXY-2-((2R4R)- 4-PROPOXY-2-PYRROLIDINYL)ETHYL)-4-PHENYLBUTANAMIDE
157, 4r92B, 0.9881, 0.48, 1.000, 386, 386, BACE-1 IN COMPLEX WITH (R)-4-(2-CYCLOHEXYLETHYL)-4-(((1S3R)-3- (ISONICOTINAMIDO)CYCLOHEXYL)METHYL)-1-METHYL-5-OXOIMIDAZOLIDIN-2- IMINIUM
158, 3l5bB, 0.9881, 0.49, 1.000, 386, 386, STRUCTURE OF BACE BOUND TO SCH713601
159, 4r8yA, 0.9880, 0.49, 1.000, 387, 386, BACE-1 IN COMPLEX WITH (R)-4-(2-CYCLOHEXYLETHYL)-4-(((R)-1-(2- CYCLOPENTYLACETYL)PYRROLIDIN-3-YL)METHYL)-1-METHYL-5-OXOIMIDAZOLIDIN- 2-IMINIUM
160, 2zhrB, 0.9880, 0.30, 1.000, 385, 385, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH OM99-2 AT PH 5.0
161, 4frsA, 0.9879, 0.49, 1.000, 386, 386, STRUCTURE OF BACE IN COMPLEX WITH (S)-4-(3-CHLORO-5-(5-(PROP-1-YN-1- YL)PYRIDIN-3-YL)THIOPHEN-2-YL)-14-DIMETHYL-6-OXOTETRAHYDROPYRIMIDIN- 2(1H)-IMINIUM
162, 5he4A, 0.9878, 0.50, 1.000, 387, 386, BACE-1 IN COMPLEX WITH (4AR7AS)-7A-(26-DIFLUOROPHENYL)-6-(5-FLUORO- 4-METHOXY-6-METHYLPYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H- PYRROLO[34-D]PYRIMIDIN-2-IMINIUM
163, 5hdxA, 0.9878, 0.50, 1.000, 387, 386, BACE-1 IN COMPLEX WITH (7AR)-7A-(5-CYANOTHIOPHEN-2-YL)-6-(4-ETHOXY-5- FLUORO-6-METHYLPYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H-PYRROLO[3 4-D]PYRIMIDIN-2-IMINIUM
164, 5he5A, 0.9877, 0.50, 1.000, 387, 386, BACE-1 IN COMPLEX WITH (7AR)-7A-(5-CYANOTHIOPHEN-2-YL)-6-(5-FLUORO-4- METHYL-6-(METHYLAMINO)PYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H- PYRROLO[34-D]PYRIMIDIN-2-IMINIUM
165, 5hd0B, 0.9877, 0.50, 1.000, 387, 386, BACE-1 IN COMPLEX WITH (7AR)-7A-(4-(3-CYANOPHENYL)THIOPHEN-2-YL)-6-(5- FLUOROPYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H-PYRROLO[34- D]PYRIMIDIN-2-IMINIUM
166, 4h1eA, 0.9877, 0.50, 1.000, 386, 386, STRUCTURE OF BACE-1 BOUND TO (7AR)-6-BENZOYL-7A-(4-(3-CYANOPHENYL) THIOPHEN-2-YL)-3-METHYL-4-OXOHEXAHYDRO-1H-PYRROLO[34-D]PYRIMIDIN- 2(3H)-IMINIUM
167, 5hdzA, 0.9876, 0.51, 1.000, 387, 386, BACE-1 IN COMPLEX WITH (7AR)-7A-(5-CYANOTHIOPHEN-2-YL)-6-(5-FLUORO-4- METHYL-6-(METHYLTHIO)PYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H- PYRROLO[34-D]PYRIMIDIN-2-IMINIUM
168, 4r92A, 0.9874, 0.55, 1.000, 388, 386, BACE-1 IN COMPLEX WITH (R)-4-(2-CYCLOHEXYLETHYL)-4-(((1S3R)-3- (ISONICOTINAMIDO)CYCLOHEXYL)METHYL)-1-METHYL-5-OXOIMIDAZOLIDIN-2- IMINIUM
169, 5hu1A, 0.9872, 0.56, 1.000, 388, 386, BACE1 IN COMPLEX WITH (R)-N-(3-(3-AMINO-25-DIMETHYL-11-DIOXIDO-56- DIHYDRO-2H-124-THIADIAZIN-5-YL)-4-FLUOROPHENYL)-5- FLUOROPICOLINAMIDE
170, 3l5cA, 0.9872, 0.55, 1.000, 387, 386, STRUCTURE OF BACE BOUND TO SCH723871
171, 3kn0A, 0.9871, 0.56, 1.000, 387, 386, STRUCTURE OF BACE BOUND TO SCH708236
172, 3skgB, 0.9870, 0.54, 1.000, 386, 386, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH (2S)-2-((3R)-3-ACETAMIDO-3-ISOBUTYL-2-OXO-1-PYRROLIDINYL)-N- ((1S2R)-1-(35-DIFLUOROBENZYL)-2-HYDROXY-2-(1234-TETRAHYDRO-3- ISOQUINOLINYL)ETHYL)-4-PHENYLBUTANAMIDE
173, 3skgA, 0.9869, 0.55, 1.000, 386, 386, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH (2S)-2-((3R)-3-ACETAMIDO-3-ISOBUTYL-2-OXO-1-PYRROLIDINYL)-N- ((1S2R)-1-(35-DIFLUOROBENZYL)-2-HYDROXY-2-(1234-TETRAHYDRO-3- ISOQUINOLINYL)ETHYL)-4-PHENYLBUTANAMIDE
174, 4trzC, 0.9868, 0.67, 1.000, 388, 387, STRUCTURE OF BACE1 COMPLEX WITH 2-THIOPHENYL HEA-TYPE INHIBITOR
175, 3l5bA, 0.9868, 0.58, 1.000, 387, 386, STRUCTURE OF BACE BOUND TO SCH713601
176, 4trzA, 0.9867, 0.66, 1.000, 388, 387, STRUCTURE OF BACE1 COMPLEX WITH 2-THIOPHENYL HEA-TYPE INHIBITOR
177, 5htzA, 0.9866, 0.59, 1.000, 388, 386, BACE1 IN COMPLEX WITH (S)-5-(3-CHLORO-5-(5-(PROP-1-YN-1-YL)PYRIDIN-3- YL)THIOPHEN-2-YL)-25-DIMETHYL-124-THIADIAZINAN-3-IMINIUM 11- DIOXIDE
178, 5hd0A, 0.9865, 0.56, 1.000, 387, 386, BACE-1 IN COMPLEX WITH (7AR)-7A-(4-(3-CYANOPHENYL)THIOPHEN-2-YL)-6-(5- FLUOROPYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H-PYRROLO[34- D]PYRIMIDIN-2-IMINIUM
179, 3skgE, 0.9863, 0.58, 1.000, 386, 386, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH (2S)-2-((3R)-3-ACETAMIDO-3-ISOBUTYL-2-OXO-1-PYRROLIDINYL)-N- ((1S2R)-1-(35-DIFLUOROBENZYL)-2-HYDROXY-2-(1234-TETRAHYDRO-3- ISOQUINOLINYL)ETHYL)-4-PHENYLBUTANAMIDE
180, 3skgD, 0.9863, 0.57, 1.000, 386, 386, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH (2S)-2-((3R)-3-ACETAMIDO-3-ISOBUTYL-2-OXO-1-PYRROLIDINYL)-N- ((1S2R)-1-(35-DIFLUOROBENZYL)-2-HYDROXY-2-(1234-TETRAHYDRO-3- ISOQUINOLINYL)ETHYL)-4-PHENYLBUTANAMIDE
181, 4h3iA, 0.9862, 0.60, 1.000, 387, 386, STRUCTURE OF BACE BOUND TO 3-(5-((7AR)-2-IMINO-6-(3-METHOXYPYRIDIN-2- YL)-3-METHYL-4-OXOOCTAHYDRO-1H-PYRROLO[34-D]PYRIMIDIN-7A-YL) THIOPHEN-3-YL)BENZONITRILE
182, 5hduA, 0.9861, 0.61, 1.000, 387, 386, BACE-1 INCOMPLEX WITH (7AR)-7A-(4-(3-CYANOPHENYL)THIOPHEN-2-YL)-6-(5- FLUORO-4-METHOXYPYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H-PYRROLO[3 4-D]PYRIMIDIN-2-IMINIUM
183, 4trwB, 0.9852, 0.85, 1.000, 389, 388, STRUCTURE OF BACE1 COMPLEX WITH A SYN-HEA-TYPE INHIBITOR
184, 4tryA, 0.9849, 0.76, 1.000, 387, 387, STRUCTURE OF BACE1 COMPLEX WITH A HEA-TYPE INHIBITOR
185, 2q11B, 0.9849, 0.89, 0.990, 388, 388, STRUCTURE OF BACE COMPLEXED TO COMPOUND 1
186, 3l5dA, 0.9847, 0.55, 1.000, 386, 385, STRUCTURE OF BACE BOUND TO SCH723873
187, 4tryB, 0.9839, 0.79, 1.000, 388, 387, STRUCTURE OF BACE1 COMPLEX WITH A HEA-TYPE INHIBITOR
188, 5he7A, 0.9834, 0.45, 1.000, 385, 384, BACE-1 IN COMPLEX WITH (4AR7AS)-7A-(24-DIFLUOROPHENYL)-6-(5-FLUORO- 4-METHOXY-6-METHYLPYRIMIDIN-2-YL)-2-IMINO-3-METHYLOCTAHYDRO-4H- PYRROLO[34-D]PYRIMIDIN-4-ONE
189, 4trzB, 0.9834, 0.80, 1.000, 388, 387, STRUCTURE OF BACE1 COMPLEX WITH 2-THIOPHENYL HEA-TYPE INHIBITOR
190, 2q11C, 0.9827, 0.96, 0.990, 388, 388, STRUCTURE OF BACE COMPLEXED TO COMPOUND 1
191, 2q11A, 0.9827, 0.97, 0.990, 388, 388, STRUCTURE OF BACE COMPLEXED TO COMPOUND 1
192, 5hdvA, 0.9811, 0.43, 1.000, 384, 383, BACE-1 INCOMPLEX WITH (7AR)-7A-(5-CYANOTHIOPHEN-2-YL)-6-(5-FLUORO-4- METHOXY-6-METHYLPYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H-PYRROLO[3 4-D]PYRIMIDIN-2-IMINIUM
193, 4tryC, 0.9793, 1.07, 1.000, 388, 387, STRUCTURE OF BACE1 COMPLEX WITH A HEA-TYPE INHIBITOR
194, 3u6aB, 0.9720, 1.22, 0.990, 386, 385, RATIONAL DESIGN AND SYNTHESIS OF AMINOPIPERAZINONES AS BETA SECRETASE (BACE) INHIBITORS
195, 4lc7A, 0.9718, 1.47, 0.979, 402, 388, AMINOOXAZOLINE INHIBITOR OF BACE-1
196, 4jpeA, 0.9715, 1.49, 0.979, 402, 388, SPIROCYCLIC BETA-SITE AMYLOID PRECURSOR PROTEIN CLEAVING ENZYME 1 (BACE1) INHIBITORS
197, 4jooA, 0.9712, 1.51, 0.979, 402, 388, SPIROCYCLIC BETA-SITE AMYLOID PRECURSOR PROTEIN CLEAVING ENZYME 1 (BACE1) INHIBITORS
198, 2q15A, 0.9711, 1.09, 0.990, 385, 385, STRUCTURE OF BACE COMPLEXED TO COMPOUND 3A
199, 4jpcA, 0.9708, 1.50, 0.979, 402, 388, SPIROCYCLIC BETA-SITE AMYLOID PRECURSOR PROTEIN CLEAVING ENZYME 1 (BACE1) INHIBITORS
200, 4jp9A, 0.9697, 1.53, 0.979, 402, 388, SPIROCYCLIC BETA-SITE AMYLOID PRECURSOR PROTEIN CLEAVING ENZYME 1 (BACE1) INHIBITORS
201, 3u6aC, 0.9696, 1.11, 0.995, 384, 383, RATIONAL DESIGN AND SYNTHESIS OF AMINOPIPERAZINONES AS BETA SECRETASE (BACE) INHIBITORS
202, 5mcqA, 0.9691, 1.69, 1.000, 393, 387, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH ACTIVE SITE AND EXOSITE BINDING PEPTIDE INHIBITOR
203, 4pzxA, 0.9680, 1.39, 0.979, 400, 386, SYNTHESIS CHARACTERIZATION AND PK/PD STUDIES OF A SERIES OF SPIROCYCLIC PYRANOCHROMENE BACE1 INHIBITORS
204, 3qi1A, 0.9661, 1.06, 0.984, 382, 382, DESIGN AND SYNTHESIS OF HYDROXYETHYLAMINE (HEA) BACE-1 INHIBITORS: PRIME SIDE CHROMANE-CONTAINING INHIBITORS
205, 5f01A, 0.9655, 1.20, 0.992, 384, 383, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH (1SR2SR)-2-((R)-2-AMINO- 55-DIFLUORO-4-METHYL-56-DIHYDRO-4H-13-OXAZIN-4-YL)-N-(3- CHLOROQUINOLIN-8-YL)CYCLOPROPANECARBOXAMIDE
206, 1ym4A, 0.9652, 0.80, 0.995, 379, 379, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH NVP-AMK640
207, 3zmgA, 0.9650, 1.21, 0.992, 385, 383, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH CHEMICAL LIGAND
208, 4pzwA, 0.9647, 1.24, 0.984, 397, 383, SYNTHESIS CHARACTERIZATION AND PK/PD STUDIES OF A SERIES OF SPIROCYCLIC PYRANOCHROMENE BACE1 INHIBITORS
209, 3hvgA, 0.9646, 0.68, 0.997, 379, 378, STRUCTURE OF BACE (BETA SECRETASE) IN COMPLEX WITH EV0
210, 1ym4C, 0.9643, 0.81, 0.992, 379, 379, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH NVP-AMK640
211, 6dhcB, 0.9640, 0.85, 0.995, 380, 379, X-RAY STRUCTURE OF BACE1 IN COMPLEX WITH A BICYCLIC ISOXAZOLINE CARBOXAMIDE AS THE P3 LIGAND 
212, 4lxkB, 0.9625, 0.78, 0.995, 378, 378, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH COMPOUND 11D
213, 3dv1B, 0.9625, 0.66, 0.997, 378, 377, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE IN COMPLEX WITH NVP-ARV999
214, 4lxaB, 0.9624, 0.78, 0.995, 378, 378, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH COMPOUND 11A
215, 3udhA, 0.9621, 1.17, 0.984, 394, 381, CRYSTAL STRUCTURE OF BACE WITH COMPOUND 1
216, 3udyA, 0.9615, 1.18, 0.984, 394, 381, CRYSTAL STRUCTURE OF BACE WITH COMPOUND 11
217, 3udmA, 0.9615, 1.19, 0.984, 394, 381, CRYSTAL STRUCTURE OF BACE WITH COMPOUND 8
218, 2f3fB, 0.9615, 0.69, 0.997, 377, 377, CRYSTAL STRUCTURE OF THE BACE COMPLEX WITH BDF488 A MACROCYCLIC INHIBITOR
219, 2f3eC, 0.9615, 1.22, 0.995, 381, 381, CRYSTAL STRUCTURE OF THE BACE COMPLEX WITH AXQ093 A MACROCYCLIC INHIBITOR
220, 3udrA, 0.9614, 1.18, 0.984, 394, 381, CRYSTAL STRUCTURE OF BACE WITH COMPOUND 14
221, 3udqA, 0.9614, 1.18, 0.984, 394, 381, CRYSTAL STRUCTURE OF BACE WITH COMPOUND 13
222, 3pi5C, 0.9613, 1.20, 0.995, 381, 381, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH BFG356
223, 3udpA, 0.9612, 1.18, 0.984, 394, 381, CRYSTAL STRUCTURE OF BACE WITH COMPOUND 12
224, 5mxdC, 0.9611, 0.83, 0.997, 380, 378, BACE-1 IN COMPLEX WITH LIGAND 32397778
225, 4d8cC, 0.9611, 1.22, 0.995, 381, 381, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BXD552 DERIVED FROM A CO-CRYSTALLIZATION EXPERIMENT
226, 4wy1A, 0.9609, 1.21, 0.984, 394, 381, CRYSTAL STRUCTURE OF HUMAN BACE-1 BOUND TO COMPOUND 24B
227, 4lxkC, 0.9609, 1.24, 0.995, 381, 381, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH COMPOUND 11D
228, 3udkA, 0.9609, 1.19, 0.984, 394, 381, CRYSTAL STRUCTURE OF BACE WITH COMPOUND 6
229, 3pi5B, 0.9609, 0.73, 0.997, 377, 377, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH BFG356
230, 3dv5C, 0.9609, 1.21, 0.995, 381, 381, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE IN COMPLEX WITH NVP-BAV544
231, 3dv1C, 0.9609, 1.22, 0.995, 381, 381, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE IN COMPLEX WITH NVP-ARV999
232, 2f3eB, 0.9609, 0.73, 0.997, 377, 377, CRYSTAL STRUCTURE OF THE BACE COMPLEX WITH AXQ093 A MACROCYCLIC INHIBITOR
233, 3udnA, 0.9608, 1.20, 0.984, 394, 381, CRYSTAL STRUCTURE OF BACE WITH COMPOUND 9
234, 3udjA, 0.9608, 1.21, 0.984, 394, 381, CRYSTAL STRUCTURE OF BACE WITH COMPOUND 5
235, 4j0zA, 0.9605, 1.11, 0.989, 381, 380, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((4S5R)-2-AMINO-5-FLUORO-4-FLUOROMETHYL-56- DIHYDRO-4H-[13]OXAZIN-4-YL)-4-FLUORO-PHENYL]-AMIDE
236, 4d8cA, 0.9605, 0.74, 0.997, 377, 377, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BXD552 DERIVED FROM A CO-CRYSTALLIZATION EXPERIMENT
237, 1ym2B, 0.9604, 0.78, 0.997, 377, 377, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH NVP-AUR200
238, 4lxaC, 0.9603, 1.25, 0.995, 381, 381, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH COMPOUND 11A
239, 4fm8A, 0.9602, 1.22, 0.984, 394, 381, CRYSTAL STRUCTURE OF BACE WITH COMPOUND 12A
240, 4d83A, 0.9601, 0.76, 0.997, 377, 377, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BUR436 DERIVED FROM A CO-CRYSTALLIZATION EXPERIMENT
241, 5ygxA, 0.9600, 1.20, 0.990, 381, 381, STRUCTURE OF BACE1 IN COMPLEX WITH N-(3-((4R;5R;6S)-2-AMINO-6-(1;1- DIFLUOROETHYL)-5-FLUORO-4-METHYL-5;6-DIHYDRO-4H-1;3-OXAZIN-4-YL)-4- FLUOROPHENYL)-5-(FLUOROMETHOXY)PYRAZINE-2-CARBOXAMIDE 
242, 2f3eA, 0.9600, 0.77, 0.997, 377, 377, CRYSTAL STRUCTURE OF THE BACE COMPLEX WITH AXQ093 A MACROCYCLIC INHIBITOR
243, 4d8cB, 0.9598, 0.78, 0.997, 377, 377, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BXD552 DERIVED FROM A CO-CRYSTALLIZATION EXPERIMENT
244, 4lxmC, 0.9597, 1.26, 0.995, 381, 381, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH COMPOUND 12A
245, 4d83B, 0.9597, 0.78, 0.997, 377, 377, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BUR436 DERIVED FROM A CO-CRYSTALLIZATION EXPERIMENT
246, 3pi5A, 0.9597, 0.78, 0.997, 377, 377, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH BFG356
247, 6dhcA, 0.9596, 1.02, 0.997, 378, 378, X-RAY STRUCTURE OF BACE1 IN COMPLEX WITH A BICYCLIC ISOXAZOLINE CARBOXAMIDE AS THE P3 LIGAND 
248, 4fm7A, 0.9594, 1.25, 0.984, 394, 381, CRYSTAL STRUCTURE OF BACE WITH COMPOUND 14G
249, 3k5fB, 0.9594, 0.80, 0.997, 377, 377, HUMAN BACE-1 COMPLEX WITH AYH011
250, 4lxmB, 0.9592, 0.81, 0.997, 377, 377, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH COMPOUND 12A
251, 3k5gC, 0.9592, 1.27, 0.995, 381, 381, HUMAN BACE-1 COMPLEX WITH BJC060
252, 3k5cB, 0.9592, 0.80, 0.997, 377, 377, HUMAN BACE-1 COMPLEX WITH NB-216
253, 3dv1A, 0.9592, 0.80, 0.997, 377, 377, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE IN COMPLEX WITH NVP-ARV999
254, 3ckpA, 0.9592, 0.68, 0.992, 379, 376, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH INHIBITOR
255, 4j0tA, 0.9589, 1.15, 0.989, 381, 380, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-ETHOXY-PYRIDINE-2- CARBOXYLIC ACID [3-((R)-2-AMINO-55-DIFLUORO-4-METHYL-56-DIHYDRO-4H- [13]OXAZIN-4-YL)-4-FLUORO-PHENYL]-AMIDE
256, 4lxmA, 0.9588, 0.81, 0.997, 377, 377, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH COMPOUND 12A
257, 3uqrA, 0.9586, 0.73, 0.995, 377, 376, CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR
258, 3k5dC, 0.9586, 0.57, 1.000, 376, 375, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH AHM178
259, 3ckrA, 0.9584, 0.71, 0.992, 379, 376, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH INHIBITOR
260, 2oahA, 0.9584, 0.72, 0.995, 378, 376, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH INHIBITOR
261, 3k5gB, 0.9583, 0.83, 0.997, 377, 377, HUMAN BACE-1 COMPLEX WITH BJC060
262, 3k5cA, 0.9582, 0.84, 0.997, 377, 377, HUMAN BACE-1 COMPLEX WITH NB-216
263, 1ym4B, 0.9582, 0.85, 0.997, 377, 377, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH NVP-AMK640
264, 1ym2A, 0.9582, 0.73, 1.000, 376, 376, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH NVP-AUR200
265, 3qbhB, 0.9581, 0.74, 0.997, 376, 376, STRUCTURE BASED DESIGN SYNTHESIS AND SAR OF CYCLIC HYDROXYETHYLAMINE (HEA) BACE-1 INHIBITORS
266, 3k5dA, 0.9581, 0.60, 1.000, 375, 375, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH AHM178
267, 3k5cC, 0.9581, 1.30, 0.995, 381, 381, HUMAN BACE-1 COMPLEX WITH NB-216
268, 2ntrA, 0.9580, 0.88, 0.992, 379, 377, CRYSTAL STRUCTURE OF HUMAN BACE-1 BOUND TO INHIBITOR
269, 3dv5B, 0.9579, 0.86, 0.997, 377, 377, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE IN COMPLEX WITH NVP-BAV544
270, 2f3fC, 0.9579, 0.84, 0.997, 377, 377, CRYSTAL STRUCTURE OF THE BACE COMPLEX WITH BDF488 A MACROCYCLIC INHIBITOR
271, 3dv5A, 0.9578, 0.85, 0.997, 377, 377, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE IN COMPLEX WITH NVP-BAV544
272, 4lxaA, 0.9575, 0.76, 0.997, 376, 376, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH COMPOUND 11A
273, 2f3fA, 0.9575, 0.62, 1.000, 375, 375, CRYSTAL STRUCTURE OF THE BACE COMPLEX WITH BDF488 A MACROCYCLIC INHIBITOR
274, 5t1uA, 0.9574, 1.18, 0.992, 380, 380, AMINOMETHYL-DERIVED BETA SECRETASE (BACE1) INHIBITORS: ENGAGING GLY230 WITHOUT AN ANILIDE FUNCTIONALITY
275, 3k5gA, 0.9574, 0.86, 0.997, 377, 377, HUMAN BACE-1 COMPLEX WITH BJC060
276, 4lxkA, 0.9573, 0.77, 0.997, 376, 376, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH COMPOUND 11D
277, 3qbhA, 0.9573, 0.64, 1.000, 375, 375, STRUCTURE BASED DESIGN SYNTHESIS AND SAR OF CYCLIC HYDROXYETHYLAMINE (HEA) BACE-1 INHIBITORS
278, 3tplB, 0.9572, 0.65, 0.989, 377, 375, APO STRUCTURE OF BACE1
279, 4n00A, 0.9567, 1.25, 0.984, 393, 380, DISCOVERY OF 7-THP CHROMANS: BACE1 INHIBITORS THAT REDUCE A-BETA IN THE CNS
280, 4rrsA, 0.9566, 1.26, 0.984, 393, 380, 8-TETRAHYDROPYRAN-2-YL CHROMANS: HIGHLY SELECTIVE BETA-SITE AMYLOID PRECURSOR PROTEIN CLEAVING ENZYME 1 (BACE1) INHIBITORS
281, 4rrnA, 0.9565, 1.27, 0.984, 393, 380, 8-TETRAHYDROPYRAN-2-YL CHROMANS: HIGHLY SELECTIVE BETA-SITE AMYLOID PRECURSOR PROTEIN CLEAVING ENZYME 1 (BACE1) INHIBITORS
282, 1ym2C, 0.9562, 0.80, 1.000, 376, 376, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH NVP-AUR200
283, 4gmiA, 0.9561, 1.15, 0.992, 380, 379, BACE-1 IN COMPLEX WITH HEA-TYPE MACROCYCLIC INHIBITOR MV078571
284, 2wjoA, 0.9561, 1.02, 0.989, 380, 378, HUMAN BACE (BETA SECRETASE) IN COMPLEX WITH CYCLOHEXANECARBOXYLIC ACID (2-(2-AM INO-6-PHENOXY-4H- QUINAZOLIN-3-YL)-2-CYCLOHEXYL-ETHYL)-AMIDE
285, 4rroA, 0.9560, 1.27, 0.984, 393, 380, 8-TETRAHYDROPYRAN-2-YL CHROMANS: HIGHLY SELECTIVE BETA-SITE AMYLOID PRECURSOR PROTEIN CLEAVING ENZYME 1 (BACE1) INHIBITORS
286, 3k5fC, 0.9560, 0.93, 0.997, 377, 377, HUMAN BACE-1 COMPLEX WITH AYH011
287, 5mcoA, 0.9559, 1.10, 0.992, 383, 378, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH ACTIVE SITE INHIBITOR GRL- 8234 AND EXOSITE PEPTIDE
288, 4j0yA, 0.9559, 1.10, 0.995, 379, 378, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((4R5S)-2-AMINO-5-FLUORO-4-METHYL-56-DIHYDRO-4H- [13]OXAZIN-4-YL)-4-FLUORO-PHENYL]-AMIDE
289, 2is0A, 0.9559, 0.98, 0.995, 379, 377, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE COMPLEXED WITH INHIBITOR
290, 3uqrC, 0.9558, 0.61, 0.997, 377, 374, CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR
291, 2irzA, 0.9557, 0.99, 0.995, 379, 377, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE COMPLEXED WITH INHIBITOR
292, 4r5nA, 0.9556, 1.30, 0.984, 393, 380, 8-TETRAHYDROPYRAN-2-YL CHROMANS: HIGHLY SELECTIVE BETA-SITE AMYLOID PRECURSOR PROTEIN CLEAVING ENZYME 1 (BACE1) INHIBITORS
293, 4j17A, 0.9556, 1.09, 0.995, 379, 378, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((S)-2-AMINO-4-DIFLUOROMETHYL-56-DIHYDRO-4H-[1 3]OXAZIN-4-YL)-4-FLUORO-PHENYL]-AMIDE
294, 4j0vA, 0.9556, 1.11, 0.995, 379, 378, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((4R5R)-2-AMINO-5-FLUORO-4-METHYL-56-DIHYDRO-4H- [13]OXAZIN-4-YL)-4-FLUORO-PHENYL]-AMIDE
295, 4j1eA, 0.9555, 1.10, 0.995, 379, 378, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((4S6S)-2-AMINO-4-FLUOROMETHYL-6-TRIFLUOROMETHYL- 56-DIHYDRO-4H-[13]OXAZIN-4-YL)-4-FLUORO-PHENYL]-AMIDE
296, 4i0fA, 0.9555, 1.16, 0.992, 393, 379, DESIGN AND SYNTHESIS OF THIOPHENE DIHYDROISOQUINOLINS AS NOVEL BACE-1 INHIBITORS
297, 4dv9A, 0.9555, 1.06, 0.995, 379, 377, CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR
298, 4d83C, 0.9555, 0.94, 0.997, 377, 377, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BUR436 DERIVED FROM A CO-CRYSTALLIZATION EXPERIMENT
299, 3ivhA, 0.9555, 1.14, 0.981, 379, 378, DESIGN AND SYNTHESIS OF POTENT BACE-1 INHIBITORS WITH CELLULAR ACTIVITY: STRUCTURE-ACTIVITY RELATIONSHIP OF P1 SUBSTITUENTS
300, 6dhcC, 0.9554, 0.96, 0.997, 377, 377, X-RAY STRUCTURE OF BACE1 IN COMPLEX WITH A BICYCLIC ISOXAZOLINE CARBOXAMIDE AS THE P3 LIGAND 
301, 3ckpC, 0.9551, 0.75, 0.992, 377, 375, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH INHIBITOR
302, 2b8lA, 0.9551, 1.01, 0.989, 379, 377, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH INHIBITOR
303, 2zjmA, 0.9548, 0.98, 0.995, 377, 377, CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH N-[1-(5-CHLORO-2-ISOPROPOXY-3-METHOXY-BENZYL)- PIPERIDIN-4-YL]-2-(4-SULFAMOYL-PHENOXY)-ACETAMIDE
304, 3k5dB, 0.9547, 0.76, 1.000, 375, 375, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH AHM178
305, 3ckrC, 0.9547, 0.76, 0.989, 377, 375, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH INHIBITOR
306, 4i11A, 0.9544, 1.46, 0.982, 397, 382, STRUCTURE-BASED DESIGN OF NOVEL DIHYDROISOQUINOLINE BACE-1 INHIBITORS THAT DO NOT ENGAGE THE CATALYTIC ASPARTATES.
307, 4i0eA, 0.9544, 1.10, 0.992, 393, 378, DESIGN AND SYNTHESIS OF THIOPHENE DIHYDROISOQUINOLINS AS NOVEL BACE-1 INHIBITORS
308, 2qzkA, 0.9544, 0.92, 0.995, 376, 376, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH I21
309, 2p8hA, 0.9544, 1.05, 0.989, 379, 377, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH INHIBITOR
310, 3tpjA, 0.9540, 0.81, 0.987, 377, 375, APO STRUCTURE OF BACE1
311, 3veuA, 0.9536, 1.26, 1.000, 380, 379, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-AVI326
312, 3qbhC, 0.9536, 0.81, 1.000, 375, 375, STRUCTURE BASED DESIGN SYNTHESIS AND SAR OF CYCLIC HYDROXYETHYLAMINE (HEA) BACE-1 INHIBITORS
313, 5ezzA, 0.9534, 1.22, 0.995, 379, 378, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH (4S)-4-[3-(5-CHLORO-3- PYRIDYL)PHENYL]-4-[4-(DIFLUOROMETHOXY)-3-METHYL-PHENYL]-5H-OXAZOL-2- AMINE
314, 4hztA, 0.9534, 1.12, 0.992, 393, 378, STRUCTURE-BASED DESIGN OF NOVEL DIHYDROISOQUINOLINE BACE-1 INHIBITORS THAT DO NOT ENGAGE THE CATALYTIC ASPARTATES
315, 6c2iA, 0.9533, 1.16, 0.992, 379, 378, STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH : N-(3-((1R5S 6R)-3-AMINO-5-METHYL-2-OXA-4-AZABICYCLO[4.1.0]HEPT-3-EN-5-YL)-4- FLUOROPHENYL)-5-METHOXYPYRAZINE-2-CARBOXAMIDE
316, 5ygyA, 0.9533, 1.16, 0.995, 381, 378, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH (S)-N-(3-(2-AMINO-6- (FLUOROMETHYL)-4 -METHYL-4H-1;3-OXAZIN-4-YL)-4-FLUOROPHENYL)-5- CYANOPICOLINAMIDE 
317, 4exgA, 0.9528, 1.08, 0.992, 377, 377, DESIGN AND SYNTHESIS OF POTENT HYDROXYETHYLAMINE (HEA) BACE-1 INHIBITORS
318, 3ckrB, 0.9527, 0.96, 0.997, 377, 376, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH INHIBITOR
319, 3iviA, 0.9525, 1.41, 0.992, 380, 379, DESIGN AND SYNTHESIS OF POTENT BACE-1 INHIBITORS WITH CELLULAR ACTIVITY: STRUCTURE-ACTIVITY RELATIONSHIP OF P1 SUBSTITUENTS
320, 5v0nC, 0.9520, 1.04, 0.995, 377, 376, BACE1 IN COMPLEX WITH INHIBITOR 5G
321, 3uqpA, 0.9519, 0.78, 0.992, 374, 374, CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR
322, 4i0hA, 0.9518, 0.80, 0.995, 374, 374, SPR AND STRUCTURAL ANALYSIS YIELD INSIGHT TOWARDS MECHANISM OF INHIBITION OF BACE INHIBITORS.
323, 4ewoA, 0.9518, 1.11, 0.995, 377, 377, DESIGN AND SYNTHESIS OF POTENT HYDROXYETHYLAMINE (HEA) BACE-1 INHIBITORS
324, 4dvfA, 0.9518, 0.67, 0.987, 374, 373, CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR
325, 3i25C, 0.9518, 0.69, 0.992, 373, 373, POTENT BETA-SECRETASE 1 HYDROXYETHYLENE INHIBITOR
326, 4i10A, 0.9517, 1.10, 0.992, 390, 377, STRUCTURE-BASED DESIGN OF NOVEL DIHYDROISOQUINOLINE BACE-1 INHIBITORS THAT DO NOT ENGAGE THE CATALYTIC ASPARTATES
327, 4i0gA, 0.9517, 1.19, 0.992, 393, 378, DESIGN AND SYNTHESIS OF THIOPHENE DIHYDROISOQUINOLINS AS NOVEL BACE-1 INHIBITORS
328, 4j0pA, 0.9516, 0.89, 0.992, 376, 375, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((S)-2-AMINO-4-METHYL-56-DIHYDRO-4H-[13]OXAZIN- 4-YL)-4-FLUORO-PHENYL]-AMIDE
329, 3ckpB, 0.9516, 0.92, 0.997, 376, 375, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH INHIBITOR
330, 2fdpC, 0.9516, 0.81, 0.997, 374, 374, CRYSTAL STRUCTURE OF BETA-SECRETASE COMPLEXED WITH AN AMINO- ETHYLENE INHIBITOR
331, 4j1fA, 0.9513, 0.90, 0.987, 376, 375, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((4S6S)-2-AMINO-4-METHYL-6-TRIFLUOROMETHYL-56- DIHYDRO-4H-[13]OXAZIN-4-YL)-4-FLUORO-PHENYL]-AMIDE
332, 3u6aA, 0.9513, 0.81, 0.995, 374, 374, RATIONAL DESIGN AND SYNTHESIS OF AMINOPIPERAZINONES AS BETA SECRETASE (BACE) INHIBITORS
333, 4i0zA, 0.9511, 1.11, 0.992, 390, 377, STRUCTURE-BASED DESIGN OF NOVEL DIHYDROISOQUINOLINE BACE-1 INHIBITORS THAT DO NOT ENGAGE THE CATALYTIC ASPARTATES
334, 3n4lA, 0.9511, 0.81, 0.997, 375, 374, BACE-1 IN COMPLEX WITH ELN380842
335, 5i3wA, 0.9509, 1.09, 0.995, 377, 376, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH 2-AMINOOXAZOLINE-3- AZAXANTHENE INHIBITOR 2
336, 4fgxA, 0.9508, 0.71, 0.989, 374, 373, CRYSTAL STRUCTURE OF BACE1 WITH NOVEL INHIBITOR
337, 1w51A, 0.9508, 0.81, 0.987, 374, 374, BACE (BETA SECRETASE) IN COMPLEX WITH A NANOMOLAR NON- PEPTIDIC INHIBITOR
338, 4d85A, 0.9507, 0.81, 0.995, 374, 374, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BVI151
339, 3iviB, 0.9504, 1.40, 0.995, 378, 377, DESIGN AND SYNTHESIS OF POTENT BACE-1 INHIBITORS WITH CELLULAR ACTIVITY: STRUCTURE-ACTIVITY RELATIONSHIP OF P1 SUBSTITUENTS
340, 4fcoA, 0.9501, 0.90, 0.989, 374, 374, CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR
341, 3msjC, 0.9501, 0.86, 0.997, 375, 374, STRUCTURE OF BACE (BETA SECRETASE) IN COMPLEX WITH INHIBITOR
342, 2ohuA, 0.9501, 1.21, 0.995, 377, 377, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 8B
343, 2qzlA, 0.9500, 0.91, 0.989, 375, 374, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH IXS
344, 4i0iB, 0.9498, 1.16, 0.992, 376, 375, SPR AND STRUCTURAL ANALYSIS YIELD INSIGHT TOWARDS MECHANISM OF INHIBITION OF BACE INHIBITORS
345, 3nshB, 0.9498, 1.16, 0.992, 376, 375, BACE-1 IN COMPLEX WITH ELN475957
346, 2ohkA, 0.9498, 1.17, 0.995, 377, 377, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH 1- AMINO-ISOQUINOLINE
347, 3n4lB, 0.9496, 0.77, 0.995, 375, 373, BACE-1 IN COMPLEX WITH ELN380842
348, 3ixjA, 0.9496, 0.80, 0.997, 373, 373, CRYSTAL STRUCTURE OF BETA-SECRETASE 1 IN COMPLEX WITH SELECTIVE BETA-SECRETASE 1 INHIBITOR
349, 2va5A, 0.9495, 1.21, 0.995, 377, 377, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 8C
350, 3r1gB, 0.9494, 1.20, 0.981, 381, 378, STRUCTURE BASIS OF ALLOSTERIC INHIBITION OF BACE1 BY AN EXOSITE- BINDING ANTIBODY
351, 3i25A, 0.9494, 0.80, 0.997, 373, 373, POTENT BETA-SECRETASE 1 HYDROXYETHYLENE INHIBITOR
352, 2ohmA, 0.9494, 1.22, 0.995, 377, 377, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH N~3~-BENZYLPYRIDINE-23-DIAMINE
353, 3tppA, 0.9493, 0.93, 0.989, 375, 374, CRYSTAL STRUCTURE OF BACE1 COMPLEXED WITH AN INHIBITOR
354, 3n4lC, 0.9493, 0.96, 0.995, 375, 375, BACE-1 IN COMPLEX WITH ELN380842
355, 3msjA, 0.9493, 0.79, 0.997, 373, 373, STRUCTURE OF BACE (BETA SECRETASE) IN COMPLEX WITH INHIBITOR
356, 2ohlA, 0.9492, 1.22, 0.995, 377, 377, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH 2- AMINOQUINOLINE
357, 5ezxA, 0.9490, 0.79, 0.989, 374, 373, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH {(1R2R)-2-[(R)-2-AMINO-4- (4-DIFLUOROMETHOXY-PHENYL)-45-DIHYDRO-OXAZOL-4-YL]-CYCLOPROPYL}-(5- CHLORO-PYRIDIN-3-YL)-METHANONE
358, 4ivtA, 0.9490, 0.80, 0.992, 375, 373, CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR
359, 3hw1C, 0.9490, 0.90, 0.992, 375, 374, STRUCTURE OF BACE (BETA SECRETASE) IN COMPLEX WITH LIGAND EV2
360, 2iqgA, 0.9490, 0.99, 0.987, 375, 374, CRYSTAL STRUCTURE OF HYDROXYETHYL SECONDARY AMINE-BASED PEPTIDOMIMETIC INHIBITOR OF HUMAN BETA-SECRETASE (BACE)
361, 2hm1A, 0.9490, 0.98, 0.987, 375, 374, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE (BACE) IN THE PRESENCE OF AN INHIBITOR (2)
362, 4i0hB, 0.9489, 1.03, 0.995, 375, 374, SPR AND STRUCTURAL ANALYSIS YIELD INSIGHT TOWARDS MECHANISM OF INHIBITION OF BACE INHIBITORS.
363, 3ixkA, 0.9489, 0.83, 0.997, 373, 373, POTENT BETA-SECRETASE 1 INHIBITOR
364, 4ivsA, 0.9488, 0.80, 0.992, 373, 373, CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR
365, 3duyC, 0.9488, 0.92, 0.997, 374, 374, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE IN COMPLEX WITH NVP-AFJ144
366, 5clmA, 0.9485, 1.09, 0.989, 376, 376, 14-OXAZINE BACE1 INHIBITORS
367, 2ohqA, 0.9485, 1.23, 0.995, 377, 377, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 4
368, 3uquA, 0.9484, 0.88, 0.992, 374, 373, CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR
369, 6fgyA, 0.9483, 1.12, 0.997, 379, 376, CRYSTAL STRUCTURE OF HUMAN BACE-1 IN COMPLEX WITH AMINO-1;4-OXAZINE COMPOUND 4 
370, 4xxsA, 0.9483, 0.83, 0.992, 376, 373, CRYSTAL STRUCTURE OF BACE1 WITH A PYRAZOLE-SUBSTITUTED TETRAHYDROPYRAN THIOAMIDINE
371, 2va6A, 0.9482, 1.16, 0.995, 376, 376, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 24
372, 3uqxA, 0.9481, 0.90, 0.992, 375, 373, CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR
373, 3s2oA, 0.9481, 1.24, 0.995, 377, 377, FRAGMENT BASED DISCOVERY AND OPTIMISATION OF BACE-1 INHIBITORS
374, 4i0jA, 0.9480, 0.86, 0.992, 388, 373, SPR AND STRUCTURAL ANALYSIS YIELD INSIGHT TOWARDS MECHANISM OF INHIBITION OF BACE INHIBITORS
375, 3exoA, 0.9480, 0.84, 0.989, 373, 373, CRYSTAL STRUCTURE OF BACE1 BOUND TO INHIBITOR
376, 1w50A, 0.9480, 1.24, 0.995, 377, 377, APO STRUCTURE OF BACE (BETA SECRETASE)
377, 2ohrA, 0.9479, 1.18, 0.995, 377, 377, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 6A
378, 4dvfB, 0.9478, 0.75, 0.992, 373, 372, CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR
379, 3k5fA, 0.9478, 0.87, 0.995, 373, 373, HUMAN BACE-1 COMPLEX WITH AYH011
380, 2ohnA, 0.9476, 1.26, 0.995, 377, 377, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH 4- (4-FLUOROBENZYL)PIPERIDINE
381, 4dpfA, 0.9475, 1.08, 1.000, 375, 375, BACE-1 IN COMPLEX WITH A HEA-MACROCYCLIC TYPE INHIBITOR
382, 3uqrB, 0.9475, 0.89, 0.992, 374, 373, CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR
383, 5v0nB, 0.9474, 1.01, 0.992, 373, 373, BACE1 IN COMPLEX WITH INHIBITOR 5G
384, 4ke0A, 0.9474, 1.03, 0.995, 375, 373, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH HYDROXYETHYLAMINE- MACROCYCLIC INHIBITOR 13
385, 2p83B, 0.9474, 0.65, 0.995, 372, 371, POTENT AND SELECTIVE ISOPHTHALAMIDE S2 HYDROXYETHYLAMINE INHIBITOR OF BACE1
386, 4ke0C, 0.9472, 0.67, 0.997, 372, 371, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH HYDROXYETHYLAMINE- MACROCYCLIC INHIBITOR 13
387, 3mskA, 0.9472, 1.25, 0.995, 377, 377, FRAGMENT BASED DISCOVERY AND OPTIMISATION OF BACE-1 INHIBITORS
388, 3iviC, 0.9472, 0.77, 0.997, 373, 372, DESIGN AND SYNTHESIS OF POTENT BACE-1 INHIBITORS WITH CELLULAR ACTIVITY: STRUCTURE-ACTIVITY RELATIONSHIP OF P1 SUBSTITUENTS
389, 2hizB, 0.9472, 0.65, 0.995, 372, 371, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE (BACE) IN THE PRESENCE OF AN INHIBITOR
390, 3ixjC, 0.9471, 0.71, 0.997, 371, 371, CRYSTAL STRUCTURE OF BETA-SECRETASE 1 IN COMPLEX WITH SELECTIVE BETA-SECRETASE 1 INHIBITOR
391, 4k8sA, 0.9469, 0.68, 0.997, 371, 371, HYDROXYETHYLAMINE-BASED INHIBITORS OF BACE1: P1-P3 MACROCYCLIZATION CAN IMPROVE POTENCY SELECTIVITY AND CELL ACTIVITY
392, 3vf3A, 0.9469, 1.10, 1.000, 375, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BQQ711
393, 2of0A, 0.9469, 1.28, 0.995, 377, 377, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 5
394, 4di2B, 0.9468, 1.05, 0.995, 375, 375, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH HYDROXYETHYLAMINE INHIBITOR 37
395, 4d88A, 0.9468, 1.10, 1.000, 375, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BXQ490
396, 3uflA, 0.9468, 0.89, 0.995, 373, 373, DISCOVERY OF PYRROLIDINE-BASED B-SECRETASE INHIBITORS: LEAD ADVANCEMENT THROUGH CONFORMATIONAL DESIGN FOR MAINTENANCE OF LIGAND BINDING EFFICIENCY
397, 2ohtA, 0.9468, 1.30, 0.995, 377, 377, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 7
398, 4ke0B, 0.9467, 0.97, 0.995, 374, 374, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH HYDROXYETHYLAMINE- MACROCYCLIC INHIBITOR 13
399, 4wy6A, 0.9465, 0.89, 0.992, 373, 373, CRYSTAL STRUCTURE OF HUMAN BACE-1 BOUND TO COMPOUND 36
400, 6ej2A, 0.9464, 1.14, 0.989, 377, 375, BACE1 COMPOUND 28 
401, 3ixkC, 0.9463, 0.74, 0.997, 371, 371, POTENT BETA-SECRETASE 1 INHIBITOR
402, 3hvgC, 0.9463, 0.79, 0.997, 373, 372, STRUCTURE OF BACE (BETA SECRETASE) IN COMPLEX WITH EV0
403, 2zjjA, 0.9463, 0.54, 0.992, 370, 370, CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH 4-(4-FLUORO-BENZYL)-PIPERAZINE-2-CARBOXYLIC ACID (2-MERCAPTO-ETHYL)- AMIDE
404, 5dqcA, 0.9462, 0.81, 0.995, 372, 372, CO-CRYSTAL OF BACE1 WITH COMPOUND 0211
405, 4i0iA, 0.9462, 0.82, 0.997, 372, 372, SPR AND STRUCTURAL ANALYSIS YIELD INSIGHT TOWARDS MECHANISM OF INHIBITION OF BACE INHIBITORS
406, 3nshA, 0.9462, 0.82, 0.997, 372, 372, BACE-1 IN COMPLEX WITH ELN475957
407, 3hvgB, 0.9461, 0.55, 1.000, 370, 370, STRUCTURE OF BACE (BETA SECRETASE) IN COMPLEX WITH EV0
408, 2hizA, 0.9461, 0.69, 0.997, 371, 371, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE (BACE) IN THE PRESENCE OF AN INHIBITOR
409, 3ixjB, 0.9460, 0.92, 0.997, 373, 373, CRYSTAL STRUCTURE OF BETA-SECRETASE 1 IN COMPLEX WITH SELECTIVE BETA-SECRETASE 1 INHIBITOR
410, 2wf2A, 0.9460, 1.04, 0.987, 374, 374, HUMAN BACE-1 IN COMPLEX WITH 8-ETHYL-N-((1S2R)-2-HYDROXY-3- (((3-(METHYLOXY)PHENYL)METHYL)AMINO)-1-(PHENYLMETHYL) PROPYL)-1-METHYL-3478-TETRAHYDRO-1H6H-(125) THIADIAZEPINO(543-DE)QUINOXALINE-10-CARBOXAMIDE 22- DIOXIDE
411, 2wf1A, 0.9460, 1.03, 0.987, 374, 374, HUMAN BACE-1 IN COMPLEX WITH 7-ETHYL-N-((1S2R)-2-HYDROXY-3- (((3-(METHYLOXY)PHENYL(METHYL)AMINO)-1-(PHENYLMETHYL) PROPYL)-1-METHYL-34-DIHYDRO-1H-(125)THIADIAZEPINO(345- HI)INDOLE-9-CARBOXAMIDE 22-DIOXIDE
412, 2p83A, 0.9460, 0.70, 0.997, 371, 371, POTENT AND SELECTIVE ISOPHTHALAMIDE S2 HYDROXYETHYLAMINE INHIBITOR OF BACE1
413, 3h0bC, 0.9459, 0.95, 0.997, 373, 373, DISCOVERY OF AMINOHETEROCYCLES AS A NOVEL BETA-SECRETASE INHIBITOR CLASS
414, 2ohpA, 0.9458, 1.32, 0.995, 377, 377, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 3
415, 3h0bB, 0.9457, 0.96, 0.997, 373, 373, DISCOVERY OF AMINOHETEROCYCLES AS A NOVEL BETA-SECRETASE INHIBITOR CLASS
416, 2va7A, 0.9457, 1.07, 1.000, 374, 374, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 27
417, 2vnnA, 0.9456, 1.05, 0.987, 374, 374, HUMAN BACE-1 IN COMPLEX WITH 7-ETHYL-N-((1S2R)-2-HYDROXY-1- (PHENYLMETHYL)-3-(((3-(TRIFLUOROMETHYL)PHENYL)METHYL)AMINO) PROPYL)-1-METHYL-34-DIHYDRO-1H-(125)THIADIAZEPINO(345- HI)INDOLE-9-CARBOXAMIDE 22-DIOXIDE
418, 4l7jA, 0.9455, 1.00, 0.987, 374, 373, DIETHYLAMINOSULFUR TRIFLUORIDE-MEDIATED INTRAMOLECULAR CYCLIZATION OF 2-HYDROXY-BENZYLUREAS TO FUSED BICYCLIC AMINOOXAZOLINE COMPOUNDS AND EVALUATION OF THEIR BIOCHEMICAL ACTIVITY AGAINST BETA-SECRETASE-1 (BACE-1)
419, 4frjA, 0.9455, 0.93, 0.989, 373, 373, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH AMINOOXAZOLINE XANTHENE 9L
420, 2wf3A, 0.9455, 1.05, 0.987, 374, 374, HUMAN BACE-1 IN COMPLEX WITH 6-(ETHYLAMINO)-N-((1S2R)-2- HYDROXY-3-(((3-(METHYLOXY)PHENYL)METHYL)AMINO)-1-( PHENYLMETHYL)PROPYL)-1-METHYL-1345-TETRAHYDRO-21- BENZOTHIAZEPINE-8-CARBOXAMIDE 22-DIOXIDE
421, 2vnmA, 0.9455, 1.06, 0.987, 374, 374, HUMAN BACE-1 IN COMPLEX WITH 3-(11-DIOXIDOTETRAHYDRO-2H-1 2-THIAZIN-2-YL)-5-(ETHYLAMINO)-N-((1S2R)-2-HYDROXY-1-( PHENYLMETHYL)-3-(((3-(TRIFLUOROMETHYL)PHENYL)METHYL)AMINO) PROPYL)BENZAMIDE
422, 4di2A, 0.9454, 0.85, 0.995, 375, 372, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH HYDROXYETHYLAMINE INHIBITOR 37
423, 3ixkB, 0.9454, 0.93, 0.997, 373, 373, POTENT BETA-SECRETASE 1 INHIBITOR
424, 5v0nA, 0.9453, 0.76, 0.995, 371, 371, BACE1 IN COMPLEX WITH INHIBITOR 5G
425, 4i0iC, 0.9453, 1.41, 0.989, 376, 376, SPR AND STRUCTURAL ANALYSIS YIELD INSIGHT TOWARDS MECHANISM OF INHIBITION OF BACE INHIBITORS
426, 3nshC, 0.9453, 1.41, 0.989, 376, 376, BACE-1 IN COMPLEX WITH ELN475957
427, 3i25B, 0.9453, 0.94, 0.992, 373, 373, POTENT BETA-SECRETASE 1 HYDROXYETHYLENE INHIBITOR
428, 2hizC, 0.9453, 0.83, 0.995, 373, 372, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE (BACE) IN THE PRESENCE OF AN INHIBITOR
429, 5dqcC, 0.9452, 0.96, 0.997, 373, 373, CO-CRYSTAL OF BACE1 WITH COMPOUND 0211
430, 4k8sB, 0.9452, 0.75, 0.997, 371, 371, HYDROXYETHYLAMINE-BASED INHIBITORS OF BACE1: P1-P3 MACROCYCLIZATION CAN IMPROVE POTENCY SELECTIVITY AND CELL ACTIVITY
431, 2p83C, 0.9452, 0.84, 0.995, 373, 372, POTENT AND SELECTIVE ISOPHTHALAMIDE S2 HYDROXYETHYLAMINE INHIBITOR OF BACE1
432, 2fdpA, 0.9452, 0.95, 0.997, 373, 373, CRYSTAL STRUCTURE OF BETA-SECRETASE COMPLEXED WITH AN AMINO- ETHYLENE INHIBITOR
433, 1tqfA, 0.9452, 0.76, 0.995, 371, 371, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH INHIBITOR
434, 4d89A, 0.9450, 1.19, 1.000, 375, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BXD552 DERIVED FROM A SOAKING EXPERIMENT
435, 4b77A, 0.9450, 1.17, 1.000, 376, 375, AMINOIMIDAZOLES AS BACE-1 INHIBITORS: FROM DE NOVO DESIGN TO AB-LOWERING IN BRAIN
436, 3vg1A, 0.9450, 1.29, 1.000, 376, 376, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BUR436 DERIVED FROM A SOAKING EXPERIMENT
437, 2ph6A, 0.9448, 0.79, 0.992, 371, 371, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH INHIBITOR
438, 3msjB, 0.9445, 0.88, 0.997, 373, 372, STRUCTURE OF BACE (BETA SECRETASE) IN COMPLEX WITH INHIBITOR
439, 3hw1B, 0.9445, 0.66, 0.997, 371, 370, STRUCTURE OF BACE (BETA SECRETASE) IN COMPLEX WITH LIGAND EV2
440, 3tplC, 0.9444, 0.65, 0.995, 370, 370, APO STRUCTURE OF BACE1
441, 3duyB, 0.9444, 0.68, 0.997, 370, 370, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE IN COMPLEX WITH NVP-AFJ144
442, 4k9hA, 0.9443, 0.67, 0.997, 370, 370, BACE-1 INHIBITOR COMPLEX
443, 5t1wA, 0.9442, 0.77, 0.997, 371, 371, AMINOMETHYL-DERIVED BETA SECRETASE (BACE1) INHIBITORS: ENGAGING GLY230 WITHOUT AN ANILIDE FUNCTIONALITY
444, 4l7hA, 0.9442, 1.05, 0.987, 374, 373, DIETHYLAMINOSULFUR TRIFLUORIDE-MEDIATED INTRAMOLECULAR CYCLIZATION OF 2-HYDROXY-BENZYLUREAS TO FUSED BICYCLIC AMINOOXAZOLINE COMPOUNDS AND EVALUATION OF THEIR BIOCHEMICAL ACTIVITY AGAINST BETA-SECRETASE-1 (BACE-1)
445, 4b72A, 0.9442, 1.20, 1.000, 376, 375, AMINOIMIDAZOLES AS BACE-1 INHIBITORS: FROM DE NOVO DESIGN TO AB-LOWERING IN BRAIN
446, 2b8vA, 0.9442, 0.83, 0.995, 373, 371, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE COMPLEXED WITH L- L000430469
447, 5mxdB, 0.9441, 0.68, 1.000, 370, 370, BACE-1 IN COMPLEX WITH LIGAND 32397778
448, 3hw1A, 0.9440, 0.66, 1.000, 370, 370, STRUCTURE OF BACE (BETA SECRETASE) IN COMPLEX WITH LIGAND EV2
449, 4di2C, 0.9439, 0.71, 0.997, 371, 370, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH HYDROXYETHYLAMINE INHIBITOR 37
450, 2ohsA, 0.9439, 1.08, 1.000, 374, 374, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 6B
451, 4b00A, 0.9438, 1.13, 1.000, 375, 374, DESIGN AND SYNTHESIS OF BACE1 INHIBITORS WITH IN VIVO BRAIN REDUCTION OF BETA-AMYLOID PEPTIDES (COMPOUND (R)-41)
452, 2vijA, 0.9437, 1.03, 0.989, 373, 373, HUMAN BACE-1 IN COMPLEX WITH 3-(11-DIOXIDOTETRAHYDRO-2H-1 2-THIAZIN-2-YL)-5-(ETHYLAMINO)-N-((1S2R)-2-HYDROXY-1-( PHENYLMETHYL)-3-(1234-TETRAHYDRO-1-NAPHTHALENYLAMINO) PROPYL)BENZAMIDE
453, 3duyA, 0.9436, 0.71, 0.997, 370, 370, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE IN COMPLEX WITH NVP-AFJ144
454, 2zjkA, 0.9436, 0.68, 0.997, 371, 370, CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH 4-(4-FLUORO-BENZYL)-PIPERAZINE-2-CARBOXYLIC ACID(3-MERCAPTO-PROPYL)-AMIDE
455, 4i0dA, 0.9435, 0.99, 1.000, 387, 373, DESIGN AND SYNTHESIS OF THIOPHENE DIHYDROISOQUINOLINS AS NOVEL BACE-1 INHIBITORS
456, 4dpiA, 0.9435, 1.05, 1.000, 373, 373, BACE-1 IN COMPLEX WITH HEA-MACROCYCLIC INHIBITOR MV078512
457, 2zjkC, 0.9435, 0.69, 0.997, 371, 370, CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH 4-(4-FLUORO-BENZYL)-PIPERAZINE-2-CARBOXYLIC ACID(3-MERCAPTO-PROPYL)-AMIDE
458, 2vieA, 0.9435, 1.05, 0.989, 373, 373, HUMAN BACE-1 IN COMPLEX WITH N-((1S2R)-1-BENZYL-2-HYDROXY- 3-((115-TRIMETHYLHEXYL)AMINO)PROPYL)-3-(ETHYLAMINO)-5-(2- OXOPYRROLIDIN-1-YL)BENZAMIDE
459, 4wtuA, 0.9434, 0.80, 0.995, 371, 371, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH 2-AMINOOXAZOLINE 3-AZA-4- FLUORO-XANTHENE INHIBITOR 22
460, 4bfdA, 0.9432, 0.82, 0.995, 372, 371, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH CHEMICAL LIGAND
461, 4zpfA, 0.9431, 0.84, 0.989, 371, 371, BACE1 IN COMPLEX WITH 8-(3-((1-AMINOPROPAN-2-YL)OXY)BENZYL)-4- (CYCLOHEXYLAMINO)-1-(3-FLUOROPHENYL)-138-TRIAZASPIRO[4.5]DEC-3-EN- 2-ONE
462, 4x2lA, 0.9430, 0.82, 0.997, 371, 371, CRYSTAL STRUCTURE OF HUMAN BACE-1 BOUND TO COMPOUND 6
463, 4azyA, 0.9430, 1.15, 1.000, 375, 374, DESIGN AND SYNTHESIS OF BACE1 INHIBITORS WITH IN VIVO BRAIN REDUCTION OF BETA-AMYLOID PEPTIDES (COMPOUND 10)
464, 2xfjA, 0.9429, 1.05, 0.987, 373, 373, HUMAN BACE-1 IN COMPLEX WITH N-((1S2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-(ETHYLAMINO)-5-(2-OXO-1- PYRROLIDINYL)BENZAMIDE
465, 4b1dA, 0.9427, 1.25, 1.000, 376, 375, NEW AMINOIMIDAZOLES AS BACE-1 INHIBITORS: FROM RATIONAL DESIGN TO AB-LOWERING IN BRAIN
466, 3uqwA, 0.9426, 1.05, 0.992, 375, 373, CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR
467, 4i0hC, 0.9424, 1.25, 0.992, 374, 374, SPR AND STRUCTURAL ANALYSIS YIELD INSIGHT TOWARDS MECHANISM OF INHIBITION OF BACE INHIBITORS.
468, 4friA, 0.9423, 0.86, 0.995, 372, 371, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH BIARYLSPIRO AMINOOXAZOLINE 2 6
469, 5uyuA, 0.9421, 0.75, 0.995, 370, 370, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH 2-AMINOOXAZOLINE-3- AZAXANTHENE COMPOUND 12
470, 3rsxA, 0.9421, 1.27, 0.992, 375, 375, STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH 6-(THIOPHEN-3- YL)QUINOLIN-2-AMINE
471, 4b1eA, 0.9418, 1.19, 1.000, 375, 374, NEW AMINOIMIDAZOLES AS BACE-1 INHIBITORS: FROM RATIONAL DESIGN TO AB-LOWERING IN BRAIN
472, 2xfiA, 0.9418, 1.01, 0.989, 372, 372, HUMAN BACE-1 IN COMPLEX WITH N-((1S2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-((METHYLSULFONYL)(PHENYL)AMINO) BENZAMIDE
473, 2viyA, 0.9418, 1.01, 0.989, 372, 372, HUMAN BACE-1 IN COMPLEX WITH N-((1S2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-(PENTYLSULFONYL)BENZAMIDE
474, 5tolA, 0.9416, 1.16, 0.997, 374, 373, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 COMPLEXED WITH N- (3-((4AS7AS)-2-AMINO-44A56-TETRAHYDRO-7AH-FURO[23-D][1 3]THIAZIN-7A-YL)-4-FLUOROPHENYL)-5-BROMO-2-PYRIDINECARBOXAMIDE
475, 3mslA, 0.9416, 1.36, 0.992, 377, 377, FRAGMENT BASED DISCOVERY AND OPTIMISATION OF BACE-1 INHIBITORS
476, 4b1cA, 0.9415, 1.01, 0.997, 375, 372, NEW AMINOIMIDAZOLES AS BACE-1 INHIBITORS: FROM RATIONAL DESIGN TO AB-LOWERING IN BRAIN
477, 3h0bA, 0.9415, 1.01, 0.997, 372, 372, DISCOVERY OF AMINOHETEROCYCLES AS A NOVEL BETA-SECRETASE INHIBITOR CLASS
478, 2fdpB, 0.9415, 0.70, 0.997, 369, 369, CRYSTAL STRUCTURE OF BETA-SECRETASE COMPLEXED WITH AN AMINO- ETHYLENE INHIBITOR
479, 4l7gA, 0.9414, 1.13, 0.971, 373, 373, DIETHYLAMINOSULFUR TRIFLUORIDE-MEDIATED INTRAMOLECULAR CYCLIZATION OF 2-HYDROXY-BENZYLUREAS TO FUSED BICYCLIC AMINOOXAZOLINE COMPOUNDS AND EVALUATION OF THEIR BIOCHEMICAL ACTIVITY AGAINST BETA-SECRETASE-1 (BACE1)
480, 2zjkB, 0.9410, 0.69, 0.997, 369, 369, CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH 4-(4-FLUORO-BENZYL)-PIPERAZINE-2-CARBOXYLIC ACID(3-MERCAPTO-PROPYL)-AMIDE
481, 4j1cA, 0.9409, 0.81, 0.995, 371, 370, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((S)-2-AMINO-55-DIFLUORO-4-FLUOROMETHYL-56- DIHYDRO-4H-[13]OXAZIN-4-YL)-4-FLUORO-PHENYL]-AMIDE
482, 2wf4A, 0.9409, 1.04, 0.989, 372, 372, HUMAN BACE-1 IN COMPLEX WITH 6-ETHYL-1-METHYL-N-((1S)-2-OXO- 1-(PHENYLMETHYL)-3-(TETRAHYDRO-2H-PYRAN-4-YLAMINO)PROPYL)- 1346-TETRAHYDRO(12)THIAZEPINO(543-CD)INDOLE-8- CARBOXAMIDE 22-DIOXIDE
483, 4j1iA, 0.9408, 0.82, 0.995, 371, 370, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((4R5R6R)-2-AMINO-5-FLUORO-4-METHYL-6- TRIFLUOROMETHYL-56-DIHYDRO-4H-[13]OXAZIN-4-YL)-4-FLUORO-PHENYL]- AMIDE
484, 4acuA, 0.9408, 0.96, 0.997, 372, 371, AMINOIMIDAZOLES AS BACE-1 INHIBITORS. X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 14
485, 2wezA, 0.9408, 1.04, 0.989, 372, 372, HUMAN BACE-1 IN COMPLEX WITH 1-ETHYL-N-((1S2R)-2-HYDROXY-3- (((3-(METHYLOXY)PHENYL)METHYL)AMINO)-1-(PHENYLMETHYL) PROPYL)-4-(2-OXO-1-PYRROLIDINYL)-1H-INDOLE-6-CARBOXAMIDE
486, 2wf0A, 0.9407, 1.04, 0.989, 372, 372, HUMAN BACE-1 IN COMPLEX WITH 4-ETHYL-N-((1S2R)-2-HYDROXY-1- (PHENYLMETHYL)-3-(((3-(TRIFLUOROMETHYL)PHENYL)METHYL)AMINO) PROPYL)-8-(2-OXO-1-PYRROLIDINYL)-6-QUINOLINECARBOXAMIDE
487, 4bekA, 0.9406, 0.82, 0.995, 371, 370, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH CHEMICAL LIGAND
488, 3tplA, 0.9406, 0.59, 0.995, 371, 368, APO STRUCTURE OF BACE1
489, 4k8sC, 0.9405, 0.92, 0.997, 371, 371, HYDROXYETHYLAMINE-BASED INHIBITORS OF BACE1: P1-P3 MACROCYCLIZATION CAN IMPROVE POTENCY SELECTIVITY AND CELL ACTIVITY
490, 3zovA, 0.9405, 0.82, 0.995, 371, 370, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH CHEMICAL LIGAND
491, 4k9hB, 0.9404, 0.75, 1.000, 369, 369, BACE-1 INHIBITOR COMPLEX
492, 2xfkA, 0.9404, 0.98, 0.992, 371, 371, HUMAN BACE-1 IN COMPLEX WITH N-((1S2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-(ETHYLAMINO)-5-((METHYLSULFONYL)( PHENYL)AMINO)BENZAMIDE
493, 5f00A, 0.9398, 0.85, 0.995, 371, 370, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-[3-[(3-CHLORO-8- QUINOLYL)AMINO]PHENYL]-5-METHYL-26-DIHYDRO-14-OXAZIN-3-AMINE
494, 3rthA, 0.9396, 0.97, 0.995, 371, 371, STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH 6-(2-(33- DIMETHYLBUT-1-YNYL)PHENYL)QUINOLIN-2-AMINE
495, 4b70A, 0.9393, 1.09, 1.000, 372, 372, AMINOIMIDAZOLES AS BACE-1 INHIBITORS: FROM DE NOVO DESIGN TO AB-LOWERING IN BRAIN
496, 5dqcB, 0.9391, 0.68, 0.997, 369, 368, CO-CRYSTAL OF BACE1 WITH COMPOUND 0211
497, 4rcfA, 0.9390, 0.79, 0.992, 370, 369, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH 2-AMINOOXAZOLINE 4- FLUOROXANTHENE INHIBITOR 49
498, 2vj9A, 0.9388, 0.92, 0.992, 374, 370, HUMAN BACE-1 IN COMPLEX WITH N-((1S2R)-3-(CYCLOHEXYLAMINO)- 2-HYDROXY-1-(PHENYLMETHYL)PROPYL)-3-(ETHYLAMINO)-5-(2-OXO- 1-PYRROLIDINYL)BENZAMIDE
499, 2vizA, 0.9388, 0.93, 0.992, 370, 370, HUMAN BACE-1 IN COMPLEX WITH N-((1S2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-(2-OXO-1-PYRROLIDINYL)-5-(PROPYLOXY) BENZAMIDE
500, 4zpeA, 0.9387, 0.81, 0.992, 369, 369, BACE1 IN COMPLEX WITH 4-(CYCLOHEXYLAMINO)-1-(3-FLUOROPHENYL)-8-(3- ISOPROPOXYBENZYL)-138-TRIAZASPIRO[4.5]DEC-3-EN-2-ONE
501, 3dm6B, 0.9386, 0.71, 0.997, 368, 368, BETA-SECRETASE 1 COMPLEXED WITH STATINE-BASED INHIBITOR
502, 4zpgA, 0.9383, 0.82, 0.989, 369, 369, BACE1 IN COMPLEX WITH 8-BENZYL-4-(CYCLOHEXYLAMINO)-1-(3-FLUOROPHENYL)- 7-METHYL-138-TRIAZASPIRO[4.5]DEC-3-EN-2-ONE
503, 4k9hC, 0.9383, 0.91, 0.997, 370, 370, BACE-1 INHIBITOR COMPLEX
504, 4acxA, 0.9383, 0.91, 0.997, 370, 370, AMINOIMIDAZOLES AS BACE-1 INHIBITORS. X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 23
505, 2vj7A, 0.9381, 0.95, 0.992, 370, 370, HUMAN BACE-1 IN COMPLEX WITH 3-(ETHYLAMINO)-N-((1S2R)-2- HYDROXY-1-(PHENYLMETHYL)-3-(((3-(TRIFLUOROMETHYL)PHENYL) METHYL)AMINO)PROPYL)-5-(2-OXO-1-PYRROLIDINYL)BENZAMIDE
506, 2vj6A, 0.9381, 0.95, 0.992, 370, 370, HUMAN BACE-1 IN COMPLEX WITH N-((1S2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-(ETHYLAMINO)-5-(2-OXO-1- PYRROLIDINYL)BENZAMIDE
507, 4frkA, 0.9375, 0.83, 0.995, 369, 369, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH AMINOOXAZOLINE XANTHENE 11A
508, 3dm6A, 0.9375, 0.88, 0.997, 369, 369, BETA-SECRETASE 1 COMPLEXED WITH STATINE-BASED INHIBITOR
509, 2zjiA, 0.9373, 0.86, 0.992, 370, 369, CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH N-[1-(26-DIMETHOXY-BENZYL)-PIPERIDIN-4-YL]-4-MERCAPTO-BUTYRAMIDE
510, 4j1hA, 0.9369, 0.88, 0.995, 370, 369, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((4S6R)-2-AMINO-4-METHYL-6-TRIFLUOROMETHYL-56- DIHYDRO-4H-[13]OXAZIN-4-YL)-4-FLUORO-PHENYL]-AMIDE
511, 4b78A, 0.9369, 1.19, 1.000, 372, 372, AMINOIMIDAZOLES AS BACE-1 INHIBITORS: FROM DE NOVO DESIGN TO AB-LOWERING IN BRAIN
512, 4b0qA, 0.9367, 0.89, 0.997, 369, 369, LEAD GENERATION OF BACE1 INHIBITORS BY COUPLING NON-AMIDINE NEW WARHEADS TO A KNOWN BINDING SCAFFOLD
513, 3s7mA, 0.9365, 1.16, 0.987, 371, 371, PYRAZOLYL AND THIENYL AMINOHYDANTOINS AS POTENT BACE1 INHIBITORS
514, 5i3vA, 0.9361, 0.92, 0.992, 370, 369, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH AMINOQUINOLINE COMPOUND 1
515, 5i3xA, 0.9360, 1.14, 0.989, 373, 371, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH AMINOQUINOLINE INHIBITOR 6
516, 2zhvA, 0.9359, 0.99, 0.995, 370, 370, CRYSTAL STRUCTURE OF BACE1 AT PH 7.0
517, 4rcdA, 0.9357, 0.80, 0.995, 368, 368, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH A 2-AMINOOXAZOLINE 4- AZAXANTHENE INHIBITOR
518, 3in3A, 0.9356, 1.07, 0.992, 370, 370, BACE1 WITH COMPOUND 30
519, 3fktA, 0.9356, 0.84, 0.992, 368, 368, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH SPIROPIPERDINE IMINOHYDANTOIN INHIBITOR
520, 4b05A, 0.9348, 0.98, 0.995, 371, 369, PRECLINICAL CHARACTERIZATION OF AZD3839 A NOVEL CLINICAL CANDIDATE BACE1 INHIBITOR FOR THE TREATMENT OF ALZHEIMER DISEASE
521, 2zhuA, 0.9347, 1.06, 0.995, 370, 370, CRYSTAL STRUCTURE OF BACE1 AT PH 5.0
522, 2zhtA, 0.9347, 1.06, 0.992, 370, 370, CRYSTAL STRUCTURE OF BACE1 AT PH 4.5
523, 2zhsA, 0.9346, 1.05, 0.995, 370, 370, CRYSTAL STRUCTURE OF BACE1 AT PH 4.0
524, 3rviA, 0.9345, 0.96, 0.995, 369, 369, STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH 2-((2-AMINO-6-O- TOLYLQUINOLIN-3-YL)METHYL)-N-(CYCLOHEXYLMETHYL)PENTANAMIDE
525, 3dm6C, 0.9344, 0.77, 1.000, 367, 367, BETA-SECRETASE 1 COMPLEXED WITH STATINE-BASED INHIBITOR
526, 3buhA, 0.9343, 0.88, 0.995, 370, 368, BACE-1 COMPLEXED WITH COMPOUND 4
527, 3igbA, 0.9341, 1.05, 0.986, 369, 369, BACE-1 WITH COMPOUND 3
528, 5i3yA, 0.9337, 1.02, 0.992, 369, 369, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH AMINOQUINOLINE INHIBITOR 9
529, 4dh6A, 0.9337, 0.77, 0.995, 367, 367, STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH (2R)-N-((2S3R)- 1-(BENZO[D][13]DIOXOL-5-YL)-3-HYDROXY-4-((S)-6 -NEOPENTYL-3 4 - DIHYDROSPIRO[CYCLOBUTANE-12 -PYRANO[23-B]PYRIDINE]-4 -YLAMINO) BUTAN-2-YL)-2-METHOXYPROPANAMIDE
530, 3rtmA, 0.9337, 0.97, 0.995, 369, 369, STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH 3-(2- AMINOQUINOLIN-3-YL)-N-CYCLOHEXYL-N-METHYLPROPANAMIDE
531, 2zdzA, 0.9336, 1.18, 0.989, 370, 370, X-RAY STRUCTURE OF BACE-1 IN COMPLEX WITH COMPOUND 3.B.10
532, 3lhgA, 0.9334, 1.10, 0.986, 369, 369, BACE1 IN COMPLEX WITH THE AMINOHYDANTOIN COMPOUND 4G
533, 3in4A, 0.9333, 1.16, 0.992, 370, 370, BACE1 WITH COMPOUND 38
534, 3indA, 0.9332, 1.06, 0.989, 370, 369, BACE1 WITH THE AMINOHYDANTOIN COMPOUND 29
535, 4j1kA, 0.9327, 0.84, 0.995, 368, 367, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((4R5R6S)-2-AMINO-5-FLUORO-4-METHYL-6- TRIFLUOROMETHYL-56-DIHYDRO-4H-[13]OXAZIN-4-YL)-4-FLUORO-PHENYL]- AMIDE
536, 3braA, 0.9327, 0.94, 0.995, 370, 368, BACE-1 COMPLEXED WITH COMPOUND 1
537, 3s7lA, 0.9326, 1.12, 0.986, 369, 369, PYRAZOLYL AND THIENYL AMINOHYDANTOINS AS POTENT BACE1 INHIBITORS
538, 3oozA, 0.9323, 1.02, 0.986, 368, 368, BACE1 IN COMPLEX WITH THE AMINOHYDANTOIN COMPOUND 102
539, 6ej3A, 0.9321, 0.74, 1.000, 368, 366, BACE1 COMPOUND 23 
540, 3tprA, 0.9320, 0.93, 0.997, 368, 368, CRYSTAL STRUCTURE OF BACE1 COMPLEXED WITH AN INHIBITOR
541, 2ph8A, 0.9316, 0.65, 0.992, 365, 365, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH INHIBITOR
542, 2ewyD, 0.9312, 1.36, 0.544, 374, 373, CRYSTAL STRUCTURE OF HUMAN BACE2 IN COMPLEX WITH A HYDROXYETHYLENAMINE TRANSITION-STATE INHIBITOR
543, 2ewyC, 0.9312, 1.36, 0.544, 374, 373, CRYSTAL STRUCTURE OF HUMAN BACE2 IN COMPLEX WITH A HYDROXYETHYLENAMINE TRANSITION-STATE INHIBITOR
544, 2ewyB, 0.9312, 1.36, 0.544, 374, 373, CRYSTAL STRUCTURE OF HUMAN BACE2 IN COMPLEX WITH A HYDROXYETHYLENAMINE TRANSITION-STATE INHIBITOR
545, 2ewyA, 0.9312, 1.36, 0.544, 374, 373, CRYSTAL STRUCTURE OF HUMAN BACE2 IN COMPLEX WITH A HYDROXYETHYLENAMINE TRANSITION-STATE INHIBITOR
546, 3ineA, 0.9298, 0.99, 0.989, 367, 367, BACE1 WITH THE AMINOHYDANTOIN COMPOUND S-34
547, 3zkqA, 0.9297, 1.59, 0.549, 376, 375, BACE2 XAPERONE COMPLEX
548, 2zjnA, 0.9293, 0.92, 0.995, 367, 367, CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH N-[1-(5-CHLORO-2-ISOPROPOXY-3-METHOXY-BENZYL)- PIPERIDIN-4-YL]-2-(2-METHYL-4-SULFAMOYL-PHENOXY)-ACETAMIDE
549, 3kyrA, 0.9287, 0.81, 0.997, 365, 365, BACE-1 IN COMPLEX WITH A NORSTATINE TYPE INHIBITOR
550, 2qu3A, 0.9281, 1.21, 0.981, 368, 368, BACE1 WITH COMPOUND 2
551, 3rtnA, 0.9279, 1.01, 0.995, 367, 367, STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH 3-(2-AMINO-6-O- TOLYLQUINOLIN-3-YL)-N-CYCLOHEXYLPROPANAMIDE
552, 4dusA, 0.9259, 0.88, 0.995, 365, 365, STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH N-((2S3R)-1-(4- FLUOROPHENYL)-3-HYDROXY-4-((6 -NEOPENTYL-3 4 - DIHYDROSPIRO[CYCLOBUTANE-12 -PYRANO[23-B]PYRIDIN]-4 -YL)AMINO) BUTAN-2-YL)ACETAMIDE
553, 3inhA, 0.9251, 0.97, 0.992, 366, 365, BACE1 WITH THE AMINOHYDANTOIN COMPOUND R-58
554, 3infA, 0.9249, 1.12, 0.984, 367, 366, BACE1 WITH THE AMINOHYDANTOIN COMPOUND 37
555, 4rceA, 0.9246, 0.84, 0.995, 364, 364, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH AMINOOXAZOLINE XANTHENE INHIBITOR 2
556, 4bfbB, 0.9240, 1.63, 0.552, 374, 373, BACE2 XAPERONE COMPLEX
557, 4xkxA, 0.9238, 0.77, 0.994, 363, 363, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH 2-AMINOOXAZOLINE 3- AZAXANTHENE INHIBITOR 28
558, 4i1cA, 0.9228, 1.09, 1.000, 378, 366, DESIGN AND SYNTHESIS OF THIOPHENE DIHYDROISOQUINOLINS AS NOVEL BACE-1 INHIBITORS
559, 4bfbA, 0.9226, 1.64, 0.554, 373, 372, BACE2 XAPERONE COMPLEX
560, 3rsvA, 0.9215, 0.96, 0.978, 364, 364, STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH (R)-3-(2-AMINO-6- O-TOLYLQUINOLIN-3-YL)-N-((R)-22-DIMETHYLTETRAHYDRO-2H-PYRAN-4-YL)-2- METHYLPROPANAMIDE
561, 3kyrB, 0.9212, 0.89, 0.997, 363, 363, BACE-1 IN COMPLEX WITH A NORSTATINE TYPE INHIBITOR
562, 3l3aA, 0.9207, 1.16, 0.989, 365, 365, BACE-1 WITH THE AMINOPYRIDINE COMPOUND 32
563, 3l38A, 0.9204, 1.10, 0.986, 364, 364, BACE1 IN COMPLEX WITH THE AMINOPYRIDINE COMPOUND 44
564, 3kyrC, 0.9195, 0.63, 0.997, 360, 360, BACE-1 IN COMPLEX WITH A NORSTATINE TYPE INHIBITOR
565, 3ru1A, 0.9192, 0.95, 0.975, 363, 363, STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH 3-(2- AMINOQUINOLIN-3-YL)-N-(CYCLOHEXYLMETHYL)PROPANAMIDE
566, 3vv7A, 0.9172, 0.84, 0.997, 361, 361, CRYSTAL STRUCTURE OF BETA SECETASE IN COMPLEX WITH 2-AMINO-6-((1S2R)- 2-(3 -METHOXYBIPHENYL-3-YL)CYCLOPROPYL)-3-METHYLPYRIMIDIN-4(3H)-ONE
567, 3zkxA, 0.9171, 1.47, 0.556, 370, 369, TERNARY BACE2 XAPERONE COMPLEX
568, 3wb5A, 0.9163, 0.87, 0.994, 361, 361, CRYSTAL STRUCTURE OF BETA SECETASE IN COMPLEX WITH (6S)-2-AMINO-36- DIMETHYL-6-[(1R2R)-2-PHENYLCYCLOPROPYL]-3456-TETRAHYDROPYRIMIDIN- 4-ONE
569, 2qu2A, 0.9156, 1.35, 0.984, 364, 364, BACE1 WITH COMPOUND 1
570, 5ie1A, 0.9143, 0.99, 0.992, 361, 361, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH 3-(2-AMINO-6-(O-TOLYL) QUINOLIN-3-YL)-N-(33-DIMETHYLBUTYL)PROPANAMIDE
571, 3vv6A, 0.9140, 0.85, 0.997, 360, 360, CRYSTAL STRUCTURE OF BETA SECETASE IN COMPLEX WITH 2-AMINO-3-METHYL-6- ((1S 2R)-2-PHENYLCYCLOPROPYL)PYRIMIDIN-4(3H)-ONE
572, 3zlqB, 0.9139, 1.62, 0.556, 370, 369, BACE2 XAPERONE COMPLEX
573, 5enkA, 0.9127, 0.80, 0.997, 359, 359, COMPOUND 18
574, 5kr8A, 0.9126, 0.82, 0.997, 359, 359, (4~{S}6~{S})-4-[24-BIS(FLUORANYL)PHENYL]-6-(35-DIMETHYL-12-OXAZOL- 4-YL)-4-METHYL-56-DIHYDRO-13-THIAZIN-2-AMINE (COMPOUND 5) BOUND TO BACE1
575, 2ze1A, 0.9122, 1.00, 0.994, 360, 360, X-RAY STRUCTURE OF BACE-1 IN COMPLEX WITH COMPOUND 6G
576, 5enmA, 0.9116, 0.85, 0.997, 359, 359, COMPOUND 10
577, 5kqfA, 0.9098, 0.83, 1.000, 358, 358, (4~{S}6~{S})-4-[24-BIS(FLUORANYL)PHENYL]-4-METHYL-6-PYRIMIDIN-5-YL- 56-DIHYDRO-13-THIAZIN-2-AMINE (COMPOUND 12) BOUND TO BACE1
578, 3wb4A, 0.9097, 1.00, 0.992, 360, 360, CRYSTAL STRUCTURE OF BETA SECETASE IN COMPLEX WITH 2-AMINO-36- DIMETHYL-6-(2-PHENYLETHYL)-3456-TETRAHYDROPYRIMIDIN-4-ONE
579, 4i12A, 0.9089, 1.15, 0.997, 374, 361, DESIGN AND SYNTHESIS OF THIOPHENE DIHYDROISOQUINOLINS AS NOVEL BACE-1 INHIBITORS
580, 3vv8A, 0.9086, 0.87, 0.994, 358, 358, CRYSTAL STRUCTURE OF BETA SECETASE IN COMPLEX WITH 2-AMINO-3-METHYL-6- ((1S2R)-2-(3 -METHYLBIPHENYL-4-YL)CYCLOPROPYL)PYRIMIDIN-4(3H)-ONE
581, 3zkmA, 0.9068, 2.04, 0.543, 375, 370, BACE2 FAB COMPLEX
582, 3zlqA, 0.9061, 1.64, 0.557, 367, 366, BACE2 XAPERONE COMPLEX
583, 3zkgA, 0.9061, 1.39, 0.567, 364, 363, BACE2 MUTANT APO STRUCTURE
584, 2zjhA, 0.9057, 0.77, 0.997, 356, 356, CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH N-(1-BENZYL-PIPERIDIN-4-YL)-4-MERCAPTO-BUTYRAMIDE
585, 3zkmB, 0.9056, 2.10, 0.541, 375, 370, BACE2 FAB COMPLEX
586, 3zknB, 0.9049, 2.07, 0.543, 375, 370, BACE2 FAB INHIBITOR COMPLEX
587, 3zkiA, 0.9044, 1.51, 0.566, 365, 364, BACE2 MUTANT STRUCTURE WITH LIGAND
588, 4ke1A, 0.9043, 0.74, 0.994, 355, 355, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH HYDROXYETHYLAMINE- MACROCYCLIC INHIBITOR 19
589, 3bufA, 0.9041, 0.97, 0.994, 359, 357, BACE-1 COMPLEXED WITH COMPOUND 2
590, 3zknA, 0.9033, 2.15, 0.541, 375, 370, BACE2 FAB INHIBITOR COMPLEX
591, 3bugA, 0.9027, 0.92, 0.994, 357, 356, BACE-1 COMPLEXED WITH COMPOUND 3
592, 4belA, 0.8957, 1.27, 0.571, 358, 357, BACE2 XAPERONE COMPLEX
593, 3zl7A, 0.8955, 1.65, 0.552, 363, 362, BACE2 FYNOMER COMPLEX
594, 3zkiB, 0.8945, 1.51, 0.564, 361, 360, BACE2 MUTANT STRUCTURE WITH LIGAND
595, 3zksA, 0.8943, 1.50, 0.560, 360, 359, BACE2 XAPERONE COMPLEX WITH INHIBITOR
596, 3zkgB, 0.8936, 1.38, 0.567, 359, 358, BACE2 MUTANT APO STRUCTURE
597, 4belB, 0.8910, 1.31, 0.573, 357, 356, BACE2 XAPERONE COMPLEX
598, 2zjlA, 0.8749, 0.78, 0.997, 344, 344, CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH N-[1-(5-BROMO-23-DIMETHOXY-BENZYL)-PIPERIDIN- 4-YL]-4-MERCAPTO-BUTYRAMIDE
599, 2rmpA, 0.7843, 2.55, 0.203, 358, 335, RMP-PEPSTATIN A COMPLEX
600, 2asiA, 0.7775, 2.57, 0.201, 356, 333, ASPARTIC PROTEINASE
601, 1mppA, 0.7762, 2.62, 0.219, 357, 334, X-RAY ANALYSES OF ASPARTIC PROTEINASES. V. STRUCTURE AND REFINEMENT AT 2.0 ANGSTROMS RESOLUTION OF THE ASPARTIC PROTEINASE FROM MUCOR PUSILLUS
602, 5ux4B, 0.7683, 2.52, 0.276, 340, 326, CRYSTAL STRUCTURE OF RAT CATHEPSIN D WITH (5S)-3-(5;6-DIHYDRO-2H- PYRAN-3-YL)-1-FLUORO- 7-(2-FLUOROPYRIDIN-3-YL)SPIRO[CHROMENO[2;3- C]PYRIDINE-5;4 -[1;3]OXAZOL]-2 -AMINE 
603, 5ux4A, 0.7610, 2.53, 0.279, 337, 323, CRYSTAL STRUCTURE OF RAT CATHEPSIN D WITH (5S)-3-(5;6-DIHYDRO-2H- PYRAN-3-YL)-1-FLUORO- 7-(2-FLUOROPYRIDIN-3-YL)SPIRO[CHROMENO[2;3- C]PYRIDINE-5;4 -[1;3]OXAZOL]-2 -AMINE 
604, 5n71A, 0.7598, 2.44, 0.237, 337, 321, CRYSTAL STRUCTURE OF MATURE CATHEPSIN D FROM THE TICK IXODES RICINUS (IRCD1)
605, 5n7nB, 0.7566, 2.49, 0.237, 361, 321, CRYSTAL STRUCTURE OF CATHEPSIN D ZYMOGEN FROM THE TICK IXODES RICINUS (IRCD1)
606, 5n7qA, 0.7564, 2.64, 0.242, 337, 322, CRYSTAL STRUCTURE OF MATURE CATHEPSIN D FROM THE TICK IXODES RICINUS (IRCD1) IN COMPLEX WITH THE INHIBITOR PEPSTATIN A
607, 1fq8A, 0.7562, 2.39, 0.252, 329, 318, X-RAY STRUCTURE OF DIFLUOROSTATINE INHIBITOR CP81198 BOUND TO SACCHAROPEPSIN
608, 5n7nA, 0.7560, 2.49, 0.237, 361, 321, CRYSTAL STRUCTURE OF CATHEPSIN D ZYMOGEN FROM THE TICK IXODES RICINUS (IRCD1)
609, 5n7qB, 0.7559, 2.65, 0.242, 337, 322, CRYSTAL STRUCTURE OF MATURE CATHEPSIN D FROM THE TICK IXODES RICINUS (IRCD1) IN COMPLEX WITH THE INHIBITOR PEPSTATIN A
610, 2jxrA, 0.7559, 2.40, 0.252, 329, 318, STRUCTURE OF YEAST PROTEINASE A
611, 2i4qB, 0.7558, 2.80, 0.245, 336, 323, HUMAN RENIN/PF02342674 COMPLEX
612, 4zl4B, 0.7553, 2.75, 0.201, 395, 324, PLASMEPSIN V FROM PLASMODIUM VIVAX BOUND TO A TRANSITION STATE MIMETIC (WEHI-842)
613, 4zl4A, 0.7552, 2.76, 0.201, 395, 324, PLASMEPSIN V FROM PLASMODIUM VIVAX BOUND TO A TRANSITION STATE MIMETIC (WEHI-842)
614, 1fq6A, 0.7552, 2.39, 0.252, 329, 318, X-RAY STRUCTURE OF GLYCOL INHIBITOR PD-133450 BOUND TO SACCHAROPEPSIN
615, 5n7nD, 0.7549, 2.52, 0.234, 360, 321, CRYSTAL STRUCTURE OF CATHEPSIN D ZYMOGEN FROM THE TICK IXODES RICINUS (IRCD1)
616, 1fq7A, 0.7549, 2.44, 0.248, 329, 318, X-RAY STRUCTURE OF INHIBITOR CP-72647 BOUND TO SACCHAROPEPSIN
617, 1fq4A, 0.7549, 2.42, 0.255, 329, 318, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN HYDROXYETHYLENE INHIBITOR CP- 108420 AND YEAST ASPARTIC PROTEINASE A
618, 1fq5A, 0.7544, 2.42, 0.245, 329, 318, X-RAY STRUCTURE OF A CYCLIC STATINE INHIBITOR PD-129541 BOUND TO YEAST PROTEINASE A
619, 5n7nC, 0.7538, 2.60, 0.233, 361, 322, CRYSTAL STRUCTURE OF CATHEPSIN D ZYMOGEN FROM THE TICK IXODES RICINUS (IRCD1)
620, 3oqkB, 0.7538, 2.62, 0.247, 337, 320, CRYSTAL STRUCTURE ANALYSIS OF RENIN-INDOLE-PIPERAZIN INHIBITOR COMPLEXES
621, 3oqfB, 0.7536, 2.71, 0.249, 337, 321, CRYSTAL STRUCTURE ANALYSIS OF RENIN-INDOLE-PIPERAZINE INHIBITOR COMPLEXES
622, 3ootB, 0.7535, 2.79, 0.248, 337, 322, CRYSTAL STRUCTURE ANALYSIS OF RENIN-INDOLE-PIPERAZIN INHIBITOR COMPLEXES
623, 5mlgA, 0.7530, 2.40, 0.245, 364, 318, CRYSTAL STRUCTURE OF RAT PRORENIN
624, 2il2B, 0.7529, 2.75, 0.252, 338, 321, CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH INHIBITOR
625, 3sfcB, 0.7524, 2.65, 0.250, 340, 320, STRUCTURE-BASED OPTIMIZATION OF POTENT 4- AND 6-AZAINDOLE-3- CARBOXAMIDES AS RENIN INHIBITORS
626, 2ikuB, 0.7523, 2.76, 0.249, 337, 321, CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH INHIBITORS
627, 6c4gA, 0.7522, 2.68, 0.201, 394, 323, PLASMEPSIN V FROM PLASMODIUM VIVAX BOUND TO A TRANSITION STATE MIMETIC (WEHI-601) 
628, 4gjbB, 0.7522, 2.73, 0.253, 335, 320, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-BBV031 (COMPOUND 6)
629, 4gj9B, 0.7521, 2.71, 0.253, 335, 320, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH GP055321 (COMPOUND 4)
630, 4gj8B, 0.7519, 2.73, 0.253, 335, 320, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH PKF909-724 (COMPOUND 3)
631, 5nfgA, 0.7513, 2.45, 0.261, 333, 318, STRUCTURE OF RECOMBINANT CARDOSIN B FROM CYNARA CARDUNCULUS
632, 3vswB, 0.7511, 2.67, 0.250, 340, 320, HUMAN RENIN IN COMPLEX WITH COMPOUND 8
633, 2g1yB, 0.7509, 2.56, 0.252, 333, 318, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
634, 2g1sB, 0.7509, 2.57, 0.255, 333, 318, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
635, 4xx4B, 0.7508, 2.67, 0.251, 338, 319, RENIN IN COMPLEX WITH (4S)-4-ISOPROPYL-4-METHYL-6-OXO-1-(3-(2-OXO-4- PHENYLPYRROLIDIN-1-YL)BENZYL)TETRAHYDROPYRIMIDIN-2(1H)-IMINIUM
636, 2g1nB, 0.7508, 2.58, 0.248, 333, 318, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
637, 4s1gB, 0.7507, 2.67, 0.251, 338, 319, REIN IN COMPLEX WITH (S)-1-(3-FLUORO-5-(((S)-1-PHENYLETHYL)CARBAMOYL) BENZYL)-4-ISOPROPYL-4-METHYL-6-OXOTETRAHYDROPYRIMIDIN-2(1H)-IMINIUM
638, 2g1rB, 0.7507, 2.56, 0.252, 333, 318, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
639, 3q5hB, 0.7504, 2.78, 0.249, 338, 321, CLINICALLY USEFUL ALKYL AMINE RENIN INHIBITORS
640, 3q4bB, 0.7504, 2.83, 0.242, 337, 322, CLINICALLY USEFUL ALKYL AMINE RENIN INHIBITORS
641, 3vsxB, 0.7503, 2.69, 0.250, 340, 320, HUMAN RENIN IN COMPLEX WITH COMPOUND 18
642, 5v8vA, 0.7502, 2.84, 0.245, 337, 322, CRYSTAL STRUCTURE OF HUMAN RENIN IN COMPLEX WITH A BIPHENYLPIPDERIDINYLCARBINOL
643, 2i4qA, 0.7501, 2.85, 0.242, 336, 322, HUMAN RENIN/PF02342674 COMPLEX
644, 4aa8A, 0.7500, 2.31, 0.255, 323, 314, BOVINE CHYMOSIN AT 1.8A RESOLUTION
645, 1bilB, 0.7500, 2.68, 0.252, 333, 318, CRYSTALLOGRAPHIC STUDIES ON THE BINDING MODES OF P2-P3 BUTANEDIAMIDE RENIN INHIBITORS
646, 5v8vB, 0.7499, 2.86, 0.245, 337, 322, CRYSTAL STRUCTURE OF HUMAN RENIN IN COMPLEX WITH A BIPHENYLPIPDERIDINYLCARBINOL
647, 4xx3B, 0.7499, 2.69, 0.248, 338, 319, RENIN IN COMPLEX WITH (S)-1-(3-(BENZYLCARBAMOYL)BENZYL)-4-ISOPROPYL-4- METHYL-6-OXOTETRAHYDROPYRIMIDIN-2(1H)-IMINIUM
648, 6aprE, 0.7498, 2.45, 0.208, 325, 317, STRUCTURES OF COMPLEXES OF RHIZOPUSPEPSIN WITH PEPSTATIN AND OTHER STATINE-CONTAINING INHIBITORS
649, 4aucA, 0.7498, 2.30, 0.258, 323, 314, BOVINE CHYMOSIN IN COMPLEX WITH PEPSTATIN A
650, 5vpmB, 0.7497, 2.73, 0.244, 335, 320, CRYSTAL STRUCTURE OF HUMAN RENIN IN COMPLEX WITH A BIPHENYLPIPDERIDINYLCARBINOL
651, 2g22B, 0.7497, 2.60, 0.255, 333, 318, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
652, 1qrpE, 0.7497, 2.32, 0.273, 326, 315, HUMAN PEPSIN 3A IN COMPLEX WITH A PHOSPHONATE INHIBITOR IVA-VAL-VAL- LEU(P)-(O)PHE-ALA-ALA-OME
653, 3q3tA, 0.7496, 2.82, 0.249, 337, 321, ALKYL AMINE RENIN INHIBITORS: FILLING S1 FROM S3
654, 4rz1B, 0.7494, 2.66, 0.245, 336, 318, RENIN IN COMPLEXED WITH (3S4S)-4-({[4-METHOXY-3-(3-METHOXYPROPOXY) BENZOYL](PROPAN-2-YL)AMINO}METHYL)PYRROLIDIN-3-YL BENZYLCARBAMATE INHIBITOR
655, 3ownB, 0.7494, 2.70, 0.248, 334, 319, POTENT MACROCYCLIC RENIN INHIBITORS
656, 2g1oB, 0.7494, 2.52, 0.246, 333, 317, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
657, 5tmgB, 0.7492, 2.56, 0.252, 334, 317, OPTIMIZATION OF 35-DISUBSTITUED PIPERIDINE: DISCOVERY OF NON-PEPTIDE MIMETICS AS AN ORALLY ACTIVE RENIN INHIBITOR
658, 5sxnB, 0.7492, 2.64, 0.252, 336, 318, STRUCTURE-BASED DESIGN OF A NEW SERIES OF N-PIPERIDIN-3-YLPYRIMIDINE- 5-CARBOXAMIDES AS RENIN INHIBITORS
659, 4gjcB, 0.7492, 2.66, 0.248, 337, 318, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-BCH965 (COMPOUND 9)
660, 3sfcA, 0.7492, 2.84, 0.246, 340, 321, STRUCTURE-BASED OPTIMIZATION OF POTENT 4- AND 6-AZAINDOLE-3- CARBOXAMIDES AS RENIN INHIBITORS
661, 3q5hA, 0.7492, 2.82, 0.249, 337, 321, CLINICALLY USEFUL ALKYL AMINE RENIN INHIBITORS
662, 3km4A, 0.7491, 2.84, 0.249, 337, 321, OPTIMIZATION OF ORALLY BIOAVAILABLE ALKYL AMINE RENIN INHIBITORS
663, 5aprE, 0.7490, 2.46, 0.208, 325, 317, STRUCTURES OF COMPLEXES OF RHIZOPUSPEPSIN WITH PEPSTATIN AND OTHER STATINE-CONTAINING INHIBITORS
664, 3aprE, 0.7490, 2.46, 0.208, 325, 317, BINDING OF A REDUCED PEPTIDE INHIBITOR TO THE ASPARTIC PROTEINASE FROM RHIZOPUS CHINENSIS. IMPLICATIONS FOR A MECHANISM OF ACTION
665, 2ikoA, 0.7490, 2.82, 0.243, 338, 321, CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH INHIBITOR
666, 2g20B, 0.7490, 2.52, 0.249, 333, 317, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
667, 1bimB, 0.7490, 2.61, 0.252, 333, 317, CRYSTALLOGRAPHIC STUDIES ON THE BINDING MODES OF P2-P3 BUTANEDIAMIDE RENIN INHIBITORS
668, 4rygB, 0.7489, 2.67, 0.252, 337, 318, RENIN IN COMPLEXED WITH N-({(3S4S)-4-[(BENZYLSULFONYL) AMINO]PYRROLIDIN-3-YL}METHYL)-4-METHOXY-3-(3-METHOXYPROPOXY)-N- (PROPAN-2-YL)BENZAMIDE INHIBITOR
669, 4gjaB, 0.7489, 2.67, 0.248, 337, 318, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-AYL747 (COMPOUND 5)
670, 2il2A, 0.7489, 2.83, 0.243, 338, 321, CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH INHIBITOR
671, 4gjbA, 0.7488, 2.68, 0.248, 335, 319, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-BBV031 (COMPOUND 6)
672, 3vsxA, 0.7488, 2.87, 0.242, 340, 322, HUMAN RENIN IN COMPLEX WITH COMPOUND 18
673, 1uh7A, 0.7488, 2.46, 0.208, 325, 317, CRYSTAL STRUCTURE OF RHIZOPUSPEPSIN AT PH 4.6
674, 2ikuA, 0.7487, 2.78, 0.247, 337, 320, CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH INHIBITORS
675, 4q1nB, 0.7486, 2.62, 0.252, 336, 317, STRUCTURE-BASED DESIGN OF 4-HYDROXY-35-SUBSTITUTED PIPERIDINES AS DIRECT RENIN INHIBITORS
676, 1psoE, 0.7486, 2.28, 0.274, 326, 314, THE CRYSTAL STRUCTURE OF HUMAN PEPSIN AND ITS COMPLEX WITH PEPSTATIN
677, 4gj9A, 0.7485, 2.79, 0.247, 333, 320, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH GP055321 (COMPOUND 4)
678, 3q4bA, 0.7485, 2.89, 0.245, 337, 322, CLINICALLY USEFUL ALKYL AMINE RENIN INHIBITORS
679, 1uh9A, 0.7485, 2.47, 0.208, 325, 317, CRYSTAL STRUCTURE OF RHIZOPUSPEPSIN AT PH 7.0
680, 1psnA, 0.7485, 2.34, 0.270, 326, 315, THE CRYSTAL STRUCTURE OF HUMAN PEPSIN AND ITS COMPLEX WITH PEPSTATIN
681, 5sy3A, 0.7484, 2.62, 0.249, 333, 317, STRUCTURE-BASED DESIGN OF A NEW SERIES OF N-PIPERIDIN-3-YLPYRIMIDINE- 5-CARBOXAMIDES AS RENIN INHIBITORS
682, 2aprA, 0.7484, 2.47, 0.208, 325, 317, STRUCTURE AND REFINEMENT AT 1.8 ANGSTROMS RESOLUTION OF THE ASPARTIC PROTEINASE FROM RHIZOPUS CHINENSIS
683, 1cziE, 0.7483, 2.30, 0.252, 323, 314, CHYMOSIN COMPLEX WITH THE INHIBITOR CP-113972
684, 4xx4A, 0.7482, 2.90, 0.242, 339, 322, RENIN IN COMPLEX WITH (4S)-4-ISOPROPYL-4-METHYL-6-OXO-1-(3-(2-OXO-4- PHENYLPYRROLIDIN-1-YL)BENZYL)TETRAHYDROPYRIMIDIN-2(1H)-IMINIUM
685, 4rycB, 0.7482, 2.68, 0.248, 336, 318, RENIN IN COMPLEXED WITH 4-METHOXY-3-(3-METHOXYPROPOXY)-N-{[(3S4S)-4- {[(4-METHYLPHENYL)SULFONYL]AMINO}PYRROLIDIN-3-YL]METHYL}-N-(PROPAN-2- YL)BENZAMIDE INHIBITOR
686, 3vydB, 0.7482, 2.58, 0.252, 337, 317, HUMAN RENIN IN COMPLEX WITH INHIBITOR 6
687, 1qdmA, 0.7482, 2.85, 0.258, 430, 322, CRYSTAL STRUCTURE OF PROPHYTEPSIN A ZYMOGEN OF A BARLEY VACUOLAR ASPARTIC PROTEINASE.
688, 5kotB, 0.7481, 2.54, 0.250, 333, 316, DISCOVERY OF TAK-272: A NOVEL POTENT AND ORALLY ACTIVE RENIN IN- HIBITOR
689, 4xx3A, 0.7481, 2.91, 0.242, 339, 322, RENIN IN COMPLEX WITH (S)-1-(3-(BENZYLCARBAMOYL)BENZYL)-4-ISOPROPYL-4- METHYL-6-OXOTETRAHYDROPYRIMIDIN-2(1H)-IMINIUM
690, 4aprE, 0.7481, 2.47, 0.208, 325, 317, STRUCTURES OF COMPLEXES OF RHIZOPUSPEPSIN WITH PEPSTATIN AND OTHER STATINE-CONTAINING INHIBITORS
691, 2g1yA, 0.7481, 2.69, 0.245, 333, 319, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
692, 2g1sA, 0.7481, 2.69, 0.245, 333, 319, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
693, 3vswA, 0.7480, 2.86, 0.246, 340, 321, HUMAN RENIN IN COMPLEX WITH COMPOUND 8
694, 3gw5A, 0.7479, 2.85, 0.249, 337, 321, CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH A NOVEL INHIBITOR
695, 4s1gA, 0.7477, 2.92, 0.242, 339, 322, REIN IN COMPLEX WITH (S)-1-(3-FLUORO-5-(((S)-1-PHENYLETHYL)CARBAMOYL) BENZYL)-4-ISOPROPYL-4-METHYL-6-OXOTETRAHYDROPYRIMIDIN-2(1H)-IMINIUM
696, 3d91B, 0.7477, 2.81, 0.250, 337, 320, HUMAN RENIN IN COMPLEX WITH REMIKIREN
697, 1uh8A, 0.7477, 2.48, 0.208, 325, 317, CRYSTAL STRUCTURE OF RHIZOPUSPEPSIN AT PH 8.0
698, 4pyvB, 0.7476, 2.67, 0.255, 334, 318, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH COMPOUND4
699, 3d91A, 0.7476, 2.66, 0.245, 334, 318, HUMAN RENIN IN COMPLEX WITH REMIKIREN
700, 2g1rA, 0.7476, 2.71, 0.245, 333, 319, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
701, 4gjdB, 0.7475, 2.61, 0.252, 337, 317, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-BGQ311 (COMPOUND 12)
702, 1m43B, 0.7473, 2.64, 0.226, 331, 319, CRYSTAL STRUCTURE OF PMII IN COMPLEX WITH PEPSTATIN A TO 2.4 A
703, 2g1nA, 0.7471, 2.71, 0.245, 333, 319, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
704, 3oqfA, 0.7470, 2.89, 0.246, 337, 321, CRYSTAL STRUCTURE ANALYSIS OF RENIN-INDOLE-PIPERAZINE INHIBITOR COMPLEXES
705, 2g1oA, 0.7470, 2.72, 0.245, 333, 319, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
706, 1hrnB, 0.7470, 2.66, 0.246, 333, 317, HIGH RESOLUTION CRYSTAL STRUCTURES OF RECOMBINANT HUMAN RENIN IN COMPLEX WITH POLYHYDROXYMONOAMIDE INHIBITORS
707, 3utlA, 0.7469, 2.32, 0.271, 326, 314, HUMAN PEPSIN 3B
708, 1flhA, 0.7469, 2.31, 0.271, 326, 314, CRYSTAL STRUCTURE OF HUMAN UROPEPSIN AT 2.45 A RESOLUTION
709, 1xdhB, 0.7468, 2.57, 0.230, 329, 318, STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH PEPSTATIN A
710, 3vucB, 0.7467, 2.67, 0.252, 338, 318, HUMAN RENIN IN COMPLEX WITH COMPOUND 5
711, 1dp5A, 0.7467, 2.62, 0.259, 329, 317, THE STRUCTURE OF PROTEINASE A COMPLEXED WITH A IA3 MUTANT INHIBITOR
712, 2g22A, 0.7466, 2.73, 0.245, 333, 319, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
713, 1f34A, 0.7466, 2.34, 0.271, 325, 314, CRYSTAL STRUCTURE OF ASCARIS PEPSIN INHIBITOR-3 BOUND TO PORCINE PEPSIN
714, 3oqkA, 0.7464, 2.86, 0.243, 337, 321, CRYSTAL STRUCTURE ANALYSIS OF RENIN-INDOLE-PIPERAZIN INHIBITOR COMPLEXES
715, 1g0vA, 0.7464, 2.59, 0.259, 329, 317, THE STRUCTURE OF PROTEINASE A COMPLEXED WITH A IA3 MUTANT MVV
716, 5pepA, 0.7463, 2.35, 0.271, 326, 314, X-RAY ANALYSES OF ASPARTIC PROTEASES. II. THREE-DIMENSIONAL STRUCTURE OF THE HEXAGONAL CRYSTAL FORM OF PORCINE PEPSIN AT 2.3 ANGSTROMS RESOLUTION
717, 1fmxA, 0.7462, 2.38, 0.259, 325, 313, STRUCTURE OF NATIVE PROTEINASE A IN THE SPACE GROUP P21
718, 5vpmA, 0.7461, 2.68, 0.255, 334, 318, CRYSTAL STRUCTURE OF HUMAN RENIN IN COMPLEX WITH A BIPHENYLPIPDERIDINYLCARBINOL
719, 4gj7B, 0.7461, 2.67, 0.249, 336, 317, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-BCA079 (COMPOUND 12A)
720, 4gjaA, 0.7459, 2.80, 0.245, 337, 319, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-AYL747 (COMPOUND 5)
721, 3vucA, 0.7459, 2.96, 0.245, 340, 322, HUMAN RENIN IN COMPLEX WITH COMPOUND 5
722, 3ootA, 0.7459, 2.77, 0.250, 337, 320, CRYSTAL STRUCTURE ANALYSIS OF RENIN-INDOLE-PIPERAZIN INHIBITOR COMPLEXES
723, 4rz1A, 0.7457, 2.82, 0.245, 336, 319, RENIN IN COMPLEXED WITH (3S4S)-4-({[4-METHOXY-3-(3-METHOXYPROPOXY) BENZOYL](PROPAN-2-YL)AMINO}METHYL)PYRROLIDIN-3-YL BENZYLCARBAMATE INHIBITOR
724, 4gjcA, 0.7456, 2.81, 0.245, 337, 319, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-BCH965 (COMPOUND 9)
725, 1dpjA, 0.7455, 2.64, 0.259, 329, 317, THE STRUCTURE OF PROTEINASE A COMPLEXED WITH IA3 PEPTIDE INHIBITOR
726, 4gj8A, 0.7454, 2.75, 0.252, 334, 318, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH PKF909-724 (COMPOUND 3)
727, 4pyvA, 0.7453, 2.81, 0.245, 335, 319, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH COMPOUND4
728, 1yx9A, 0.7453, 2.37, 0.271, 326, 314, EFFECT OF DIMETHYL SULPHOXIDE ON THE CRYSTAL STRUCTURE OF PORCINE PEPSIN
729, 5kosB, 0.7452, 2.55, 0.251, 332, 315, DISCOVERY OF TAK-272: A NOVEL POTENT AND ORALLY ACTIVE RENIN IN- HIBITOR
730, 4gj6B, 0.7452, 2.79, 0.251, 333, 319, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-AYZ832 (COMPOUND 6A)
731, 3k1wB, 0.7452, 2.80, 0.254, 337, 319, NEW CLASSES OF POTENT AND BIOAVAILABLE HUMAN RENIN INHIBITORS
732, 1w6iC, 0.7452, 2.64, 0.230, 329, 318, PLASMEPSIN II-PEPSTATIN A COMPLEX
733, 1cmsA, 0.7452, 2.27, 0.259, 323, 313, THE THREE-DIMENSIONAL STRUCTURE OF RECOMBINANT BOVINE CHYMOSIN AT 2.3 ANGSTROMS RESOLUTION
734, 5sz9B, 0.7451, 2.54, 0.251, 332, 315, STRUCTURE-BASED DESIGN OF A NEW SERIES OF N-PIPERIDIN-3-YLPYRIMIDINE- 5-CARBOXAMIDES AS RENIN INHIBITORS
735, 2v0zC, 0.7451, 2.87, 0.244, 338, 320, CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 10 (ALISKIREN)
736, 1psaB, 0.7451, 2.38, 0.271, 326, 314, STRUCTURE OF A PEPSIN(SLASH)RENIN INHIBITOR COMPLEX REVEALS A NOVEL CRYSTAL PACKING INDUCED BY MINOR CHEMICAL ALTERATIONS IN THE INHIBITOR
737, 1psaA, 0.7451, 2.44, 0.267, 326, 315, STRUCTURE OF A PEPSIN(SLASH)RENIN INHIBITOR COMPLEX REVEALS A NOVEL CRYSTAL PACKING INDUCED BY MINOR CHEMICAL ALTERATIONS IN THE INHIBITOR
738, 1bilA, 0.7451, 2.72, 0.248, 334, 318, CRYSTALLOGRAPHIC STUDIES ON THE BINDING MODES OF P2-P3 BUTANEDIAMIDE RENIN INHIBITORS
739, 5vrpA, 0.7450, 2.74, 0.248, 333, 318, CRYSTAL STRUCTURE OF HUMAN RENIN IN COMPLEX WITH A BIPHENYLPIPDERIDINYLCARBINOL
740, 1bimA, 0.7450, 2.80, 0.248, 334, 319, CRYSTALLOGRAPHIC STUDIES ON THE BINDING MODES OF P2-P3 BUTANEDIAMIDE RENIN INHIBITORS
741, 2g24B, 0.7449, 2.46, 0.252, 329, 314, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
742, 2g21B, 0.7449, 2.46, 0.252, 329, 314, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
743, 1hrnA, 0.7449, 2.84, 0.248, 334, 319, HIGH RESOLUTION CRYSTAL STRUCTURES OF RECOMBINANT HUMAN RENIN IN COMPLEX WITH POLYHYDROXYMONOAMIDE INHIBITORS
744, 5vrpB, 0.7448, 2.69, 0.252, 333, 317, CRYSTAL STRUCTURE OF HUMAN RENIN IN COMPLEX WITH A BIPHENYLPIPDERIDINYLCARBINOL
745, 4rygA, 0.7448, 2.82, 0.245, 336, 319, RENIN IN COMPLEXED WITH N-({(3S4S)-4-[(BENZYLSULFONYL) AMINO]PYRROLIDIN-3-YL}METHYL)-4-METHOXY-3-(3-METHOXYPROPOXY)-N- (PROPAN-2-YL)BENZAMIDE INHIBITOR
746, 3ownA, 0.7448, 2.84, 0.245, 334, 319, POTENT MACROCYCLIC RENIN INHIBITORS
747, 1smrG, 0.7448, 2.59, 0.249, 331, 317, THE 3-D STRUCTURE OF MOUSE SUBMAXILLARY RENIN COMPLEXED WITH A DECAPEPTIDE INHIBITOR CH-66 BASED ON THE 4-16 FRAGMENT OF RAT ANGIOTENSINOGEN
748, 1smrE, 0.7448, 2.59, 0.249, 331, 317, THE 3-D STRUCTURE OF MOUSE SUBMAXILLARY RENIN COMPLEXED WITH A DECAPEPTIDE INHIBITOR CH-66 BASED ON THE 4-16 FRAGMENT OF RAT ANGIOTENSINOGEN
749, 1smrC, 0.7448, 2.59, 0.249, 331, 317, THE 3-D STRUCTURE OF MOUSE SUBMAXILLARY RENIN COMPLEXED WITH A DECAPEPTIDE INHIBITOR CH-66 BASED ON THE 4-16 FRAGMENT OF RAT ANGIOTENSINOGEN
750, 1smrA, 0.7448, 2.59, 0.249, 331, 317, THE 3-D STRUCTURE OF MOUSE SUBMAXILLARY RENIN COMPLEXED WITH A DECAPEPTIDE INHIBITOR CH-66 BASED ON THE 4-16 FRAGMENT OF RAT ANGIOTENSINOGEN
751, 1fmxB, 0.7447, 2.36, 0.259, 325, 313, STRUCTURE OF NATIVE PROTEINASE A IN THE SPACE GROUP P21
752, 3vyfB, 0.7446, 2.56, 0.254, 335, 315, HUMAN RENIN IN COMPLEX WITH INHIBITOR 9
753, 3g70B, 0.7446, 2.76, 0.251, 337, 319, DESIGN AND PREPARATION OF POTENT NON-PEPTIDIC BIOAVAILABLE RENIN INHIBITORS
754, 1xe6B, 0.7445, 2.52, 0.233, 329, 317, STRUCTURE OF PLASMEPSIN II IN COMPLEX OF AN PEPSTATIN ANALOGUE
755, 4gj5B, 0.7444, 2.65, 0.250, 331, 316, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-AMQ838 (COMPOUND 5)
756, 3vydA, 0.7444, 2.74, 0.245, 337, 318, HUMAN RENIN IN COMPLEX WITH INHIBITOR 6
757, 3vyeB, 0.7442, 2.58, 0.254, 335, 315, HUMAN RENIN IN COMPLEX WITH INHIBITOR 7
758, 2v16O, 0.7442, 2.70, 0.249, 331, 317, CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 3
759, 5nfgB, 0.7441, 2.34, 0.262, 328, 313, STRUCTURE OF RECOMBINANT CARDOSIN B FROM CYNARA CARDUNCULUS
760, 4cmsA, 0.7441, 2.37, 0.256, 320, 313, X-RAY ANALYSES OF ASPARTIC PROTEINASES IV. STRUCTURE AND REFINEMENT AT 2.2 ANGSTROMS RESOLUTION OF BOVINE CHYMOSIN
761, 1xe5B, 0.7441, 2.53, 0.230, 329, 317, STRUCTURE OF PLASMEPSIN II IN COMPLEX OF AN PEPSTATIN ANALOGUE
762, 1am5A, 0.7441, 2.29, 0.275, 324, 313, THE CRYSTAL STRUCTURE AND PROPOSED AMINO ACID SEQUENCE OF A PEPSIN FROM ATLANTIC COD (GADUS MORHUA)
763, 4q1nA, 0.7440, 2.79, 0.245, 336, 318, STRUCTURE-BASED DESIGN OF 4-HYDROXY-35-SUBSTITUTED PIPERIDINES AS DIRECT RENIN INHIBITORS
764, 4gj6A, 0.7440, 2.79, 0.248, 333, 319, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-AYZ832 (COMPOUND 6A)
765, 3pepA, 0.7440, 2.38, 0.268, 326, 314, REVISED 2.3 ANGSTROMS STRUCTURE OF PORCINE PEPSIN. EVIDENCE FOR A FLEXIBLE SUBDOMAIN
766, 3cmsA, 0.7439, 2.26, 0.260, 320, 312, ENGINEERING ENZYME SUB-SITE SPECIFICITY: PREPARATION KINETIC CHARACTERIZATION AND X-RAY ANALYSIS AT 2.0-ANGSTROMS RESOLUTION OF VAL111PHE SITE-MUTATED CALF CHYMOSIN
767, 5koqA, 0.7437, 2.84, 0.244, 335, 320, DISCOVERY OF TAK-272: A NOVEL POTENT AND ORALLY ACTIVE RENIN IN- HIBITOR
768, 3q3tB, 0.7437, 2.75, 0.248, 333, 318, ALKYL AMINE RENIN INHIBITORS: FILLING S1 FROM S3
769, 3g72B, 0.7437, 2.69, 0.256, 336, 317, DESIGN AND PREPARATION OF POTENT NON-PEPTIDIC BIOAVAILABLE RENIN INHIBITORS
770, 1me6B, 0.7437, 2.67, 0.230, 329, 318, CRYSTAL STRUCTURE OF PLASMEPSIN II AN ASPARTYL PROTEASE FROM PLASMODIUM FALCIPARUM IN COMPLEX WITH A STATINE-BASED INHIBITOR
771, 5tmkB, 0.7436, 2.48, 0.249, 330, 313, OPTIMIZATION OF 35-DISUBSTITUED PIPERIDINE: DISCOVERY OF NON-PEPTIDE MIMETICS AS AN ORALLY ACTIVE RENIN INHIBITOR
772, 5koqB, 0.7436, 2.63, 0.244, 333, 316, DISCOVERY OF TAK-272: A NOVEL POTENT AND ORALLY ACTIVE RENIN IN- HIBITOR
773, 2g20A, 0.7436, 2.77, 0.245, 333, 319, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
774, 1wkrA, 0.7436, 2.80, 0.242, 340, 318, CRYSTAL STRUCTURE OF ASPARTIC PROTEINASE FROM IRPEX LACTEUS
775, 1bbsB, 0.7436, 2.68, 0.249, 331, 317, X-RAY ANALYSES OF PEPTIDE INHIBITOR COMPLEXES DEFINE THE STRUCTURAL BASIS OF SPECIFICITY FOR HUMAN AND MOUSE RENINS
776, 1bbsA, 0.7436, 2.68, 0.249, 331, 317, X-RAY ANALYSES OF PEPTIDE INHIBITOR COMPLEXES DEFINE THE STRUCTURAL BASIS OF SPECIFICITY FOR HUMAN AND MOUSE RENINS
777, 3g70A, 0.7435, 2.82, 0.248, 334, 319, DESIGN AND PREPARATION OF POTENT NON-PEPTIDIC BIOAVAILABLE RENIN INHIBITORS
778, 1smeB, 0.7435, 2.70, 0.230, 329, 318, PLASMEPSIN II A HEMOGLOBIN-DEGRADING ENZYME FROM PLASMODIUM FALCIPARUM IN COMPLEX WITH PEPSTATIN A
779, 2v10O, 0.7433, 2.57, 0.254, 331, 315, CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 9
780, 2v0zO, 0.7433, 2.67, 0.247, 336, 316, CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 10 (ALISKIREN)
781, 4rycA, 0.7430, 2.86, 0.245, 336, 319, RENIN IN COMPLEXED WITH 4-METHOXY-3-(3-METHOXYPROPOXY)-N-{[(3S4S)-4- {[(4-METHYLPHENYL)SULFONYL]AMINO}PYRROLIDIN-3-YL]METHYL}-N-(PROPAN-2- YL)BENZAMIDE INHIBITOR
782, 4gjdA, 0.7430, 2.82, 0.245, 335, 318, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-BGQ311 (COMPOUND 12)
783, 5sxnA, 0.7429, 2.88, 0.245, 336, 319, STRUCTURE-BASED DESIGN OF A NEW SERIES OF N-PIPERIDIN-3-YLPYRIMIDINE- 5-CARBOXAMIDES AS RENIN INHIBITORS
784, 5tmgA, 0.7428, 2.86, 0.245, 334, 319, OPTIMIZATION OF 35-DISUBSTITUED PIPERIDINE: DISCOVERY OF NON-PEPTIDE MIMETICS AS AN ORALLY ACTIVE RENIN INHIBITOR
785, 4gj5A, 0.7428, 2.67, 0.250, 332, 316, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-AMQ838 (COMPOUND 5)
786, 3g72A, 0.7428, 2.79, 0.248, 333, 318, DESIGN AND PREPARATION OF POTENT NON-PEPTIDIC BIOAVAILABLE RENIN INHIBITORS
787, 2v12O, 0.7427, 2.60, 0.251, 331, 315, CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 8
788, 2v11O, 0.7426, 2.67, 0.250, 331, 316, CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 6
789, 3k1wA, 0.7424, 2.80, 0.248, 333, 318, NEW CLASSES OF POTENT AND BIOAVAILABLE HUMAN RENIN INHIBITORS
790, 3g6zA, 0.7424, 2.76, 0.252, 337, 318, DESIGN AND PREPARATION OF POTENT NON-PEPTIDIC BIOAVAILABLE RENIN INHIBITORS
791, 1qdmC, 0.7423, 2.47, 0.266, 427, 316, CRYSTAL STRUCTURE OF PROPHYTEPSIN A ZYMOGEN OF A BARLEY VACUOLAR ASPARTIC PROTEINASE.
792, 4pepA, 0.7422, 2.38, 0.272, 325, 313, THE MOLECULAR AND CRYSTAL STRUCTURES OF MONOCLINIC PORCINE PEPSIN REFINED AT 1.8 ANGSTROMS RESOLUTION
793, 3km4B, 0.7422, 2.79, 0.252, 333, 317, OPTIMIZATION OF ORALLY BIOAVAILABLE ALKYL AMINE RENIN INHIBITORS
794, 5sz9A, 0.7421, 2.77, 0.245, 334, 318, STRUCTURE-BASED DESIGN OF A NEW SERIES OF N-PIPERIDIN-3-YLPYRIMIDINE- 5-CARBOXAMIDES AS RENIN INHIBITORS
795, 3vyeA, 0.7421, 2.80, 0.246, 335, 317, HUMAN RENIN IN COMPLEX WITH INHIBITOR 7
796, 5sy3B, 0.7418, 2.83, 0.248, 335, 318, STRUCTURE-BASED DESIGN OF A NEW SERIES OF N-PIPERIDIN-3-YLPYRIMIDINE- 5-CARBOXAMIDES AS RENIN INHIBITORS
797, 4gj7A, 0.7417, 2.83, 0.245, 335, 318, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-BCA079 (COMPOUND 12A)
798, 3vyfA, 0.7417, 2.85, 0.245, 336, 318, HUMAN RENIN IN COMPLEX WITH INHIBITOR 9
799, 3g6zB, 0.7417, 2.76, 0.248, 334, 318, DESIGN AND PREPARATION OF POTENT NON-PEPTIDIC BIOAVAILABLE RENIN INHIBITORS
800, 4ya8C, 0.7416, 2.64, 0.230, 329, 318, STRUCTURE OF PLASMEPSIN II FROM PLASMODIUM FALCIPARUM COMPLEXED WITH INHIBITOR PG394
801, 2g21A, 0.7416, 2.61, 0.248, 329, 315, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
802, 3gw5B, 0.7414, 2.76, 0.249, 332, 317, CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH A NOVEL INHIBITOR
803, 2g24A, 0.7414, 2.63, 0.244, 329, 315, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
804, 1ls5B, 0.7411, 2.66, 0.223, 328, 318, CRYSTAL STRUCTURE OF PLASMEPSIN IV FROM P. FALCIPARUM IN COMPLEX WITH PEPSTATIN A
805, 1qdmB, 0.7410, 2.76, 0.270, 430, 319, CRYSTAL STRUCTURE OF PROPHYTEPSIN A ZYMOGEN OF A BARLEY VACUOLAR ASPARTIC PROTEINASE.
806, 1fmuA, 0.7410, 2.25, 0.251, 322, 311, STRUCTURE OF NATIVE PROTEINASE A IN P3221 SPACE GROUP.
807, 2x0bG, 0.7409, 2.64, 0.248, 329, 315, CRYSTAL STRUCTURE OF HUMAN ANGIOTENSINOGEN COMPLEXED WITH RENIN
808, 2x0bE, 0.7409, 2.64, 0.248, 329, 315, CRYSTAL STRUCTURE OF HUMAN ANGIOTENSINOGEN COMPLEXED WITH RENIN
809, 2x0bC, 0.7409, 2.64, 0.248, 329, 315, CRYSTAL STRUCTURE OF HUMAN ANGIOTENSINOGEN COMPLEXED WITH RENIN
810, 2x0bA, 0.7409, 2.64, 0.248, 329, 315, CRYSTAL STRUCTURE OF HUMAN ANGIOTENSINOGEN COMPLEXED WITH RENIN
811, 2fs4A, 0.7409, 2.64, 0.248, 329, 315, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
812, 2bksA, 0.7409, 2.64, 0.248, 329, 315, CRYSTAL STRUCTURE OF RENIN-PF00074777 COMPLEX
813, 5sy2A, 0.7408, 2.76, 0.246, 335, 317, STRUCTURE-BASED DESIGN OF A NEW SERIES OF N-PIPERIDIN-3-YLPYRIMIDINE- 5-CARBOXAMIDES AS RENIN INHIBITORS
814, 5t4sA, 0.7405, 2.69, 0.251, 334, 315, NOVEL APPROACH OF FRAGMENT-BASED LEAD DISCOVERY APPLIED TO RENIN INHIBITORS
815, 2g26A, 0.7404, 2.65, 0.244, 329, 315, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
816, 4ya8B, 0.7402, 2.69, 0.220, 329, 318, STRUCTURE OF PLASMEPSIN II FROM PLASMODIUM FALCIPARUM COMPLEXED WITH INHIBITOR PG394
817, 5tmkA, 0.7399, 2.87, 0.245, 333, 318, OPTIMIZATION OF 35-DISUBSTITUED PIPERIDINE: DISCOVERY OF NON-PEPTIDE MIMETICS AS AN ORALLY ACTIVE RENIN INHIBITOR
818, 2v12C, 0.7398, 2.74, 0.249, 333, 317, CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 8
819, 5t4sB, 0.7397, 2.65, 0.245, 331, 314, NOVEL APPROACH OF FRAGMENT-BASED LEAD DISCOVERY APPLIED TO RENIN INHIBITORS
820, 2qzxB, 0.7397, 2.63, 0.235, 342, 315, SECRETED ASPARTIC PROTEINASE (SAP) 5 FROM CANDIDA ALBICANS
821, 2v11C, 0.7393, 2.80, 0.246, 333, 317, CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 6
822, 1xdhA, 0.7393, 2.71, 0.233, 329, 318, STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH PEPSTATIN A
823, 4ckuB, 0.7392, 2.60, 0.228, 327, 316, THREE DIMENSIONAL STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH HYDROXYETHYLAMINE-BASED INHIBITOR
824, 1rneA, 0.7391, 2.76, 0.244, 329, 315, THE CRYSTAL STRUCTURE OF RECOMBINANT GLYCOSYLATED HUMAN RENIN ALONE AND IN COMPLEX WITH A TRANSITION STATE ANALOG INHIBITOR
825, 2bktB, 0.7390, 2.67, 0.248, 329, 315, CRYSTAL STRUCTURE OF RENIN-PF00257567 COMPLEX
826, 2v10C, 0.7389, 2.80, 0.246, 333, 317, CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 9
827, 2v16C, 0.7388, 2.80, 0.246, 333, 317, CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 3
828, 1w6iA, 0.7387, 2.73, 0.233, 329, 318, PLASMEPSIN II-PEPSTATIN A COMPLEX
829, 1me6A, 0.7383, 2.74, 0.230, 329, 318, CRYSTAL STRUCTURE OF PLASMEPSIN II AN ASPARTYL PROTEASE FROM PLASMODIUM FALCIPARUM IN COMPLEX WITH A STATINE-BASED INHIBITOR
830, 1m43A, 0.7383, 2.83, 0.226, 331, 319, CRYSTAL STRUCTURE OF PMII IN COMPLEX WITH PEPSTATIN A TO 2.4 A
831, 1w6hA, 0.7381, 2.48, 0.229, 325, 314, NOVEL PLASMEPSIN II-INHIBITOR COMPLEX
832, 5kotA, 0.7379, 2.78, 0.244, 332, 316, DISCOVERY OF TAK-272: A NOVEL POTENT AND ORALLY ACTIVE RENIN IN- HIBITOR
833, 3qs1B, 0.7378, 2.72, 0.218, 327, 317, CRYSTAL STRUCTURE OF KNI-10006 COMPLEX OF PLASMEPSIN I (PMI) FROM PLASMODIUM FALCIPARUM
834, 2qzxA, 0.7377, 2.66, 0.238, 342, 315, SECRETED ASPARTIC PROTEINASE (SAP) 5 FROM CANDIDA ALBICANS
835, 1lf3A, 0.7377, 2.82, 0.223, 331, 319, CRYSTAL STRUCTURE OF PLASMEPSIN II FROM P FALCIPARUM IN COMPLEX WITH INHIBITOR EH58
836, 4ckuF, 0.7376, 2.78, 0.220, 329, 318, THREE DIMENSIONAL STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH HYDROXYETHYLAMINE-BASED INHIBITOR
837, 2ikoB, 0.7376, 2.76, 0.248, 332, 315, CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH INHIBITOR
838, 2g27B, 0.7376, 2.55, 0.249, 328, 313, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
839, 2r9bA, 0.7375, 2.73, 0.233, 329, 318, STRUCTURAL ANALYSIS OF PLASMEPSIN 2 FROM PLASMODIUM FALCIPARUM COMPLEXED WITH A PEPTIDE-BASED INHIBITOR
840, 2g26B, 0.7375, 2.60, 0.252, 329, 314, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
841, 1xe6A, 0.7373, 2.75, 0.230, 329, 318, STRUCTURE OF PLASMEPSIN II IN COMPLEX OF AN PEPSTATIN ANALOGUE
842, 1xe5A, 0.7373, 2.76, 0.230, 329, 318, STRUCTURE OF PLASMEPSIN II IN COMPLEX OF AN PEPSTATIN ANALOGUE
843, 4ya8D, 0.7370, 2.71, 0.221, 328, 317, STRUCTURE OF PLASMEPSIN II FROM PLASMODIUM FALCIPARUM COMPLEXED WITH INHIBITOR PG394
844, 1smeA, 0.7370, 2.79, 0.230, 329, 318, PLASMEPSIN II A HEMOGLOBIN-DEGRADING ENZYME FROM PLASMODIUM FALCIPARUM IN COMPLEX WITH PEPSTATIN A
845, 2bktA, 0.7368, 2.70, 0.253, 329, 316, CRYSTAL STRUCTURE OF RENIN-PF00257567 COMPLEX
846, 1ls5A, 0.7368, 2.74, 0.223, 328, 318, CRYSTAL STRUCTURE OF PLASMEPSIN IV FROM P. FALCIPARUM IN COMPLEX WITH PEPSTATIN A
847, 5yiaA, 0.7367, 2.72, 0.233, 328, 317, CRYSTAL STRUCTURE OF KNI-10343 BOUND PLASMEPSIN II (PMII) FROM PLASMODIUM FALCIPARUM 
848, 2fs4B, 0.7366, 2.62, 0.252, 329, 314, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
849, 2bksB, 0.7366, 2.62, 0.252, 329, 314, CRYSTAL STRUCTURE OF RENIN-PF00074777 COMPLEX
850, 5yicA, 0.7365, 2.63, 0.234, 328, 316, CRYSTAL STRUCTURE OF KNI-10333 BOUND PLASMEPSIN II (PMII) FROM PLASMODIUM FALCIPARUM 
851, 5yieA, 0.7363, 2.56, 0.232, 327, 315, CRYSTAL STRUCTURE OF KNI-10742 BOUND PLASMEPSIN II (PMII) FROM PLASMODIUM FALCIPARUM 
852, 5yidA, 0.7363, 2.55, 0.232, 327, 315, CRYSTAL STRUCTURE OF KNI-10395 BOUND PLASMEPSIN II (PMII) FROM PLASMODIUM FALCIPARUM 
853, 1w6hB, 0.7363, 2.55, 0.229, 325, 314, NOVEL PLASMEPSIN II-INHIBITOR COMPLEX
854, 1qs8B, 0.7363, 2.74, 0.224, 328, 317, CRYSTAL STRUCTURE OF THE P. VIVAX ASPARTIC PROTEINASE PLASMEPSIN COMPLEXED WITH THE INHIBITOR PEPSTATIN A
855, 3qs1A, 0.7362, 2.76, 0.218, 327, 317, CRYSTAL STRUCTURE OF KNI-10006 COMPLEX OF PLASMEPSIN I (PMI) FROM PLASMODIUM FALCIPARUM
856, 2v13A, 0.7359, 2.70, 0.252, 329, 314, CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 7
857, 5yibA, 0.7358, 2.74, 0.233, 328, 317, CRYSTAL STRUCTURE OF KNI-10743 BOUND PLASMEPSIN II (PMII) FROM PLASMODIUM FALCIPARUM 
858, 4ya8A, 0.7354, 2.80, 0.220, 329, 318, STRUCTURE OF PLASMEPSIN II FROM PLASMODIUM FALCIPARUM COMPLEXED WITH INHIBITOR PG394
859, 2r9bB, 0.7350, 2.73, 0.233, 329, 317, STRUCTURAL ANALYSIS OF PLASMEPSIN 2 FROM PLASMODIUM FALCIPARUM COMPLEXED WITH A PEPTIDE-BASED INHIBITOR
860, 5kosA, 0.7349, 2.79, 0.248, 331, 315, DISCOVERY OF TAK-272: A NOVEL POTENT AND ORALLY ACTIVE RENIN IN- HIBITOR
861, 3qrvB, 0.7349, 2.77, 0.223, 329, 318, CRYSTAL STRUCTURE OF PLASMEPSIN I (PMI) FROM PLASMODIUM FALCIPARUM
862, 2g27A, 0.7346, 2.71, 0.248, 328, 315, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
863, 2renA, 0.7344, 2.24, 0.254, 320, 307, STRUCTURE OF RECOMBINANT HUMAN RENIN A TARGET FOR CARDIOVASCULAR- ACTIVE DRUGS AT 2.5 ANGSTROMS RESOLUTION
864, 3qs1C, 0.7341, 2.73, 0.218, 326, 316, CRYSTAL STRUCTURE OF KNI-10006 COMPLEX OF PLASMEPSIN I (PMI) FROM PLASMODIUM FALCIPARUM
865, 2bjuA, 0.7341, 2.80, 0.230, 329, 318, PLASMEPSIN II COMPLEXED WITH A HIGHLY ACTIVE ACHIRAL INHIBITOR
866, 3qs1D, 0.7340, 2.72, 0.218, 326, 316, CRYSTAL STRUCTURE OF KNI-10006 COMPLEX OF PLASMEPSIN I (PMI) FROM PLASMODIUM FALCIPARUM
867, 5n70A, 0.7338, 2.63, 0.243, 339, 313, CRYSTAL STRUCTURE OF MATURE CATHEPSIN D FROM THE TICK IXODES RICINUS (IRCD1) IN COMPLEX WITH THE N-TERMINAL OCTAPEPTIDE OF THE PROPEPTID
868, 2psgA, 0.7337, 2.56, 0.272, 369, 313, REFINED STRUCTURE OF PORCINE PEPSINOGEN AT 1.8 ANGSTROMS RESOLUTION
869, 2anlB, 0.7334, 2.68, 0.241, 327, 315, X-RAY CRYSTAL STRUCTURE OF THE ASPARTIC PROTEASE PLASMEPSIN 4 FROM THE MALARIAL PARASITE PLASMODIUM MALARIAE BOUND TO AN ALLOPHENYLNORSTATINE BASED INHIBITOR
870, 2anlA, 0.7334, 2.68, 0.241, 327, 315, X-RAY CRYSTAL STRUCTURE OF THE ASPARTIC PROTEASE PLASMEPSIN 4 FROM THE MALARIAL PARASITE PLASMODIUM MALARIAE BOUND TO AN ALLOPHENYLNORSTATINE BASED INHIBITOR
871, 1lf2A, 0.7334, 2.84, 0.233, 329, 318, CRYSTAL STRUCTURE OF PLASMEPSIN II FROM P FALCIPARUM IN COMPLEX WITH INHIBITOR RS370
872, 1leeA, 0.7333, 2.91, 0.232, 331, 319, CRYSTAL STRUCTURE OF PLASMEPSIN FROM P. FALCIPARUM IN COMPLEX WITH INHIBITOR RS367
873, 3f9qA, 0.7331, 2.58, 0.232, 325, 314, RE-REFINEMENT OF UNCOMPLEXED PLASMEPSIN II FROM PLASMODIUM FALCIPARUM.
874, 4ckuD, 0.7330, 2.46, 0.231, 323, 312, THREE DIMENSIONAL STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH HYDROXYETHYLAMINE-BASED INHIBITOR
875, 3emyA, 0.7330, 2.74, 0.228, 328, 316, CRYSTAL STRUCTURE OF TRICHODERMA REESEI ASPARTIC PROTEINASE COMPLEXED WITH PEPSTATIN A
876, 4y6mA, 0.7307, 2.96, 0.220, 329, 318, STRUCTURE OF PLASMEPSIN II FROM PLASMODIUM FALCIPARUM COMPLEXED WITH INHIBITOR PG418
877, 5i70B, 0.7305, 2.42, 0.232, 321, 310, CRYSTAL STRUCTURE OF PLASMEPSIN IV
878, 1epmE, 0.7302, 2.72, 0.241, 330, 315, A STRUCTURAL COMPARISON OF 21 INHIBITOR COMPLEXES OF THE ASPARTIC PROTEINASE FROM ENDOTHIA PARASITICA
879, 1lf4A, 0.7301, 2.60, 0.230, 325, 313, STRUCTURE OF PLASMEPSIN II
880, 4er2E, 0.7299, 2.73, 0.241, 330, 315, THE ACTIVE SITE OF ASPARTIC PROTEINASES
881, 1epqE, 0.7298, 2.73, 0.241, 330, 315, ENDOTHIA ASPARTIC PROTEINASE (ENDOTHIAPEPSIN) COMPLEXED WITH PD-133 450 (SOT PHE GLY+SCC GCL)
882, 4er1E, 0.7297, 2.73, 0.241, 330, 315, THE ACTIVE SITE OF ASPARTIC PROTEINASES
883, 1eppE, 0.7297, 2.73, 0.241, 330, 315, ENDOTHIA ASPARTIC PROTEINASE (ENDOTHIAPEPSIN) COMPLEXED WITH PD-130 693 (MAS PHE LYS+MTF STA MBA)
884, 1epnE, 0.7296, 2.73, 0.241, 330, 315, A STRUCTURAL COMPARISON OF 21 INHIBITOR COMPLEXES OF THE ASPARTIC PROTEINASE FROM ENDOTHIA PARASITICA
885, 4y6mB, 0.7295, 2.93, 0.224, 328, 317, STRUCTURE OF PLASMEPSIN II FROM PLASMODIUM FALCIPARUM COMPLEXED WITH INHIBITOR PG418
886, 4ckuA, 0.7294, 2.61, 0.221, 323, 312, THREE DIMENSIONAL STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH HYDROXYETHYLAMINE-BASED INHIBITOR
887, 3er5E, 0.7294, 2.74, 0.241, 330, 315, THE ACTIVE SITE OF ASPARTIC PROTEINASES
888, 3c9xA, 0.7294, 2.80, 0.228, 328, 316, CRYSTAL STRUCTURE OF TRICHODERMA REESEI ASPARTIC PROTEINASE
889, 2igyA, 0.7294, 2.99, 0.223, 329, 318, ACHIRAL CHEAP AND POTENT INHIBITORS OF PLASMEPSINS II
890, 2er7E, 0.7294, 2.73, 0.241, 330, 315, X-RAY ANALYSES OF ASPARTIC PROTEINASES.III. THREE-DIMENSIONAL STRUCTURE OF ENDOTHIAPEPSIN COMPLEXED WITH A TRANSITION-STATE ISOSTERE INHIBITOR OF RENIN AT 1.6 ANGSTROMS RESOLUTION
891, 1entE, 0.7294, 2.73, 0.241, 330, 315, X-RAY ANALYSES OF ASPARTIC PROTEINASES. THE THREE-DIMENSIONAL STRUCTURE AT 2.1 ANGSTROMS RESOLUTION OF ENDOTHIAPEPSIN
892, 2igyB, 0.7293, 2.96, 0.230, 329, 318, ACHIRAL CHEAP AND POTENT INHIBITORS OF PLASMEPSINS II
893, 1eedP, 0.7292, 2.73, 0.241, 330, 315, X-RAY CRYSTALLOGRAPHIC ANALYSIS OF INHIBITION OF ENDOTHIAPEPSIN BY CYCLOHEXYL RENIN INHIBITORS
894, 5sy2B, 0.7291, 2.64, 0.248, 330, 310, STRUCTURE-BASED DESIGN OF A NEW SERIES OF N-PIPERIDIN-3-YLPYRIMIDINE- 5-CARBOXAMIDES AS RENIN INHIBITORS
895, 5er2E, 0.7291, 2.74, 0.241, 330, 315, HIGH-RESOLUTION X-RAY DIFFRACTION STUDY OF THE COMPLEX BETWEEN ENDOTHIAPEPSIN AND AN OLIGOPEPTIDE INHIBITOR. THE ANALYSIS OF THE INHIBITOR BINDING AND DESCRIPTION OF THE RIGID BODY SHIFT IN THE ENZYME
896, 1er8E, 0.7291, 2.74, 0.241, 330, 315, THE ACTIVE SITE OF ASPARTIC PROTEINASES
897, 3er3E, 0.7289, 2.74, 0.241, 330, 315, THE ACTIVE SITE OF ASPARTIC PROTEINASES
898, 4amtA, 0.7288, 2.51, 0.252, 349, 310, CRYSTAL STRUCTURE AT 2.6A OF HUMAN PRORENIN
899, 2er0E, 0.7286, 2.75, 0.241, 330, 315, X-RAY STUDIES OF ASPARTIC PROTEINASE-STATINE INHIBITOR COMPLEXES
900, 1qs8A, 0.7286, 2.79, 0.225, 327, 315, CRYSTAL STRUCTURE OF THE P. VIVAX ASPARTIC PROTEINASE PLASMEPSIN COMPLEXED WITH THE INHIBITOR PEPSTATIN A
901, 4ckuC, 0.7285, 2.58, 0.225, 322, 311, THREE DIMENSIONAL STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH HYDROXYETHYLAMINE-BASED INHIBITOR
902, 1eprE, 0.7281, 2.77, 0.241, 329, 315, ENDOTHIA ASPARTIC PROTEINASE (ENDOTHIAPEPSIN) COMPLEXED WITH PD-135 040
903, 4z22B, 0.7276, 2.99, 0.223, 329, 318, STRUCTURE OF PLASMEPSIN II FROM PLASMODIUM FALCIPARUM COMPLEXED WITH INHIBITOR DR718A
904, 4ckuE, 0.7275, 2.60, 0.225, 322, 311, THREE DIMENSIONAL STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH HYDROXYETHYLAMINE-BASED INHIBITOR
905, 3psgA, 0.7273, 2.39, 0.276, 365, 308, THE HIGH RESOLUTION CRYSTAL STRUCTURE OF PORCINE PEPSINOGEN
906, 3urjA, 0.7272, 2.78, 0.241, 328, 315, TYPE IV NATIVE ENDOTHIAPEPSIN
907, 4y6mC, 0.7271, 3.08, 0.220, 329, 318, STRUCTURE OF PLASMEPSIN II FROM PLASMODIUM FALCIPARUM COMPLEXED WITH INHIBITOR PG418
908, 2igxA, 0.7271, 2.97, 0.230, 329, 318, ACHIRAL CHEAP AND POTENT INHIBITORS OF PLASMEPSINS II
909, 3urlA, 0.7270, 2.79, 0.241, 328, 315, ENDOTHIAPEPSIN-DB6 COMPLEX.
910, 3fv3C, 0.7267, 2.65, 0.213, 339, 310, SECRETED ASPARTIC PROTEASE 1 FROM CANDIDA PARAPSILOSIS IN COMPLEX WITH PEPSTATIN A
911, 1gktA, 0.7266, 2.79, 0.241, 328, 315, NEUTRON LAUE DIFFRACTION STRUCTURE OF ENDOTHIAPEPSIN COMPLEXED WITH TRANSITION STATE ANALOGUE INHIBITOR H261
912, 1bxoA, 0.7266, 2.63, 0.228, 323, 311, ACID PROTEINASE (PENICILLOPEPSIN) (E.C.3.4.23.20) COMPLEX WITH PHOSPHONATE INHIBITOR: METHYL CYCLO[(2S)-2-[[(1R)-1-(N-(L-N-(3- METHYLBUTANOYL)VALYL-L-ASPARTYL)AMINO)-3-METHYLBUT YL] HYDROXYPHOSPHINYLOXY]-3-(3-AMINOMETHYL) PHENYLPROPANOATE
913, 3fv3A, 0.7265, 2.65, 0.213, 339, 310, SECRETED ASPARTIC PROTEASE 1 FROM CANDIDA PARAPSILOSIS IN COMPLEX WITH PEPSTATIN A
914, 2vs2A, 0.7265, 2.79, 0.241, 328, 315, NEUTRON DIFFRACTION STRUCTURE OF ENDOTHIAPEPSIN IN COMPLEX WITH A GEM-DIOL INHIBITOR.
915, 2jjiA, 0.7265, 2.79, 0.241, 328, 315, ENDOTHIAPEPSIN IN COMPLEX WITH A GEM-DIOL INHIBITOR.
916, 1bxqA, 0.7264, 2.63, 0.228, 323, 311, ACID PROTEINASE (PENICILLOPEPSIN) COMPLEX WITH PHOSPHONATE INHIBITOR.
917, 3uriA, 0.7263, 2.80, 0.241, 328, 315, ENDOTHIAPEPSIN-DB5 COMPLEX.
918, 1ppmE, 0.7263, 2.65, 0.228, 323, 311, CRYSTALLOGRAPHIC ANALYSIS OF TRANSITION-STATE MIMICS BOUND TO PENICILLOPEPSIN: PHOSPHORUS-CONTAINING PEPTIDE ANALOGUES
919, 1aptE, 0.7263, 2.64, 0.228, 323, 311, CRYSTALLOGRAPHIC ANALYSIS OF A PEPSTATIN ANALOGUE BINDING TO THE ASPARTYL PROTEINASE PENICILLOPEPSIN AT 1.8 ANGSTROMS RESOLUTION
920, 2webA, 0.7262, 2.64, 0.228, 323, 311, ACID PROTEINASE (PENICILLOPEPSIN) (E.C.3.4.23.20) COMPLEX WITH PHOSPHONATE INHIBITOR: METHYL(2S)-[1-(((N-FORMYL)-L- VALYL)AMINO-2-(2-NAPHTHYL)ETHYL)HYDROXYPHOSPHINYLOXY]-3- PHENYLPROPANOATE SODIUM SALT
921, 1gvxA, 0.7262, 2.81, 0.241, 328, 315, ENDOTHIAPEPSIN COMPLEXED WITH H256
922, 1oexA, 0.7261, 2.80, 0.241, 328, 315, ATOMIC RESOLUTION STRUCTURE OF ENDOTHIAPEPSIN IN COMPLEX WITH A HYDROXYETHYLENE TRANSITION STATE ANALOGUE INHIBITOR H261
923, 1apvE, 0.7261, 2.65, 0.228, 323, 311, CRYSTALLOGRAPHIC ANALYSIS OF TRANSITION STATE MIMICS BOUND TO PENICILLOPEPSIN: DIFLUOROSTATINE-AND DIFLUOROSTATONE-CONTAINING PEPTIDES
924, 1ppkE, 0.7260, 2.65, 0.228, 323, 311, CRYSTALLOGRAPHIC ANALYSIS OF TRANSITION STATE MIMICS BOUND TO PENICILLOPEPSIN: PHOSPHOROUS-CONTAINING PEPTIDE ANALOGUES
925, 1epoE, 0.7260, 2.78, 0.242, 330, 314, ENDOTHIA ASPARTIC PROTEINASE (ENDOTHIAPEPSIN) COMPLEXED WITH CP-81282 (MOR PHE NLE CHF NME)
926, 1apwE, 0.7260, 2.65, 0.228, 323, 311, CRYSTALLOGRAPHIC ANALYSIS OF TRANSITION STATE MIMICS BOUND TO PENICILLOPEPSIN: DIFLUOROSTATINE-AND DIFLUOROSTATONE-CONTAINING PEPTIDES
927, 1apuE, 0.7260, 2.64, 0.228, 323, 311, CRYSTALLOGRAPHIC ANALYSIS OF A PEPSTATIN ANALOGUE BINDING TO THE ASPARTYL PROTEINASE PENICILLOPEPSIN AT 1.8 ANGSTROMS RESOLUTION
928, 3fv3H, 0.7259, 2.67, 0.213, 339, 310, SECRETED ASPARTIC PROTEASE 1 FROM CANDIDA PARAPSILOSIS IN COMPLEX WITH PEPSTATIN A
929, 3fv3G, 0.7259, 2.68, 0.213, 339, 310, SECRETED ASPARTIC PROTEASE 1 FROM CANDIDA PARAPSILOSIS IN COMPLEX WITH PEPSTATIN A
930, 2qzwA, 0.7259, 2.91, 0.213, 341, 314, SECRETED ASPARTIC PROTEINASE (SAP) 1 FROM CANDIDA ALBICANS
931, 2h6tA, 0.7259, 2.88, 0.217, 340, 314, SECRETED ASPARTIC PROTEINASE (SAP) 3 FROM CANDIDA ALBICANS COMPLEXED WITH PEPSTATIN A
932, 1oewA, 0.7259, 2.80, 0.241, 328, 315, ATOMIC RESOLUTION STRUCTURE OF NATIVE ENDOTHIAPEPSIN
933, 1gvtA, 0.7259, 2.79, 0.241, 328, 315, ENDOTHIAPEPSIN COMPLEX WITH CP-80794
934, 1j71A, 0.7258, 2.74, 0.199, 334, 311, STRUCTURE OF THE EXTRACELLULAR ASPARTIC PROTEINASE FROM CANDIDA TROPICALIS YEAST.
935, 1gvvA, 0.7258, 2.80, 0.241, 328, 315, FIVE ATOMIC RESOLUTION STRUCTURES OF ENDOTHIAPEPSIN INHIBITOR COMPLEXES; IMPLICATIONS FOR THE ASPARTIC PROTEINASE MECHANISM
936, 1eplE, 0.7258, 2.80, 0.242, 330, 314, A STRUCTURAL COMPARISON OF 21 INHIBITOR COMPLEXES OF THE ASPARTIC PROTEINASE FROM ENDOTHIA PARASITICA
937, 1e5oE, 0.7258, 2.80, 0.239, 330, 314, ENDOTHIAPEPSIN COMPLEX WITH INHIBITOR DB2
938, 4z22A, 0.7257, 3.01, 0.223, 329, 318, STRUCTURE OF PLASMEPSIN II FROM PLASMODIUM FALCIPARUM COMPLEXED WITH INHIBITOR DR718A
939, 2wecA, 0.7257, 2.62, 0.232, 323, 310, ACID PROTEINASE (PENICILLOPEPSIN) (E.C.3.4.23.20) COMPLEX WITH PHOSPHONATE INHIBITOR: METHYL(2S)-[1-(((N-(1- NAPHTHALENEACETYL))-L-VALYL)AMINOMETHYL)HYDROXY PHOSPHINYLOXY]-3-PHENYLPROPANOATE SODIUM SALT
940, 1gvwA, 0.7256, 2.82, 0.241, 328, 315, ENDOTHIAPEPSIN COMPLEX WITH PD-130328
941, 2wedA, 0.7255, 2.66, 0.228, 323, 311, ACID PROTEINASE (PENICILLOPEPSIN) (E.C.3.4.23.20) COMPLEX WITH PHOSPHONATE MACROCYCLIC INHIBITOR:METHYL[CYCLO-7[(2R)- ((N-VALYL)AMINO)-2-(HYDROXYL-(1S)-1-METHYOXYCARBONYL-2- PHENYLETHOXY)PHOSPHINYLOXY-ETHYL]-1-NAPHTHALENEACETAMIDE] SODIUM SALT
942, 2jjjA, 0.7254, 2.80, 0.241, 328, 315, ENDOTHIAPEPSIN IN COMPLEX WITH A GEM-DIOL INHIBITOR.
943, 2er6E, 0.7254, 2.83, 0.241, 330, 315, THE STRUCTURE OF A SYNTHETIC PEPSIN INHIBITOR COMPLEXED WITH ENDOTHIAPEPSIN.
944, 4er4E, 0.7253, 2.82, 0.238, 330, 315, HIGH-RESOLUTION X-RAY ANALYSES OF RENIN INHIBITOR-ASPARTIC PROTEINASE COMPLEXES
945, 3fv3E, 0.7252, 2.59, 0.214, 339, 309, SECRETED ASPARTIC PROTEASE 1 FROM CANDIDA PARAPSILOSIS IN COMPLEX WITH PEPSTATIN A
946, 3wz8A, 0.7251, 2.79, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH GEWALD REACTION-DERIVED INHIBITOR (8)
947, 1zapA, 0.7251, 2.96, 0.229, 341, 314, SECRETED ASPARTIC PROTEASE FROM C. ALBICANS
948, 2er9E, 0.7250, 2.81, 0.242, 330, 314, X-RAY STUDIES OF ASPARTIC PROTEINASE-STATINE INHIBITOR COMPLEXES.
949, 1pplE, 0.7250, 2.68, 0.228, 323, 311, CRYSTALLOGRAPHIC ANALYSIS OF TRANSITION-STATE MIMICS BOUND TO PENICILLOPEPSIN: PHOSPHORUS-CONTAINING PEPTIDE ANALOGUES
950, 1gvuA, 0.7250, 2.82, 0.241, 328, 315, ENDOTHIAPEPSIN COMPLEX WITH H189
951, 5p3kA, 0.7249, 2.80, 0.242, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 173
952, 5er1E, 0.7249, 2.84, 0.238, 330, 315, A RATIONAL APPROACH TO THE DESIGN OF ANTIHYPERTENSIVES. X-RAY STUDIES OF COMPLEXES BETWEEN ASPARTIC PROTEINASES AND AMINOALCOHOL RENIN INHIBITORS
953, 4apeA, 0.7249, 2.84, 0.238, 330, 315, THE ACTIVE SITE OF ASPARTIC PROTEINASES
954, 3fv3B, 0.7249, 2.69, 0.213, 339, 310, SECRETED ASPARTIC PROTEASE 1 FROM CANDIDA PARAPSILOSIS IN COMPLEX WITH PEPSTATIN A
955, 5hcoA, 0.7248, 2.83, 0.238, 330, 315, ENDOTHIAPEPSIN IN COMPLEX WITH HYDRAZIDE
956, 4lbtA, 0.7248, 2.83, 0.238, 330, 315, ENDOTHIAPEPSIN IN COMPLEX WITH 100MM ACYLHYDRAZONE INHIBITOR
957, 5p3pA, 0.7247, 2.80, 0.242, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 178
958, 3fv3F, 0.7247, 2.71, 0.213, 339, 310, SECRETED ASPARTIC PROTEASE 1 FROM CANDIDA PARAPSILOSIS IN COMPLEX WITH PEPSTATIN A
959, 1e81E, 0.7247, 2.81, 0.242, 330, 314, ENDOTHIAPEPSIN COMPLEX WITH RENIN INHIBITOR MERCK-KGAA-EMD61395
960, 5p1qA, 0.7246, 2.81, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 109
961, 5oz1A, 0.7246, 2.81, 0.242, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 12
962, 5oyrA, 0.7246, 2.81, 0.242, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 2
963, 5hctA, 0.7246, 2.81, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH BIACYLHYDRAZONE
964, 4y3qA, 0.7246, 2.81, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 109
965, 4kupA, 0.7246, 2.80, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH 20MM ACYLHYDRAZONE INHIBITOR
966, 5p6wA, 0.7245, 2.81, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 293
967, 5p3rA, 0.7245, 2.81, 0.242, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 180
968, 5p1kA, 0.7245, 2.81, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 103
969, 4y48A, 0.7245, 2.82, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B50
970, 4y3mA, 0.7245, 2.81, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 103
971, 5p0cA, 0.7244, 2.81, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 59
972, 3wz7A, 0.7244, 2.81, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH GEWALD REACTION-DERIVED INHIBITOR (6)
973, 1e82E, 0.7244, 2.82, 0.239, 330, 314, ENDOTHIAPEPSIN COMPLEX WITH RENIN INHIBITOR MERCK-KGAA-EMD59601
974, 5oyzA, 0.7243, 2.81, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 10
975, 5oyxA, 0.7243, 2.81, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 8
976, 3pbzA, 0.7243, 2.82, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT
977, 1ibqA, 0.7243, 2.76, 0.230, 325, 313, ASPERGILLOPEPSIN FROM ASPERGILLUS PHOENICIS
978, 5p5bA, 0.7242, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 236
979, 5p3nA, 0.7242, 2.81, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 176
980, 5p0eA, 0.7242, 2.81, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 61
981, 5oysA, 0.7242, 2.81, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 3
982, 4y3jA, 0.7242, 2.82, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B30
983, 3pmuA, 0.7242, 2.82, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT
984, 5p7cA, 0.7241, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 309
985, 5p62A, 0.7241, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 263
986, 5p5dA, 0.7241, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 238
987, 5p4aA, 0.7241, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 199
988, 5p41A, 0.7241, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 190
989, 5p3yA, 0.7241, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 187
990, 5p3bA, 0.7241, 2.81, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 164
991, 5oz4A, 0.7241, 2.81, 0.242, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 15
992, 5oz2A, 0.7241, 2.81, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 13
993, 5oyyA, 0.7241, 2.82, 0.242, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 9
994, 4yd5A, 0.7241, 2.82, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 236
995, 4y44A, 0.7241, 2.81, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 164
996, 4lhhA, 0.7241, 2.82, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH 2MM ACYLHYDRAZONE INHIBITOR
997, 5p82A, 0.7240, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 335
998, 5p6kA, 0.7240, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 281
999, 5p2nA, 0.7240, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 141
1000, 5p00A, 0.7240, 2.82, 0.242, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 47
1001, 5ozlA, 0.7240, 2.85, 0.238, 330, 315, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 32
1002, 5og7A, 0.7240, 2.85, 0.238, 330, 315, ENDOTHIAPEPSIN IN COMPLEX WITH HYDRAZIDE FRAGMENT 
1003, 4y36A, 0.7240, 2.82, 0.242, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 4
1004, 4lp9A, 0.7240, 2.82, 0.239, 330, 314, ENDOTHIAPEPSIN COMPLEXED WITH PHE-REDUCED-TYR PEPTIDE.
1005, 3tneB, 0.7240, 2.60, 0.217, 339, 309, THE CRYSTAL STRUCTURE OF PROTEASE SAPP1P FROM CANDIDA PARAPSILOSIS IN COMPLEX WITH THE HIV PROTEASE INHIBITOR RITONAVIR
1006, 5p8uA, 0.7239, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 363
1007, 5p6nA, 0.7239, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 284
1008, 5p66A, 0.7239, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 267
1009, 5p63A, 0.7239, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 264
1010, 5p60A, 0.7239, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 261
1011, 5p51A, 0.7239, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 226
1012, 5p4tA, 0.7239, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 218
1013, 5p4dA, 0.7239, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 202
1014, 5p40A, 0.7239, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 189
1015, 5p3sA, 0.7239, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 181
1016, 5p3aA, 0.7239, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 163
1017, 5p2eA, 0.7239, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 132
1018, 5p2bA, 0.7239, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 129
1019, 5p26A, 0.7239, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 124
1020, 5oywA, 0.7239, 2.82, 0.242, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 7
1021, 5oytA, 0.7239, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 4
1022, 5oyqA, 0.7239, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 1
1023, 4y5cA, 0.7239, 2.82, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 267
1024, 4y5bA, 0.7239, 2.82, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 261
1025, 4y4jA, 0.7239, 2.82, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B97
1026, 4y3hA, 0.7239, 2.82, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 189
1027, 4y3aA, 0.7239, 2.82, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 181
1028, 5p8hA, 0.7238, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 350
1029, 5p7qA, 0.7238, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 323
1030, 5p7jA, 0.7238, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 316
1031, 5p75A, 0.7238, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 302
1032, 5p6vA, 0.7238, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 292
1033, 5p6iA, 0.7238, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 279
1034, 5p5qA, 0.7238, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 251
1035, 5p58A, 0.7238, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 233
1036, 5p4wA, 0.7238, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 221
1037, 5p4pA, 0.7238, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 214
1038, 5p4lA, 0.7238, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 210
1039, 5p47A, 0.7238, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 196
1040, 5p46A, 0.7238, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 195
1041, 5p43A, 0.7238, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 192
1042, 5p3lA, 0.7238, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 174
1043, 5p37A, 0.7238, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 160
1044, 5p33A, 0.7238, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 156
1045, 5p2xA, 0.7238, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 150
1046, 5p2jA, 0.7238, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 137
1047, 5p2fA, 0.7238, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 133
1048, 5p29A, 0.7238, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 127
1049, 5p03A, 0.7238, 2.82, 0.242, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 50
1050, 5p02A, 0.7238, 2.82, 0.242, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 49
1051, 5ozyA, 0.7238, 2.82, 0.242, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 45
1052, 5oz9A, 0.7238, 2.81, 0.242, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 20
1053, 5oz3A, 0.7238, 2.82, 0.242, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 14
1054, 5oyvA, 0.7238, 2.82, 0.242, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 6
1055, 4y4bA, 0.7238, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 323
1056, 3tneA, 0.7238, 2.60, 0.217, 339, 309, THE CRYSTAL STRUCTURE OF PROTEASE SAPP1P FROM CANDIDA PARAPSILOSIS IN COMPLEX WITH THE HIV PROTEASE INHIBITOR RITONAVIR
1057, 5p7uA, 0.7237, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 327
1058, 5p7rA, 0.7237, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 324
1059, 5p76A, 0.7237, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 303
1060, 5p6xA, 0.7237, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 294
1061, 5p6cA, 0.7237, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 273
1062, 5p64A, 0.7237, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 265
1063, 5p5kA, 0.7237, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 245
1064, 5p5eA, 0.7237, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 239
1065, 5p50A, 0.7237, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 225
1066, 5p4zA, 0.7237, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 224
1067, 5p4uA, 0.7237, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 219
1068, 5p4nA, 0.7237, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 212
1069, 5p42A, 0.7237, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 191
1070, 5p3wA, 0.7237, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 185
1071, 5p3uA, 0.7237, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 183
1072, 5p3tA, 0.7237, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 182
1073, 5p3eA, 0.7237, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 167
1074, 5p34A, 0.7237, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 157
1075, 5p2zA, 0.7237, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 152
1076, 5p2yA, 0.7237, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 151
1077, 5p2qA, 0.7237, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 143
1078, 5p2iA, 0.7237, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 136
1079, 5p20A, 0.7237, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 119
1080, 5p1zA, 0.7237, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 118
1081, 5p1vA, 0.7237, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 114
1082, 5p1cA, 0.7237, 2.86, 0.238, 330, 315, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 95
1083, 5ozvA, 0.7237, 2.82, 0.242, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 42
1084, 5ozuA, 0.7237, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 41
1085, 5ozqA, 0.7237, 2.82, 0.242, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 37
1086, 5oz8A, 0.7237, 2.82, 0.242, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 19
1087, 4yd3A, 0.7237, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 224
1088, 4y4uA, 0.7237, 2.83, 0.242, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 14
1089, 4y4tA, 0.7237, 2.82, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 114
1090, 4y43A, 0.7237, 2.82, 0.242, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 42
1091, 4y3zA, 0.7237, 2.82, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 41
1092, 4y3nA, 0.7237, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 273
1093, 4y38A, 0.7237, 2.85, 0.241, 329, 315, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B29
1094, 2weaA, 0.7237, 2.69, 0.228, 323, 311, ACID PROTEINASE (PENICILLOPEPSIN) (E.C.3.4.23.20) COMPLEX WITH PHOSPHONATE INHIBITOR: METHYL[CYCLO-7[(2R)-((N-VALYL) AMINO)-2-(HYDROXYL-(1S)-1-METHYOXYCARBONYL-2-PHENYLETHOXY) PHOSPHINYLOXY-ETHYL]-1-NAPHTHALENEACETAMIDE] SODIUM SALT
1095, 5p6jA, 0.7236, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 280
1096, 5p68A, 0.7236, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 269
1097, 5p65A, 0.7236, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 266
1098, 5p61A, 0.7236, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 262
1099, 5p5yA, 0.7236, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 259
1100, 5p5xA, 0.7236, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 258
1101, 5p5wA, 0.7236, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 257
1102, 5p5rA, 0.7236, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 252
1103, 5p5lA, 0.7236, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 246
1104, 5p55A, 0.7236, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 230
1105, 5p4fA, 0.7236, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 204
1106, 5p4bA, 0.7236, 2.86, 0.238, 330, 315, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 200
1107, 5p49A, 0.7236, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 198
1108, 5p45A, 0.7236, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 194
1109, 5p3mA, 0.7236, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 175
1110, 5p3gA, 0.7236, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 169
1111, 5p3dA, 0.7236, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 166
1112, 5p32A, 0.7236, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 155
1113, 5p31A, 0.7236, 2.86, 0.238, 330, 315, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 154
1114, 5p2gA, 0.7236, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 134
1115, 5p2dA, 0.7236, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 131
1116, 5p2aA, 0.7236, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 128
1117, 5p28A, 0.7236, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 126
1118, 5p25A, 0.7236, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 123
1119, 5p1fA, 0.7236, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 98
1120, 5p0hA, 0.7236, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 64
1121, 5p01A, 0.7236, 2.83, 0.242, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 48
1122, 5oz7A, 0.7236, 2.83, 0.242, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 18
1123, 5oz5A, 0.7236, 2.85, 0.241, 330, 315, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 16
1124, 5dq2A, 0.7236, 2.83, 0.242, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 48
1125, 4y4eA, 0.7236, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 131
1126, 4y4dA, 0.7236, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B51
1127, 4y3dA, 0.7236, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 321
1128, 3prsA, 0.7236, 2.86, 0.238, 330, 315, ENDOTHIAPEPSIN IN COMPLEX WITH RITONAVIR
1129, 3pm4A, 0.7236, 2.86, 0.238, 330, 315, ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT
1130, 1e80E, 0.7236, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN COMPLEX WITH RENIN INHIBITOR MERCK-KGAA-EMD56133
1131, 5p8oA, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 357
1132, 5p8fA, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 348
1133, 5p80A, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 333
1134, 5p7sA, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 325
1135, 5p77A, 0.7235, 2.86, 0.238, 330, 315, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 304
1136, 5p72A, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 299
1137, 5p71A, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 298
1138, 5p6sA, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 289
1139, 5p6qA, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 287
1140, 5p6pA, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 286
1141, 5p6gA, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 277
1142, 5p6fA, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 276
1143, 5p6eA, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 275
1144, 5p67A, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 268
1145, 5p5oA, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 249
1146, 5p5mA, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 247
1147, 5p5jA, 0.7235, 2.86, 0.238, 330, 315, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 244
1148, 5p5gA, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 241
1149, 5p5cA, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 237
1150, 5p5aA, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 235
1151, 5p59A, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 234
1152, 5p4vA, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 220
1153, 5p4eA, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 203
1154, 5p4cA, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 201
1155, 5p48A, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 197
1156, 5p3jA, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 172
1157, 5p39A, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 162
1158, 5p36A, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 159
1159, 5p30A, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 153
1160, 5p2vA, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 148
1161, 5p2oA, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 142
1162, 5p2hA, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 135
1163, 5p23A, 0.7235, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 121
1164, 5p1sA, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 111
1165, 5p1rA, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 110
1166, 5p1oA, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 107
1167, 5p1eA, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 97
1168, 5p19A, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 92
1169, 5p0sA, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 75
1170, 5p0qA, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 73
1171, 5p0nA, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 70
1172, 5oznA, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 34
1173, 5mb3A, 0.7235, 2.83, 0.239, 330, 314, FRAGMENT 333 AT A CONCENTRATION OF 50MM IN COMPLEX WITH ENDOTHIAPEPSIN
1174, 5is4A, 0.7235, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH CHIRAL BROMINATED PRIMARY AMINE FRAGMENT
1175, 5dr3A, 0.7235, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 333
1176, 4y5kA, 0.7235, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 274
1177, 4y5eA, 0.7235, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 268
1178, 4y4zA, 0.7235, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 73
1179, 4y4gA, 0.7235, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B53
1180, 4y3sA, 0.7235, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 266
1181, 4y39A, 0.7235, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 75
1182, 3appA, 0.7235, 2.68, 0.228, 323, 311, STRUCTURE AND REFINEMENT OF PENICILLOPEPSIN AT 1.8 ANGSTROMS RESOLUTION
1183, 5p8eA, 0.7234, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 347
1184, 5p8bA, 0.7234, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 344
1185, 5p83A, 0.7234, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 336
1186, 5p73A, 0.7234, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 300
1187, 5p6dA, 0.7234, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 274
1188, 5p6aA, 0.7234, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 271
1189, 5p5tA, 0.7234, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 254
1190, 5p5sA, 0.7234, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 253
1191, 5p5pA, 0.7234, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 250
1192, 5p53A, 0.7234, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 228
1193, 5p4oA, 0.7234, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 213
1194, 5p3zA, 0.7234, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 188
1195, 5p3xA, 0.7234, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 186
1196, 5p3qA, 0.7234, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 179
1197, 5p3hA, 0.7234, 2.86, 0.238, 330, 315, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 170
1198, 5p3cA, 0.7234, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 165
1199, 5p2wA, 0.7234, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 149
1200, 5p2tA, 0.7234, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 146
1201, 5p2lA, 0.7234, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 139
1202, 5p1pA, 0.7234, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 108
1203, 5p1mA, 0.7234, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 105
1204, 5p1lA, 0.7234, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 104
1205, 5p1aA, 0.7234, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 93
1206, 5p0xA, 0.7234, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 80
1207, 5p0oA, 0.7234, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 71
1208, 5mb7A, 0.7234, 2.83, 0.239, 330, 314, COCKTAIL EXPERIMENT B: FRAGMENTS 224 AND 236 AT 50MM CONCENTRATION
1209, 5lwrA, 0.7234, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A DERIVATIVE OF FRAGMENT 177
1210, 5dr0A, 0.7234, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 203
1211, 5dq1A, 0.7234, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 34
1212, 4y5lA, 0.7234, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN ITS APO FORM
1213, 4y5gA, 0.7234, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 272
1214, 4y4aA, 0.7234, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 286
1215, 4y3yA, 0.7234, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B42
1216, 4aa9A, 0.7234, 2.27, 0.273, 313, 304, CAMEL CHYMOSIN AT 1.6A RESOLUTION
1217, 5p8vA, 0.7233, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 364
1218, 5p8sA, 0.7233, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 361
1219, 5p8nA, 0.7233, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 356
1220, 5p8mA, 0.7233, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 355
1221, 5p89A, 0.7233, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 342
1222, 5p86A, 0.7233, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 339
1223, 5p7yA, 0.7233, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 331
1224, 5p7vA, 0.7233, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 328
1225, 5p7oA, 0.7233, 2.86, 0.238, 330, 315, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 321
1226, 5p7kA, 0.7233, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 317
1227, 5p7gA, 0.7233, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 313
1228, 5p78A, 0.7233, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 305
1229, 5p70A, 0.7233, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 297
1230, 5p6zA, 0.7233, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 296
1231, 5p6rA, 0.7233, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 288
1232, 5p6lA, 0.7233, 2.86, 0.238, 330, 315, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 282
1233, 5p6hA, 0.7233, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 278
1234, 5p6bA, 0.7233, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 272
1235, 5p69A, 0.7233, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 270
1236, 5p5zA, 0.7233, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 260
1237, 5p5iA, 0.7233, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 243
1238, 5p5hA, 0.7233, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 242
1239, 5p57A, 0.7233, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 232
1240, 5p54A, 0.7233, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 229
1241, 5p4yA, 0.7233, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 223
1242, 5p4xA, 0.7233, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 222
1243, 5p4sA, 0.7233, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 217
1244, 5p4mA, 0.7233, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 211
1245, 5p4kA, 0.7233, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 209
1246, 5p44A, 0.7233, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 193
1247, 5p3vA, 0.7233, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 184
1248, 5p3oA, 0.7233, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 177
1249, 5p2uA, 0.7233, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 147
1250, 5p2mA, 0.7233, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 140
1251, 5p2kA, 0.7233, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 138
1252, 5p1yA, 0.7233, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 117
1253, 5p1xA, 0.7233, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 116
1254, 5p1iA, 0.7233, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 101
1255, 5p1dA, 0.7233, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 96
1256, 5p1bA, 0.7233, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 94
1257, 5p17A, 0.7233, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 90
1258, 5p0uA, 0.7233, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 77
1259, 5p0tA, 0.7233, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 76
1260, 5p0rA, 0.7233, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 74
1261, 5p0mA, 0.7233, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 69
1262, 5p06A, 0.7233, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 53
1263, 5ozkA, 0.7233, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 31
1264, 5ozjA, 0.7233, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 30
1265, 5oyuA, 0.7233, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 5
1266, 5dq5A, 0.7233, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 209
1267, 5dpzA, 0.7233, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 31
1268, 4yckA, 0.7233, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 211
1269, 4y5mA, 0.7233, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 328
1270, 4y37A, 0.7233, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGEMENT 305
1271, 3pmyA, 0.7233, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT
1272, 5p8tA, 0.7232, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 362
1273, 5p8rA, 0.7232, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 360
1274, 5p8pA, 0.7232, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 358
1275, 5p8jA, 0.7232, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 352
1276, 5p8gA, 0.7232, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 349
1277, 5p8dA, 0.7232, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 346
1278, 5p88A, 0.7232, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 341
1279, 5p84A, 0.7232, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 337
1280, 5p7pA, 0.7232, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 322
1281, 5p7lA, 0.7232, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 318
1282, 5p7iA, 0.7232, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 315
1283, 5p74A, 0.7232, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 301
1284, 5p6yA, 0.7232, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 295
1285, 5p6tA, 0.7232, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 290
1286, 5p6mA, 0.7232, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 283
1287, 5p5vA, 0.7232, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 256
1288, 5p5nA, 0.7232, 2.87, 0.238, 330, 315, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 248
1289, 5p56A, 0.7232, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 231
1290, 5p4jA, 0.7232, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 208
1291, 5p2sA, 0.7232, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 145
1292, 5p2rA, 0.7232, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 144
1293, 5p1nA, 0.7232, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 106
1294, 5p1jA, 0.7232, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 102
1295, 5p1hA, 0.7232, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 100
1296, 5p15A, 0.7232, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 88
1297, 5p0zA, 0.7232, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 82
1298, 5p0yA, 0.7232, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 81
1299, 5p0wA, 0.7232, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 79
1300, 5p0pA, 0.7232, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 72
1301, 5p0fA, 0.7232, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 62
1302, 5ozbA, 0.7232, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 22
1303, 5oz6A, 0.7232, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 17
1304, 5isjA, 0.7232, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH CHIRAL CHLORINATED PRIMARY AMINE FRAGMENT
1305, 5dr4A, 0.7232, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 231
1306, 5dr1A, 0.7232, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 278
1307, 4ze6A, 0.7232, 2.86, 0.241, 329, 315, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B39
1308, 4y5nA, 0.7232, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 337
1309, 4y3eA, 0.7232, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 5
1310, 3pi0A, 0.7232, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT
1311, 3pgiA, 0.7232, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT
1312, 5p8qA, 0.7231, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 359
1313, 5p8lA, 0.7231, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 354
1314, 5p81A, 0.7231, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 334
1315, 5p7zA, 0.7231, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 332
1316, 5p7wA, 0.7231, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 329
1317, 5p7tA, 0.7231, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 326
1318, 5p7mA, 0.7231, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 319
1319, 5p7hA, 0.7231, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 314
1320, 5p7fA, 0.7231, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 312
1321, 5p7eA, 0.7231, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 311
1322, 5p7dA, 0.7231, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 310
1323, 5p7aA, 0.7231, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 307
1324, 5p6oA, 0.7231, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 285
1325, 5p4qA, 0.7231, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 215
1326, 5p4iA, 0.7231, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 207
1327, 5p3fA, 0.7231, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 168
1328, 5p38A, 0.7231, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 161
1329, 5p35A, 0.7231, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 158
1330, 5p24A, 0.7231, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 122
1331, 5p1wA, 0.7231, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 115
1332, 5p1uA, 0.7231, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 113
1333, 5p1gA, 0.7231, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 99
1334, 5p0iA, 0.7231, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 65
1335, 5p05A, 0.7231, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 52
1336, 5ozsA, 0.7231, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 39
1337, 5ozdA, 0.7231, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 24
1338, 5mb6A, 0.7231, 2.85, 0.239, 330, 314, COCKTAIL EXPERIMENT D: FRAGMENTS 308 AND 333 AT 50MM CONCENTRATION
1339, 5lwuA, 0.7231, 2.84, 0.239, 330, 314, STRUCTURE RESULTING FROM AN ENDOTHIAPEPSIN CRYSTAL SOAKED WITH A DIMERIC DERIVATIVE OF FRAGMENT 177
1340, 5lwtA, 0.7231, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A METHOXYLATED DERIVATIVE OF FRAGMENT 177
1341, 5j25A, 0.7231, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 158
1342, 5dr7A, 0.7231, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 311
1343, 4yd7A, 0.7231, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 255
1344, 4y51A, 0.7231, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 52
1345, 4y50A, 0.7231, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 81
1346, 4y4cA, 0.7231, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 158
1347, 4y3tA, 0.7231, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 207
1348, 4y3pA, 0.7231, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 17
1349, 4y3gA, 0.7231, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 285
1350, 4y35A, 0.7231, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 290
1351, 3t7qA, 0.7231, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH AN INHIBITOR BASED ON THE GEWALD REACTION
1352, 5p8kA, 0.7230, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 353
1353, 5p8iA, 0.7230, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 351
1354, 5p8aA, 0.7230, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 343
1355, 5p7xA, 0.7230, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 330
1356, 5p7bA, 0.7230, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 308
1357, 5p79A, 0.7230, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 306
1358, 5p52A, 0.7230, 2.85, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 227
1359, 5p4hA, 0.7230, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 206
1360, 5p2cA, 0.7230, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 130
1361, 5p1tA, 0.7230, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 112
1362, 5p18A, 0.7230, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 91
1363, 5p16A, 0.7230, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 89
1364, 5p08A, 0.7230, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 55
1365, 5ozxA, 0.7230, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 44
1366, 5ozfA, 0.7230, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 26
1367, 5ozeA, 0.7230, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 25
1368, 5dr8A, 0.7230, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 330
1369, 4yd4A, 0.7230, 2.85, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 227
1370, 4y5aA, 0.7230, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 206
1371, 4y41A, 0.7230, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 112
1372, 4y3wA, 0.7230, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 35
1373, 4lapA, 0.7230, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH THIOPHEN-BASED INHIBITOR SAP114
1374, 4l6bA, 0.7230, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH THIOPHEN-BASED INHIBITOR SAP128
1375, 5p5fA, 0.7229, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 240
1376, 5p4gA, 0.7229, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 205
1377, 5p14A, 0.7229, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 87
1378, 5p13A, 0.7229, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 86
1379, 5p12A, 0.7229, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 85
1380, 5p11A, 0.7229, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 84
1381, 5p10A, 0.7229, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 83
1382, 5p0jA, 0.7229, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 66
1383, 5p0gA, 0.7229, 2.85, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 63
1384, 5p0dA, 0.7229, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 60
1385, 5p0aA, 0.7229, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 57
1386, 5ozzA, 0.7229, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 46
1387, 5ozrA, 0.7229, 2.85, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 38
1388, 5ozpA, 0.7229, 2.85, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 36
1389, 5ozoA, 0.7229, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 35
1390, 5oziA, 0.7229, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 29
1391, 5ozhA, 0.7229, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 28
1392, 5ozgA, 0.7229, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 27
1393, 5lwsA, 0.7229, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 177 AND A DERIVATIVE THEREOF
1394, 5dq4A, 0.7229, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 66
1395, 4yd6A, 0.7229, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 240
1396, 4y57A, 0.7229, 2.85, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 63
1397, 4y3lA, 0.7229, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 205
1398, 3t7xA, 0.7229, 2.85, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH AN INHIBITOR BASED ON THE GEWALD REACTION
1399, 3lzyA, 0.7229, 2.85, 0.239, 330, 314, CRYSTAL STRUCTURE OF ENDOTHIAPESIN IN COMPLEX WITH XENON
1400, 5p8cA, 0.7228, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 345
1401, 5p87A, 0.7228, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 340
1402, 5p7nA, 0.7228, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 320
1403, 5p5uA, 0.7228, 2.87, 0.238, 330, 315, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 255
1404, 5p27A, 0.7228, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 125
1405, 5p22A, 0.7228, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 120
1406, 5p0vA, 0.7228, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 78
1407, 5p0lA, 0.7228, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 68
1408, 5oztA, 0.7228, 2.85, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 40
1409, 5ozcA, 0.7228, 2.85, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 23
1410, 5oz0A, 0.7228, 2.85, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 11
1411, 5iskA, 0.7228, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FLUORINATED PRIMARY AMINE FRAGMENT
1412, 4y56A, 0.7228, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 58
1413, 4y54A, 0.7228, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 56
1414, 4y53A, 0.7228, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 54
1415, 4y4wA, 0.7228, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 125
1416, 3pldA, 0.7228, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT
1417, 3pb5A, 0.7228, 2.85, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT
1418, 5p0bA, 0.7227, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 58
1419, 5p09A, 0.7227, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 56
1420, 4y3fA, 0.7227, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 78
1421, 3t7pA, 0.7227, 2.85, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A HYDRAZIDE DERIVATIVE
1422, 3qrvA, 0.7227, 2.66, 0.222, 323, 311, CRYSTAL STRUCTURE OF PLASMEPSIN I (PMI) FROM PLASMODIUM FALCIPARUM
1423, 5p85A, 0.7226, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 338
1424, 5p6uA, 0.7226, 2.85, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 291
1425, 5p07A, 0.7226, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 54
1426, 5ozwA, 0.7226, 2.85, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 43
1427, 5mb5A, 0.7226, 2.85, 0.239, 330, 314, COCKTAIL EXPERIMENT C: FRAGMENTS 103 AND 171 IN COMPLEX WITH ENDOTHIAPEPSIN
1428, 4zeaA, 0.7226, 2.87, 0.241, 328, 315, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B91
1429, 4y5pA, 0.7226, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 338
1430, 4y47A, 0.7226, 2.79, 0.240, 329, 313, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 162
1431, 4y45A, 0.7226, 2.85, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 291
1432, 4y3xA, 0.7226, 2.85, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 171
1433, 3pllA, 0.7226, 2.85, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT
1434, 3pbdA, 0.7226, 2.85, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT
1435, 3fv3D, 0.7226, 2.61, 0.214, 338, 308, SECRETED ASPARTIC PROTEASE 1 FROM CANDIDA PARAPSILOSIS IN COMPLEX WITH PEPSTATIN A
1436, 2v00A, 0.7226, 2.85, 0.239, 330, 314, X-RAY CRYSTAL STRUCTURE OF ENDOTHIAPEPSIN COMPLEXED WITH COMPOUND 1
1437, 5p3iA, 0.7225, 2.85, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 171
1438, 5ozmA, 0.7225, 2.85, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 33
1439, 5ozaA, 0.7225, 2.86, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 21
1440, 5mb0A, 0.7225, 2.85, 0.239, 330, 314, COCKTAIL EXPERIMENT A: FRAGMENTS 63 267 AND 291 IN COMPLEX WITH ENDOTHIAPEPSIN
1441, 5p4rA, 0.7224, 2.85, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 216
1442, 5p0kA, 0.7224, 2.85, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 67
1443, 5p04A, 0.7224, 2.85, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 51
1444, 4y4xA, 0.7224, 2.85, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 51
1445, 4rldB, 0.7224, 2.73, 0.158, 330, 311, CRYSTAL STRUCTURE OF KKF MUTANT OF BLA G 2 PROTEIN
1446, 3pcwA, 0.7224, 2.85, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT
1447, 1od1A, 0.7224, 2.85, 0.239, 330, 314, ENDOTHIAPEPSIN PD135040 COMPLEX
1448, 3t6iA, 0.7223, 2.85, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH AN AZEPIN DERIVATIVE
1449, 3pwwA, 0.7223, 2.85, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH SAQUINAVIR
1450, 3psyA, 0.7223, 2.85, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH AN INHIBITOR BASED ON THE GEWALD REACTION
1451, 3wz6A, 0.7220, 2.86, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH GEWALD REACTION-DERIVED INHIBITOR (5)
1452, 1izeA, 0.7220, 2.69, 0.226, 323, 310, CRYSTAL STRUCTURE OF ASPERGILLUS ORYZAE ASPARTIC PROTEINASE COMPLEXED WITH PEPSTATIN
1453, 1eagA, 0.7220, 2.74, 0.233, 339, 309, SECRETED ASPARTIC PROTEINASE (SAP2) FROM CANDIDA ALBICANS COMPLEXED WITH A70450
1454, 3pczA, 0.7216, 2.87, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH BENZAMIDINE
1455, 2h6sA, 0.7214, 2.87, 0.217, 340, 313, SECRETED ASPARTIC PROTEINASE (SAP) 3 FROM CANDIDA ALBICANS
1456, 1yg9A, 0.7214, 2.74, 0.158, 329, 311, THE STRUCTURE OF MUTANT (N93Q) OF BLA G 2
1457, 2nr6A, 0.7212, 2.79, 0.157, 329, 312, CRYSTAL STRUCTURE OF THE COMPLEX OF ANTIBODY AND THE ALLERGEN BLA G 2
1458, 3lizA, 0.7211, 2.74, 0.157, 329, 312, CRYSTAL STRUCTURE OF BLA G 2 COMPLEXED WITH FAB 4C3
1459, 2nr6B, 0.7210, 2.80, 0.157, 329, 312, CRYSTAL STRUCTURE OF THE COMPLEX OF ANTIBODY AND THE ALLERGEN BLA G 2
1460, 4y58A, 0.7209, 2.83, 0.236, 329, 313, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 260
1461, 1tzsA, 0.7207, 2.43, 0.262, 322, 305, CRYSTAL STRUCTURE OF AN ACTIVATION INTERMEDIATE OF CATHEPSIN E
1462, 4y3rA, 0.7206, 2.84, 0.240, 329, 313, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 306
1463, 3vcmB, 0.7204, 2.64, 0.248, 325, 306, CRYSTAL STRUCTURE OF HUMAN PRORENIN
1464, 3fntA, 0.7203, 2.78, 0.240, 323, 313, CRYSTAL STRUCTURE OF PEPSTATIN A BOUND HISTO-ASPARTIC PROTEASE (HAP) FROM PLASMODIUM FALCIPARUM
1465, 4rldA, 0.7201, 2.71, 0.158, 330, 311, CRYSTAL STRUCTURE OF KKF MUTANT OF BLA G 2 PROTEIN
1466, 4rldC, 0.7197, 2.74, 0.158, 330, 311, CRYSTAL STRUCTURE OF KKF MUTANT OF BLA G 2 PROTEIN
1467, 3fnuD, 0.7193, 2.87, 0.235, 326, 315, CRYSTAL STRUCTURE OF KNI-10006 BOUND HISTO-ASPARTIC PROTEASE (HAP) FROM PLASMODIUM FALCIPARUM
1468, 4yctA, 0.7192, 2.89, 0.239, 328, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 216
1469, 3fnuC, 0.7190, 2.87, 0.235, 326, 315, CRYSTAL STRUCTURE OF KNI-10006 BOUND HISTO-ASPARTIC PROTEASE (HAP) FROM PLASMODIUM FALCIPARUM
1470, 4ybfA, 0.7187, 2.82, 0.222, 334, 311, ASPARTIC PROTEINASE SAPP2 SECRETED FROM CANDIDA PARAPSILOSIS AT 1.25 A RESOLUTION
1471, 4rldD, 0.7185, 2.73, 0.158, 330, 310, CRYSTAL STRUCTURE OF KKF MUTANT OF BLA G 2 PROTEIN
1472, 2qzwB, 0.7175, 3.06, 0.217, 341, 314, SECRETED ASPARTIC PROTEINASE (SAP) 1 FROM CANDIDA ALBICANS
1473, 3q70A, 0.7172, 2.73, 0.235, 334, 307, SECRETED ASPARTIC PROTEASE IN COMPLEX WITH RITONAVIR
1474, 5i70A, 0.7171, 2.44, 0.230, 315, 305, CRYSTAL STRUCTURE OF PLASMEPSIN IV
1475, 5jodB, 0.7163, 3.07, 0.230, 375, 318, STRUCTURE OF PROPLASMEPSIN IV FROM PLASMODIUM FALCIPARUM
1476, 1ibqB, 0.7163, 2.90, 0.230, 325, 313, ASPERGILLOPEPSIN FROM ASPERGILLUS PHOENICIS
1477, 1avfJ, 0.7159, 2.43, 0.248, 322, 303, ACTIVATION INTERMEDIATE 2 OF HUMAN GASTRICSIN FROM HUMAN STOMACH
1478, 3pvkA, 0.7157, 2.54, 0.230, 330, 304, SECRETED ASPARTIC PROTEASE 2 IN COMPLEX WITH BENZAMIDINE
1479, 3fnuA, 0.7141, 2.97, 0.238, 326, 315, CRYSTAL STRUCTURE OF KNI-10006 BOUND HISTO-ASPARTIC PROTEASE (HAP) FROM PLASMODIUM FALCIPARUM
1480, 3fnuB, 0.7140, 2.97, 0.238, 326, 315, CRYSTAL STRUCTURE OF KNI-10006 BOUND HISTO-ASPARTIC PROTEASE (HAP) FROM PLASMODIUM FALCIPARUM
1481, 3fnsB, 0.7130, 3.00, 0.229, 325, 315, CRYSTAL STRUCTURE OF HISTO-ASPARTIC PROTEASE (HAP) FROM PLASMODIUM FALCIPARUM
1482, 3vlaA, 0.7129, 3.62, 0.168, 412, 327, CRYSTAL STRUCTURE OF EDGP
1483, 3vcmA, 0.7122, 2.80, 0.252, 335, 306, CRYSTAL STRUCTURE OF HUMAN PRORENIN
1484, 1izdA, 0.7117, 2.88, 0.226, 323, 310, CRYSTAL STRUCTURE OF ASPERGILLUS ORYZAE ASPARTIC PROTEINASE
1485, 3vlbA, 0.7113, 3.60, 0.153, 404, 326, CRYSTAL STRUCTURE OF XEG-EDGP
1486, 4y9wA, 0.7111, 2.52, 0.224, 327, 303, ASPARTIC PROTEINASE SAPP2 SECRETED FROM CANDIDA PARAPSILOSIS AT 0.82 A RESOLUTION.
1487, 3vlbC, 0.7108, 3.65, 0.153, 403, 327, CRYSTAL STRUCTURE OF XEG-EDGP
1488, 1avfA, 0.7104, 2.43, 0.239, 320, 301, ACTIVATION INTERMEDIATE 2 OF HUMAN GASTRICSIN FROM HUMAN STOMACH
1489, 3fnsA, 0.7101, 3.07, 0.232, 325, 315, CRYSTAL STRUCTURE OF HISTO-ASPARTIC PROTEASE (HAP) FROM PLASMODIUM FALCIPARUM
1490, 1htrB, 0.7097, 2.90, 0.255, 329, 306, CRYSTAL AND MOLECULAR STRUCTURES OF HUMAN PROGASTRICSIN AT 1.62 ANGSTROMS RESOLUTION
1491, 4ycyA, 0.7090, 2.84, 0.240, 323, 308, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 218
1492, 4pphE, 0.7080, 3.40, 0.172, 391, 319, CRYSTAL STRUCTURE OF CONGLUTIN GAMMA A UNIQUE BASIC 7S GLOBULIN FROM LUPINE SEEDS
1493, 4pphB, 0.7077, 3.45, 0.169, 391, 320, CRYSTAL STRUCTURE OF CONGLUTIN GAMMA A UNIQUE BASIC 7S GLOBULIN FROM LUPINE SEEDS
1494, 4pphF, 0.7064, 3.39, 0.172, 392, 319, CRYSTAL STRUCTURE OF CONGLUTIN GAMMA A UNIQUE BASIC 7S GLOBULIN FROM LUPINE SEEDS
1495, 3aupB, 0.7062, 3.31, 0.148, 372, 318, CRYSTAL STRUCTURE OF BASIC 7S GLOBULIN FROM SOYBEAN
1496, 4pphD, 0.7061, 3.44, 0.172, 392, 319, CRYSTAL STRUCTURE OF CONGLUTIN GAMMA A UNIQUE BASIC 7S GLOBULIN FROM LUPINE SEEDS
1497, 4pphC, 0.7044, 3.39, 0.173, 392, 318, CRYSTAL STRUCTURE OF CONGLUTIN GAMMA A UNIQUE BASIC 7S GLOBULIN FROM LUPINE SEEDS
1498, 5bwyA, 0.7042, 3.25, 0.226, 376, 318, STRUCTURE OF PROPLASMEPSIN II FROM PLASMODIUM FALCIPARUM SPACE GROUP P43212
1499, 4pphA, 0.7024, 3.39, 0.170, 390, 317, CRYSTAL STRUCTURE OF CONGLUTIN GAMMA A UNIQUE BASIC 7S GLOBULIN FROM LUPINE SEEDS
1500, 1t6gB, 0.7024, 3.18, 0.151, 368, 312, CRYSTAL STRUCTURE OF THE TRITICUM AESTIVUM XYLANASE INHIBITOR-I IN COMPLEX WITH ASPERGILLUS NIGER XYLANASE-I
1501, 1t6gA, 0.7018, 3.33, 0.143, 368, 314, CRYSTAL STRUCTURE OF THE TRITICUM AESTIVUM XYLANASE INHIBITOR-I IN COMPLEX WITH ASPERGILLUS NIGER XYLANASE-I
1502, 3aupC, 0.7013, 3.43, 0.180, 372, 316, CRYSTAL STRUCTURE OF BASIC 7S GLOBULIN FROM SOYBEAN
1503, 3qviC, 0.7012, 3.05, 0.224, 327, 308, CRYSTAL STRUCTURE OF KNI-10395 BOUND HISTO-ASPARTIC PROTEASE (HAP) FROM PLASMODIUM FALCIPARUM
1504, 1t6eX, 0.6998, 3.34, 0.140, 362, 314, CRYSTAL STRUCTURE OF THE TRITICUM AESTIVUM XYLANASE INHIBITOR I
1505, 3qviB, 0.6994, 3.05, 0.231, 327, 308, CRYSTAL STRUCTURE OF KNI-10395 BOUND HISTO-ASPARTIC PROTEASE (HAP) FROM PLASMODIUM FALCIPARUM
1506, 3aupA, 0.6980, 3.35, 0.156, 377, 315, CRYSTAL STRUCTURE OF BASIC 7S GLOBULIN FROM SOYBEAN
1507, 3qviD, 0.6969, 3.11, 0.231, 327, 308, CRYSTAL STRUCTURE OF KNI-10395 BOUND HISTO-ASPARTIC PROTEASE (HAP) FROM PLASMODIUM FALCIPARUM
1508, 3qvcA, 0.6957, 3.40, 0.223, 368, 318, CRYSTAL STRUCTURE OF HISTO-ASPARTIC PROTEASE (HAP) ZYMOGEN FROM PLASMODIUM FALCIPARUM
1509, 5jodA, 0.6951, 3.37, 0.218, 375, 317, STRUCTURE OF PROPLASMEPSIN IV FROM PLASMODIUM FALCIPARUM
1510, 3hd8A, 0.6940, 3.31, 0.148, 370, 311, CRYSTAL STRUCTURE OF THE TRITICUM AESTIVUM XYLANASE INHIBITOR-IIA IN COMPLEX WITH BACILLUS SUBTILIS XYLANASE
1511, 2b42A, 0.6937, 3.30, 0.145, 364, 310, CRYSTAL STRUCTURE OF THE TRITICUM XYLANSE INHIBITOR-I IN COMPLEX WITH BACILLUS SUBTILIS XYLANASE
1512, 5mktA, 0.6920, 2.39, 0.257, 329, 292, CRYSTAL STRUCTURE OF MOUSE PRORENIN
1513, 1miqB, 0.6916, 3.40, 0.221, 375, 317, CRYSTAL STRUCTURE OF PROPLASMEPSIN FROM THE HUMAN MALARIAL PATHOGEN PLASMODIUM VIVAX
1514, 1miqA, 0.6916, 3.40, 0.222, 373, 315, CRYSTAL STRUCTURE OF PROPLASMEPSIN FROM THE HUMAN MALARIAL PATHOGEN PLASMODIUM VIVAX
1515, 1pfzA, 0.6906, 3.16, 0.225, 370, 311, PROPLASMEPSIN II FROM PLASMODIUM FALCIPARUM
1516, 1pfzB, 0.6899, 3.16, 0.225, 369, 311, PROPLASMEPSIN II FROM PLASMODIUM FALCIPARUM
1517, 3hd8C, 0.6897, 3.32, 0.149, 368, 309, CRYSTAL STRUCTURE OF THE TRITICUM AESTIVUM XYLANASE INHIBITOR-IIA IN COMPLEX WITH BACILLUS SUBTILIS XYLANASE
1518, 1pfzD, 0.6887, 3.24, 0.225, 369, 311, PROPLASMEPSIN II FROM PLASMODIUM FALCIPARUM
1519, 3aupD, 0.6868, 3.31, 0.173, 360, 306, CRYSTAL STRUCTURE OF BASIC 7S GLOBULIN FROM SOYBEAN
1520, 3qviA, 0.6852, 3.23, 0.234, 323, 304, CRYSTAL STRUCTURE OF KNI-10395 BOUND HISTO-ASPARTIC PROTEASE (HAP) FROM PLASMODIUM FALCIPARUM
1521, 1pfzC, 0.6844, 3.32, 0.222, 356, 311, PROPLASMEPSIN II FROM PLASMODIUM FALCIPARUM
1522, 3q6yA, 0.6780, 2.88, 0.244, 305, 295, ENDOTHIAPEPSIN IN COMPLEX WITH A PYRROLIDINE BASED INHIBITOR
1523, 4ehcA, 0.5624, 3.41, 0.133, 275, 256, CRYSTAL STRUCTURE OF THE C-TERMINAL DOMAIN OF RV0977 OF MYCOBACTERIUM TUBERCULOSIS
1524, 1b5fA, 0.5537, 2.27, 0.250, 239, 232, NATIVE CARDOSIN A FROM CYNARA CARDUNCULUS L.
1525, 4oc6B, 0.5534, 2.51, 0.272, 243, 235, STRUCTURE OF CATHEPSIN D WITH INHIBITOR 2-BROMO-N-[(2S3S)-4-{[2-(24- DICHLOROPHENYL)ETHYL][3-(13-DIOXO-13-DIHYDRO-2H-ISOINDOL-2-YL) PROPANOYL]AMINO}-3-HYDROXY-1-(3-PHENOXYPHENYL)BUTAN-2-YL]-45- DIMETHOXYBENZAMIDE
1526, 1lyaB, 0.5529, 2.35, 0.275, 241, 233, CRYSTAL STRUCTURES OF NATIVE AND INHIBITED FORMS OF HUMAN CATHEPSIN D: IMPLICATIONS FOR LYSOSOMAL TARGETING AND DRUG DESIGN
1527, 1b5fC, 0.5519, 2.20, 0.255, 238, 231, NATIVE CARDOSIN A FROM CYNARA CARDUNCULUS L.
1528, 1lyaD, 0.5517, 2.32, 0.280, 241, 232, CRYSTAL STRUCTURES OF NATIVE AND INHIBITED FORMS OF HUMAN CATHEPSIN D: IMPLICATIONS FOR LYSOSOMAL TARGETING AND DRUG DESIGN
1529, 1lybB, 0.5516, 2.40, 0.279, 241, 233, CRYSTAL STRUCTURES OF NATIVE AND INHIBITED FORMS OF HUMAN CATHEPSIN D: IMPLICATIONS FOR LYSOSOMAL TARGETING AND DRUG DESIGN
1530, 4od9D, 0.5502, 2.48, 0.283, 241, 233, STRUCTURE OF CATHEPSIN D WITH INHIBITOR N-(34-DIMETHOXYBENZYL)- NALPHA-{N-[(34-DIMETHOXYPHENYL)ACETYL]CARBAMIMIDOYL}-D- PHENYLALANINAMIDE
1531, 1lybD, 0.5499, 2.38, 0.276, 241, 232, CRYSTAL STRUCTURES OF NATIVE AND INHIBITED FORMS OF HUMAN CATHEPSIN D: IMPLICATIONS FOR LYSOSOMAL TARGETING AND DRUG DESIGN
1532, 4od9B, 0.5493, 2.51, 0.270, 240, 233, STRUCTURE OF CATHEPSIN D WITH INHIBITOR N-(34-DIMETHOXYBENZYL)- NALPHA-{N-[(34-DIMETHOXYPHENYL)ACETYL]CARBAMIMIDOYL}-D- PHENYLALANINAMIDE
1533, 4obzB, 0.5488, 2.42, 0.276, 240, 232, STRUCTURE OF CATHEPSIN D WITH INHIBITOR 2-(34-DIMETHOXYPHENYL)-N-[N- (4-METHYLBENZYL)CARBAMIMIDOYL]ACETAMIDE
1534, 1lywD, 0.5455, 2.75, 0.269, 241, 234, CATHEPSIN D AT PH 7.5
1535, 1lywF, 0.5451, 2.74, 0.269, 241, 234, CATHEPSIN D AT PH 7.5
1536, 1lywH, 0.5450, 2.76, 0.278, 241, 234, CATHEPSIN D AT PH 7.5
1537, 1lywB, 0.5447, 2.76, 0.274, 241, 234, CATHEPSIN D AT PH 7.5
1538, 4obzD, 0.5423, 2.44, 0.284, 237, 229, STRUCTURE OF CATHEPSIN D WITH INHIBITOR 2-(34-DIMETHOXYPHENYL)-N-[N- (4-METHYLBENZYL)CARBAMIMIDOYL]ACETAMIDE
